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Hemostasis is a complex process to stop bleeding from damaged blood vessels. A disturbance 
in the hemostatic system may result in either a bleeding or a thrombotic tendency. The 
hemostatic process can be divided into platelet adhesion and aggregation, coagulation, and 
fibrinolysis also termed primary, secondary, and tertiary hemostasis. The actual hemostatic 
process, however, involves a dynamic interplay between these events. Figure 1 shows a 
schematic representation of hemostasis.
Primary hemostasis
Primary hemostasis comprises the formation of a platelet plug to close a ruptured vessel. 
After injury to the vessel wall, exposure of collagen and other subendothelial proteins initiates 
recruitment of platelets. Plasma von Willebrand factor (VWF) binds to the subendothelial 
collagen and becomes adhesive to platelets. The multimeric size of VWF is regulated by 
the protease ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 
1 motif, member 13). Platelets are slowed down by rolling over collagen bound VWF, and 
eventually adhere by multiple receptors. Then platelets become activated by various triggers, 
including collagen and thrombin, which results in the activation of the aggregation receptor 
αIIbβ3. Finally, platelet-platelet interaction, mediated by VWF or fibrinogen binding to αIIbβ3 
on two adjacent platelets, results in the formation of a platelet plug.
Secondary hemostasis
In secondary hemostasis, complex reactions of pro- and antihemostatic proteins lead to the 
generation of thrombin. Thrombin generation is required for both platelet activation and the 
cleavage of fibrinogen into fibrin. The formation of fibrin is necessary to reinforce the platelet 
plug. 
The classis cascade model of coagulation was in 1964 independently proposed by two groups 
of scientists [1,2]. This model involves the sequential activation of clotting factors leading to 
the generation of thrombin. Two coagulation pathways were proposed: the intrinsic pathway 
initiated via coagulation factor XII, and the extrinsic pathway initiated through the tissue 
factor-VIIa complex. These two pathways form the basis of the coagulation screening:  the 
intrinsic activation is used in the activated partial thromboplastin time (APTT), and the extrinsic 
activation in the prothrombin time (PT). However, the more recent cell-based theory better 
reflects hemostasis in vivo than the classic cascade model of coagulation [3-5]. This theory 
suggests that coagulation does not occur as a cascade, but in three overlapping stages: 
1) initiation occurring on a tissue factor bearing cell, 2) amplification to activate platelets 
and cofactors for the start of large scale thrombin generation, and 3) propagation with the 
generation of large amounts of thrombin on the platelet surface.
Coagulation is initiated when vessel wall damage exposes tissue factor (TF) to the 
bloodstream. TF on TF-bearing cells binds to coagulation factor VII and the FVIIa/TF complex 
activates small amounts of factors IX and X. Activated factor X is able to convert small amounts 
of prothrombin (factor II) into thrombin (activated factor II; IIa). In the amplification phase, 
thrombin activates platelets, factor V (cofactor for factor X), factor VIII (cofactor for factor IX), 
and factor XI (which can also activate factor IX). During the propagation phase, occurring on 
the surface of the activated platelets, factor IXa binds to factor VIIIa to activate factor X. Factor 
Xa combines with factor Va to convert large amounts of prothrombin into thrombin. Finally, 
thrombin will convert fibrinogen into fibrin to stabilize the clot.
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Thrombin generation is regulated by several anticoagulant proteins. For instance, tissue factor 
pathway inhibitor (TFPI) inactivates factor VIIa and Xa. Antithrombin mostly inhibits thrombin, 
but also inhibits factor IXa, factor Xa, factor XIa, and factor VIIa. Furthermore, thrombin 
binding to the endothelial receptor thrombomodulin activates protein C, which together with 
its cofactor protein S inactivates cofactors Va and VIIIa. 
Fibrinolysis
Since minor injuries are common, there are constantly clots produced to stop bleeding. If 
clots remained after the tissue is healed, the vascular bed would become obstructed with 
clots. Therefore, clots need to be broken down by fibrinolysis, also termed tertiary hemostasis. 
Plasmin is responsible for clot lysis by degrading insoluble fibrin to soluble fibrin degradation 
products. Plasmin is formed by activation of plasminogen by tissue-type plasminogen 
activator (t-PA). Plasmin generation is regulated by plasminogen activator inhibitor-1 (PAI-1), 
which is an inhibitor of t-PA, and plasmin inhibitor, which inactivates plasmin. Furthermore, 
activated factor XIII and activated thrombin activatable fibrinolysis inhibitor (TAFI), both of 
which are activated by thrombin generated in the coagulation cascade, make the fibrin clot 
more resistant to plasmin. Specifically, factor XIIIa cross-links fibrin fibers to enhance the 
stability of the fibrin clot, and TAFI interferes with plasminogen and t-PA binding to the clot by 
removing the lysine binding sites on fibrin. 
Figure 1 Schematic representation of the hemostatic system. Section A-C represents primary hemostasis with the 
formation of a platelet plug. Section D shows the coagulation cascade with the formation of fibrin and the subsequent 
degradation by the fibrinolytic system. Activation steps are indicated by the uninterrupted lines, whereas regulatory or 
inhibitory steps are indicated by interrupted lines. ADAMTS13: a disintegrin and metalloproteinase with a thrombospondin 
type 1 motif, member 13, VWF: von Willebrand factor, GP: glycoprotein, Fg: fibrinogen, TF: tissue factor, TFPI: tissue factor 
pathway inhibitor, APC: activated protein C, PS: protein S, TM: thrombomodulin, AT: antithrombin, PAI-1: plasminogen 
activator inhibitor-1, tPA: tissue-type plasminogen activator, TAFI: thrombin activatable fibrinolysis inhibitor, α2-AP: α2-
antiplasmin = plasmin inhibitor.




Hemostatic alterations in liver disease
The liver plays a central role in the hemostatic system as it synthesizes the majority of coagulation 
factors, anticoagulant proteins, and proteins involved in fibrinolysis. Furthermore, the liver 
regulates primary hemostasis mediated by platelets, VWF, and ADAMTS13. Consequently, 
acute or chronic liver diseases frequently have a profound impact on the hemostatic system 
[6]. The hemostatic changes associated with chronic liver disease will be extensively reviewed 
in Chapter 2. 
In short, the hemostatic changes in a patient with liver disease include thrombocytopenia, 
decreased levels of pro- and anticoagulant proteins, reduced levels of fibrinolytic proteins, 
and increased plasma levels of coagulation factor VIII and VWF. Historically, these changes 
were interpreted as predisposing for a bleeding tendency due to abnormal routine diagnostic 
tests of hemostasis, such as a prolonged PT and APTT. However, in recent years the concept 
of a “rebalanced hemostasis” [6] has become widely accepted (Figure 2).  This balance is the 
result of concomitant changes in both pro- and antihemostatic pathways. First, the reduced 
platelet count and functional platelet defects are accompanied by high plasma levels of the 
platelet adhesive protein VWF [7]. Furthermore, the VWF-cleaving protease ADAMTS13 is 
reduced in chronic liver disease, which may also promote platelet function [8]. Second, the 
decreased production of procoagulant proteins is accompanied by a decreased production 
of anticoagulant proteins, such as protein C, protein S, and antithrombin. Finally, the balance 
of fibrinolysis is probably also restored in patients with chronic liver disease due to the 
concomitant decrease of antifibrinolytics (PI, TAFI) and plasminogen [9]. However, some 
authors have also reported hyperfibrinolysis in patients with cirrhosis [10]. Clinically, the 
rebalanced hemostasis is reflected by the large proportion of patients with liver disease who 
can undergo major surgery without any requirement for blood transfusion [11]. In addition, 
more sophisticated laboratory tests have suggested a hemostatic balance in patients with 
liver disease. For example, several studies showed normal to increased thrombin generation 
in patients with cirrhosis compared to that of healthy volunteers, as a result of a concomitant 
decline in both pro- and anticoagulant proteins [12-15]. 
Figure 2 The hemostatic balance in 
patients with liver disease compared to 
that in healthy individuals. This figure 
depicts the stable hemostatic balance in 
healthy individuals and the rebalanced 
hemostatic system in patients with liver 
disease. Although the hemostatic system 
is in balance, the balance is fragile 
and may easily tip to either a hypo- or 
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The “rebalanced” hemostatic system in patients with liver disease, however, appears much 
more fragile compared to the hemostatic balance of healthy individuals. This precarious 
hemostatic balance contributes, in part, to the occurrence of both bleeding and thrombotic 
complications, which occur in a significant proportion of patients with liver diseases [6,16]. 
Furthermore, it has to be noted that the changes in the hemostatic system of patients with 
liver disease vary with the etiology of the disease. For instance, in patients with cholestatic 
liver disease hemostatic defects are milder as compared to that in patients with non-
cholestatic liver disease [17]. In patients with acute liver failure, thrombocytopenia is less 
common, levels of coagulation factors are generally lower, and fibrinolysis is more inhibited 
compared to patients with cirrhosis [18].  Finally, studies have suggested a hypercoagulable 
state in patients with non-alcoholic fatty liver disease (NAFLD), which might contribute to their 
increased risk of thrombosis [19-22]. In Chapter 6 of this thesis, an extensive overview of the 
hemostatic system of patients with NAFLD will be given.
Thrombosis and anticoagulant drugs in patients with liver disease
Patients with chronic liver diseases are nowadays more commonly diagnosed with thrombotic 
complications. For instance, the development of portal vein thrombosis (PVT) is a common 
complication of cirrhosis [23]. In addition, numerous studies have shown a significant 
occurrence of venous thromboembolism (VTE, i.e. deep vein thrombosis (DVT) and pulmonary 
embolism (PE)) in patients with liver disease [24-28]. Finally, evidence suggests an increased 
prevalence of arterial thrombosis in patients with NAFLD (see Chapter 6). 
Patients with liver disease may, thus, have multiple indications for antithrombotic therapy to 
prevent or treat thrombosis. A number of possible anticoagulant drugs are clinically available, 
however all these drugs have different advantages and disadvantages in patients with liver 
diseases. Heparins can be used for prevention or treatment of venous thrombosis and PVT. They 
act by binding to antithrombin to inhibit factor Xa and/or thrombin. Three classes of heparins 
are clinically available: unfractionated heparin, low molecular weight heparin (LWMH), and 
fondaparinux. LMWHs appear to be safe and effective in patients with cirrhosis and PVT or 
venous thrombosis [29-34]. However, heparin requires antithrombin to exert its anticoagulant 
effect and antithrombin levels are frequently decreased in patients with liver disease. Another 
disadvantage of heparins is their mode of administration (i.v. for unfractionated heparin, and 
s.c. for LMWH and fondaparinux), which may limit long-term use. Vitamin K antagonists are 
the most prescribed anticoagulants in the general medical population worldwide. Vitamin 
K antagonists act by decreasing vitamin K-dependent procoagulant factors II, VII, IX, X, and 
anticoagulant proteins C and S. A major advantage of vitamin K antagonist therapy is the 
oral mode of administration. However, a major drawback in patients with liver disease is the 
monitoring of the drug by INR levels which are already abnormal in cirrhotic patients. New-
generation anticoagulant drugs, including direct factor Xa inhibitors (rivaroxaban, apixaban, 
and endoxaban) and direct factor IIa inhibitor (dabigatran), are garnering increasing interest 
due to their oral mode of administration and lack of need for monitoring. Reports of success 
in cirrhotic patients are emerging [35-38], however larger clinical trials on efficacy and safety 
of these drugs in cirrhotic patients are lacking. 
Due to the profound alterations in the hemostatic system of patients with liver disease, 
anticoagulation in these patients is very challenging. While there are many antithrombotic 
agents available, little research has been done on the efficacy and safety of these agents in 




patients with liver disease. As a result, the anticoagulant drug of choice and dosing for the 
various indications is still unknown. The prevention and treatment of thrombosis in patients 
with liver disease will be further discussed in Chapter 2 of this thesis.
Aim of this thesis
In this thesis, novel concepts of the functionality of (parts) of the hemostatic system in 
patients with liver disease will be described. Furthermore, we study the efficacy of current 
available anticoagulant drugs in plasma from patients with cirrhosis. Finally, the use of routine 
coagulation assays in the monitoring of different available anticoagulant drugs in plasma 
from patients with cirrhosis is examined. The major part of this thesis is focused on gaining 
a better understanding of the hemostatic system in patients with (fatty) liver disease and to 
contribute to better strategies to prevent or treat thrombosis in these patients in the future. 
Chapter 2 describes the current literature on the hemostatic changes in patients with liver 
disease in detail. In this review we discuss the concept of a rebalanced hemostasis and its 
implications for clinical management of patients with liver disease. In chapter 3, plasma 
levels of protein S and TFPI in patients with cirrhosis are determined. Furthermore, we study 
the functionality of the TFPI/protein S anticoagulant system in these patients. Chapter 4 
describes the use of the novel Thrombodynamics analyzer to test plasma hemostatic capacity 
in patients with chronic liver disease.
Comparable to patients with liver disease, in patients following liver resection plasma levels of 
hemostatic proteins decrease, in part due to a reduced synthetic capacity of the liver remnant. 
Also conventional coagulation tests, such as the PT and APTT, suggest a hypocoagulable state 
in these patients. These tests are not reliable for the assessment of the overall hemostatic 
status in these patients, because they only asses isolated defects of procoagulants and are 
insensitive for anticoagulant factors. Thrombin generation testing is a more global hemostasis 
test and has been successfully used to reassess the hemostatic status of patients with liver 
disease. In chapter 5, we, therefore, study the perioperative coagulation status in patients 
undergoing hemi-hepatectomy using thrombin generation assays.
The next part of this thesis will focus on the hemostatic system in patients with NAFLD. 
Chapter 6 gives an extensive overview of the current literature on the hemostatic changes 
in patients with NAFLD and its relation with increased risk of cardiovascular disease. Recent 
studies have suggested a role for a hypercoagulable state in the increased risk of thrombosis 
in patients with NAFLD. However, results of these studies are inconsistent, most studies 
only reported plasma levels of individual hemostatic proteins rather than functional tests of 
global hemostasis, and patients with cirrhosis were excluded from most of these studies. The 
hemostatic status across the spectrum of NAFLD stages thus remains unclear. In chapter 7, 
we therefore study all components of the hemostatic system (i.e., platelets, coagulation, and 
fibrinolysis) using both biomarkers and functional tests in patients with various histological 
severities of NAFLD.
In the last parts of this thesis, the focus will be on the evaluation of the different available 
anticoagulant drugs in patients with liver disease. In chapter 8, we evaluate the in vitro effect 
of different anticoagulant drugs in plasma from patients with cirrhosis. In the appendix 
to chapter 8, we examine the in vitro anticoagulant potency of Apixaban (direct factor Xa 
inhibitor), which we compare to the anticoagulant potency of Rivaroxaban (another direct 
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factor Xa inhibitor) by using thrombomodulin-modified thrombin generation testing. This is 
studied in response to two recent reports on the use of these new oral anticoagulant drugs in 
the treatment of PVT. Monitoring of anticoagulant drugs may be required in patients with liver 
disease, which however, appears to be difficult due to the hemostatic changes associated 
with the underlying liver disease. The aim of chapter 9 is to determine whether different 
anticoagulant drugs can be reliably monitored using anti-Xa or anti-IIa tests in plasma from 
patients with cirrhosis. The appendix to chapter 9 reports the issues with monitoring of 
unfractionated heparin in patients with cirrhosis.
In chapter 10, the results presented in the previous chapters are discussed in a broader 
perspective. In addition, the implications for clinical management of hemostatic abnormalities 
in patients with liver disease are discussed. Finally, recommendations for future research are 
given.
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Management of coagulation 
abnormalities in liver disease
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Abstract
Liver disease is characterized by changes in all phases of hemostasis. These hemostatic 
alterations were long considered to predispose patients with liver disease towards a 
bleeding tendency, as they are associated with prolonged conventional coagulation tests. 
However, these patients may also suffer from thrombotic complications, and we now know 
that the hemostatic system in patient with liver disease is, in fact, in a rebalanced state. In 
this review we discuss the concept of rebalanced hemostasis and its implications for clinical 
management of patients with liver disease. For instance, there is no evidence that the use of 
prophylactic blood product transfusion prior to invasive procedures reduces bleeding risk. 
Clinicians should also be aware of the possibility of thrombosis occurring in patients with a 
liver disease, and regular thrombosis prophylaxis should not be withheld in these patients.
 





Chronic and acute liver diseases alter the hemostatic system tremendously [1]. Historically, 
patients with liver diseases were considered to be at high risk for bleeding complications 
due to the negative impact of the diseased liver on platelet synthesis and function, reduced 
production of coagulation factors and hyperfibrinolysis. However, the liver is also involved 
in the synthesis of various antihemostatic and antifibrinolytic proteins and therefore the 
hemostatic system is perceived to be rebalanced, as shown by recent laboratory studies 
and clinical observations [2]. This rebalance in the hemostatic system is not reflected by 
conventional coagulation tests, such as the prothrombin time (PT) and the activated partial 
thromboplastin time (APTT) [3]. Hence, these tests cannot be used to assess bleeding or 
thrombotic risk in patients with liver disease. Clinically, the rebalanced hemostatic system 
is reflected by the large proportion of patients with liver disease who can undergo major 
surgery without any requirement for blood product transfusion [4]. In fact, prophylactic use of 
blood products may even contribute to bleeding rather than prevent it. However, correcting 
the laboratory coagulopathy by transfusion of blood products prior to invasive procedures is 
still common practice in many centers [5,6].
The occurrence of both clinical thrombotic events and bleeding complications in patients 
with liver disease suggests that the balance of the hemostatic system is more fragile in these 
patients than in healthy individuals [7]. In fact, treatment and prevention for thrombotic 
complications is often necessary [8,9]. However, due to the profound hemostatic alterations 
and insufficient clinical experience, antithrombotic therapy is highly complicated in patients 
with liver disease and the best choice of drugs is still unknown.
This review summarizes the changes in the hemostatic system in patients with liver diseases. 
In addition, we review the limitations of laboratory tests in the investigation of bleeding 
or thrombotic risk in these patients. Finally, we discuss difficulties in management of both 
bleeding and thrombotic complications in liver disease patients.
The hemostatic system in patients with liver disease
The hemostatic system comprises platelet aggregation, coagulation and fibrinolysis also 
termed primary, secondary and tertiary hemostasis. Liver disease is associated with changes 
in all these phases of hemostasis (Table 1). Historically, these changes were interpreted as 
predisposing for a bleeding tendency due to the abnormal laboratory coagulation tests 
and the observation that spontaneous bleeding occurs frequently in this group of patients. 
However, several authors have pointed out shortcomings of this classical interpretation of 
the coagulopathy of liver disease [10–13] and in recent years the concept of ‘rebalanced 
hemostasis’ [2] has become widely accepted. In this concept, we suggested a new but more 
fragile balance within and between the procoagulant, anticoagulant and fibrinolytic systems.
Changes in primary hemostasis
In primary hemostasis, the formation of a platelet plug is initiated by vessel wall damage 
with the exposure of platelet adhesion proteins such as collagen. Concurrent tissue factor 
exposure activates the plasmatic coagulation cascade. Then, activated platelets capacitate 
the rapid production of a fibrin mesh by exposing activated clotting factors on their surface 
and producing a ‘thrombin burst’ through a positive feedback mechanism [14].
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A reduced platelet count is common in patients with acute or chronic liver disease. The 
etiology of thrombocytopenia in patients with liver diseases is multifactorial. An important 
cause includes pooling of platelets and sequestration in the spleen due to congestive 
splenomegaly, which is related to portal hypertension [15]. Some authors have also suggested 
a role of antiplatelet antibodies [16] and decreased production of platelets because of 
lower levels of hepatic thrombopoietin [17]. Furthermore, platelet consumption, because of 
cirrhosis-related hypercoagulability resulting in systemic or intrahepatic platelet activation, 
has also been assumed to be an etiopathologic factor of thrombocytopenia in patients with 
chronic liver disease [18].
Besides thrombocytopenia, multiple mechanisms predisposing to functional platelet defects 
have also been described [11]. On the other hand, high plasma levels of von Willebrand factor 
(VWF) might compensate for defects in platelet number and function in patients with cirrhosis 
[19]. Indeed, it has been shown that VWF levels are elevated in proportion to the severity of 
liver disease [20]. The elevated levels of VWF may be a consequence of endothelial activation 
commonly observed in patients with liver disease. Endothelial activation is considered an 
important consequence of portal hypertension, and in fact, it was shown that VWF levels are 
associated with clinically significant portal hypertension [21]. Other possible mechanisms of 
elevated levels of VWF in cirrhosis are induction of synthesis of VWF in the cirrhotic liver 
itself or reduced liver-mediated clearance. Although the concept of platelet hypofunction in 
cirrhosis has long been widely accepted, more recent work suggests that platelet function 
might not be abnormal when studied under physiological test conditions. One study showed 
that although in-vitro platelet adhesion to subendothelial structures under conditions of flow 
is substantially reduced, this was fully attributable to the reduced platelet count and reduced 
hematocrit in these patients [22]. Another study even provided evidence for enhanced 
platelet function [23].
Changes in the coagulation cascade
In secondary hemostasis, complex reactions of the pro- and antihemostatic proteins in the 
coagulation cascade lead to the formation of a fibrin clot (Figure 1). The liver produces all 
plasma proteins involved in the generation of a fibrin mesh (except factor VIII). As a result, 
levels of coagulation factors V, VII, IX, X, XI and prothrombin are commonly reduced in both 
acute and chronic liver disease [24]. In contrast, factor VIII levels are often elevated [25], 
possibly due to upregulated synthesis from extrahepatic sites, such as the lung, spleen and 
kidney [26]. Other possible causes for the high levels of FVIII may be the elevated levels of 
VWF, the carrier protein of FVIII or reduced FVIII clearance. Fibrinogen levels are frequently 
reduced (except for patients with biliary cirrhosis, in which fibrinogen levels may be elevated), 
especially in patients with acute liver failure or advanced cirrhosis. In addition, fibrinogen is 
often functionally aberrant as a result of excessive sialic acid content leading to impaired 
fibrin polymerization [27]. 
The decreased production of procoagulant factors is mostly counterbalanced by decreased 
production of anticoagulant proteins, such as protein C, protein S, protein Z, protein 
Z-dependent protease inhibitor, antithrombin (AT), heparin cofactor II and a2-macroglobulin, 
which are all produced by the liver [1]. Tissue factor pathway inhibitor (TFPI) is synthesized by 
endothelial cells, and as a result of continuous activation of the endothelium in patients with 
liver disease, these patients are assumed to have increased levels of TFPI. However, studies 




have shown either increased or normal levels of TFPI in patients with acute or chronic liver 
diseases. It has recently been established that protein S acts as a cofactor for TFPI in the 
downregulation of thrombin generation and, as a result, acquired and congenital protein S 
deficiencies are associated with a concomitant TFPI deficiency [28]. It may thus be that the 
increased TFPI release in patients with liver disease is masked by the decrease in protein S. 
Indeed, we recently reported that, despite a substantial decrease in protein S levels in patients 
with cirrhosis, TFPI levels are comparable between patients and healthy individuals. However, 
despite normal TFPI plasma levels, the TFPI/protein S anticoagulant system is functionally 
impaired in patients with cirrhosis [29, Chapter 3 of this thesis].
Studies using the thrombin generation test have examined the net balance of secondary 
hemostasis. As shown in Table 1, these studies have either shown a normo- or hypercoagulable 
state. These contrasting data may be attributed to differences in methodology, but probably 
also to differences in the disease severity of included patients. In fact, it has been hypothesized 
that progression of liver disease is correlated with a more hypercoagulable state, possibly 
due to the progressive decrease of protein C [30] and/or increase of FVIII levels [24,31] with 
increasing disease severity.
Figure 1. Schematic representation of the coagulation cascade and fibrinolytic system resulting in the generation and 
subsequent breakdown of a fibrin clot. 
In this figure, activator processes are indicated by the uninterrupted lines, whereas regulatory or inhibitory steps are 
indicated by interrupted lines. After vessel wall damage, binding of coagulation factor VII to the exposed transmembrane 
protein TF initiates a series of enzymatic reactions in which proenzymes are activated into active forms. This cascade 
results in the generation of thrombin (IIa), which then cleaves fibrinogen into fibrin. Thrombin generation is downregulated 
by TFPI and AT, which inactivate factor VIIa and Xa, and thrombin, respectively. Furthermore, activated protein C, activated 
when thrombin binds to its endothelial receptor TM, inactivates cofactors Va and VIIIa. The fibrinolytic system can break 
down the fibrin clot, which is initiated by release of plasminogen activators tPA or uPA from endothelial cells, macrophages 
or renal epithelial cells. The plasminogen activators activate plasminogen to form plasmin, an enzyme that degrades fibrin 
into fibrin degradation products. Plasmin generation is regulated by PAI-1, a direct inhibitor of tPA and uPA, and by PI, 
which inactivates plasmin. Furthermore, activated FXIII and activated TAFI, both activated by thrombin generation in 
the coagulation cascade, render the fibrin clot more resistant to plasmin. AT: Antithrombin; PAI-1: Plasminogen activator 
inhibitor type 1; PI: Plasmin inhibitor; TAFI: Thrombin activatable fibrinolysis inhibitor; TF: Tissue factor; TFPI: Tissue factor 
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Changes in the fibrinolytic system
The liver synthesizes all proteins involved in the breakdown of a fibrin clot (fibrinolysis, see 
Figure 1), except for tissue-type plasminogen activator (tPA) and plasminogen activator 
inhibitor 1 (PAI-1). Indeed, levels of plasminogen, plasmin inhibitor, thrombin activatable 
fibrinolysis inhibitor and factor XIII are frequently reduced in both acute and chronic liver 
disease [32,33]. On the other hand, plasma levels of tPA are elevated as a result of enhanced 
release by activated endothelium cells and/or due to a reduction in the clearance of tPA by 
the diseased liver. Furthermore, PAI-1 levels are substantially increased in acute liver failure 
[34], but modestly increased in chronic liver disease
[35]. The net effect of these changes has often been described as hyperfibrinolytic, but its 
mechanistic role in bleeding is still debated [11]. Although contrasting results have been 
reported (Table 1), the balance of fibrinolysis is probably restored in patients with chronic 
liver disease by the parallel changes in the profibrinolytic and antifibrinolytic proteins 
[32]. However, in patients with acute liver failure the balance is probably shifted toward 
hypofibrinolysis due to the elevated levels of PAI-1 [34], and hyperfibrinolysis may occur 
during liver transplantation as a result of lack of clearance of tPA during the anhepatic phase.
 
Table 1. Summary of studies on the changes in all phases of the hemostasis in patients with liver disease. ADAMTS 13: a 
disintegrin and metalloprotease with thrombospondin type 1 motif 13; PAI: plasminogen activator inhibitor; TAFI: thrombin-


































































Rebalanced but fragile: bleeding & thrombosis risk
Thus, despite the profound hemostatic alterations, the hemostatic system appears to be 
rebalanced in patients with liver disease. However, this balance is far more precarious and 
potentially unstable compared with the hemostatic balance in healthy individuals, which 
explains the occurrence of both bleeding and thrombotic complications in these patients. 
In fact, there are a variety of disturbances that can predispose an individual liver disease 
patient to either bleeding or thrombosis. For instance, development of renal failure is 
common in advanced liver disease and this usually leads to a bleeding tendency as a result 
of acquired platelet dysfunction, abnormal platelet–vessel wall interaction and anemia 
[36]. Another important and often coexisting modulator of hemostasis is the appearance 
of bacterial infections. Endotoxins may inhibit platelet function by prostacyclin production 
and enhancement of nitric oxide and inhibit coagulation by stimulating generation of 
heparin-like substances [37]. Bacterial infection may thus increase the risk of initiation and 
failure to control bleeding. However, some investigators also suspect a potential direct 
effect of endotoxin in the activation of the clotting cascade [38], leading to disseminated 
intravascular coagulation. Indeed, during endotoxemia or sepsis, endotoxin induces tissue 
factor expression in macrophages or endothelial cells, possibly contributing to development 
of disseminated intravascular coagulation [39,40]. Prophylactic administration of antibiotic 
drugs to patients with chronic liver disease is known to reduce mortality and improve the 
hemostatic function [41], but the exact mechanism is unknown. It is therefore recommended 
to adequately diagnose and treat infections before invasive procedures.
Variceal bleeding is one of the most common bleeding events occurring in patients with 
advanced liver disease, occurring in 20–30% of patients with cirrhosis [42]. However, the 
occurrence of variceal bleeding in patients with cirrhosis is mostly unrelated to hemostasis 
and depends more on local vascular abnormalities and portal hypertension leading to 
increased vascular pressure [43]. Indeed, prevention and treatment of variceal bleeding is 
currently not aimed at improving the hemostasis by transfusion of blood products, as these 
products may cause increased portal vein pressure and thereby aggravate bleeding, but the 
use of nonselective b-adrenergic blockers and endoscopic band ligation is recommended 
[44].
Nowadays, there is an increasing recognition of the various thrombotic complications that 
may occur in patients with liver diseases. Indeed, portal vein thrombosis (PVT) is a common 
occurrence in patients with cirrhosis, occurring in up to 26% of cirrhotic patients with end-stage 
liver disease [45]. Furthermore, the occurrence of venous thrombosis is also not uncommon 
in patients with liver disease. In fact, some studies have even suggested a significantly higher 
relative risk of venous thrombosis in these patients [9]. The incidence of thrombosis in liver 
disease is possibly underreported because of nonspecific symptoms of deep vein thrombosis 
and pulmonary embolism and the lesser attention of clinicians to the possibility of thrombosis 
in these patients. One clinical survey reported that 40% of patients admitted to the hospital 
with decompensated liver disease suffered from bleeding events (about one-half nonvariceal) 
and 7% suffered from deep venous thrombosis [46]. Finally, patients with nonalcoholic fatty 
liver disease, an increasing cause of liver disease in western counties, are known to have a 
substantially increased prevalence of arterial thrombotic events [47].
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Laboratory measurements in patients with liver disease
There is a frequent clinical need for predicting the risk of bleeding or thrombotic events during 
or after procedures. However, current clinical available tests are not accurate in predicting 
those risks in patients with liver diseases because they only evaluate narrow aspects of the 
hemostatic system. Table 2 summarizes the limitations of commonly available laboratory 
measurements in patients with liver disease.
The bleeding time, which assesses platelet function, is frequently prolonged in patients 
with liver disease. Furthermore, the classic platelet aggregation assays are also frequently 
disturbed in these patients. However, both tests correlate poorly with bleeding symptoms 
in patients with liver disease [11]. Blood platelet count has some clinical correlation with 
bleeding, but possibly only at low platelet levels (below 50 x 10E9/l) [48].
The PT is widely used as a general indicator of coagulation. Because coagulation tests, such 
as the PT and APTT, only measure procoagulant factors and are not sensitive to the reduction 
in anticoagulant factors, they cannot reliably predict the risk of bleeding in patients with 
profound hemostatic alterations such as in liver disease [11,13]. These coagulation tests thus 
cannot reflect the true hemostatic status of patients with liver diseases. Furthermore, the 
interlaboratory variability of the PT assay is substantial in these patients, making its clinical 
implication more difficult.
Recently, thrombin generation testing has been increasingly used to reassess the hemostatic 
capacity of patients with liver disease. This test measures the total amount of thrombin 
generated during in vitro coagulation, in contrast with the PT and APTT, in which the time 
to formation of a plasma clot is measured when only about 5% of the total thrombin has 
been generated. Especially in the presence of thrombomodulin, a transmembrane protein 
located on vascular endothelial cells acting as the main physiologic activator of protein C, the 
thrombin generation test is sensitive to all anticoagulant proteins in the plasma. Therefore, this 
test measures the true balance between the pro- and anticoagulant factors. In fact, thrombin 
generation testing in the presence of thrombomodulin has demonstrated normal or even 
superior thrombin generation in patients with chronic liver disease [3,31,49,50]. Furthermore, 
in patients with acute liver disease, the PT and APTT are substantially prolonged; however, 
this is not associated with lower levels of thrombin generation [51] or an increased risk of 
hemorrhage [52–54]. Some studies have also shown that thrombin generation testing is useful 
in identifying patients with an increased risk of thrombosis [55–57] or those with a bleeding 
tendency [58]. However, the thrombin generation test is not widely available, addition of 
thrombomodulin is not standardized yet and currently the test is too complicated for routine 
use in diagnostic laboratories. Therefore, studies are needed to further asses the clinical value 
of the thrombin generation assay in predicting hemostatic abnormalities in patients with liver 
disease and to standardize the test for routine use.




Table 2. Limitations of commonly available laboratory measurements in patients with liver disease 
APTT: activated partial thromboplastin time; AT: antithrombin; INR: international normalized ratio, PT: prothrombin time; 
VWF: von Willebrand Factor.
Another possible potent technique for measurement of hemostasis in liver disease is 
thromboelastography (TEG) [59,60]. By using whole blood, this test measures speed and 
strength of clot formation continuously and can thus theoretically analyze all components of 
the hemostatic system [61]. Currently there are two commercially available devices, TEG and 
rotational thrombelastometry, and both have been routinely used for guiding transfusion of 
platelet concentrates, factor repletion and fibrinolytic therapy during liver transplantation [60]. 
Although most studies imply that thromboelasthography provides an accurate assessment 
of bleeding risk in patients with liver disease, to date no studies have directly tested this 
hypothesis. Therefore, studies to assess the clinical value of the TEG to guide hemostatic 
management in patients with liver disease are urgently needed.
Prevention & treatment of bleeding complications
As mentioned before, patients with liver disease are not as prone to hypocoagulation-
associated bleeding as clinicians formerly thought, and routine coagulation tests cannot be 
reliably used to assess a bleeding tendency in these patients. Therefore, management of 
bleeding complications should be aimed at encountering clinical relevant problems instead 
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in liver transplantation, in which currently many patients can undergo transplantation without 
or with minimal transfusion of blood products [4].
Minimal transfusion of blood products prior to invasive procedures
Currently it is in many centers no longer common practice to use blood transfusion products 
prior to or during liver transplantation except in the occurrence of active bleeding. Indeed, 
there are no studies showing a beneficial effect of administration of fresh frozen plasma (FFP) 
or platelet concentrates on prevention of bleeding, specifically for patients with cirrhosis. 
There are, however, published data on the lack of efficacy of FFP administration in the 
general population [62,63]. In addition, a clinical trial in which platelet count was increased 
prior to invasive procedures by a thrombopoietin receptor agonist (Eltrombopag) was 
prematurely terminated due to thrombotic complications [64], suggesting that correction of 
thrombocytopenia in patients with liver disease does more harm than good. This may be due 
to the fact that thrombocytopenia is balanced by the highly elevated levels of VWF in patients 
with liver disease and that elevated levels of VWF in the context of normalized platelet counts 
result in a prothrombogenic state.
Despite the lack of benefits, prophylactic use of blood products prior to smaller invasive 
procedures, such as biopsies, thoracentesis and smaller surgical procedures, is still common 
practice. Indeed, FFP is frequently used to correct a prolonged PT in patients with liver disease, 
while recent transfusion guidelines specifically state that it is highly unlikely that these patients 
benefit from FFP [65]. Furthermore, in one randomized controlled trial in cirrhotic patients 
undergoing dental extractions usage of intranasal desmopressin appeared as effective, more 
convenient, better tolerated and less expensive than transfusion of FFP in the prevention of 
bleeding [66]. This indicates that there is little clinical benefit from prophylactic FFP transfusion 
before low-risk invasive procedures in patients with liver disease. Moreover, the response to 
FFP administration is unpredictable in these patients and frequently does not lead to a full 
normalization of the PT or international normalized ratio (INR) [67]. Prophylactic administration 
of FFP may even lead to volume overload and exacerbation of portal hypertension, and 
thereby paradoxically increasing the risk of bleeding [11]. Other side effects of FFP may be 
the risk of infection and the risk of transfusion-related acute lung injury. Since the benefits of 
FFP are unclear and given the side effects that may occur, we strongly advise against routinely 
correcting a prolonged PT or INR with transfusion of FFP prior to procedures in patients 
with liver disease. Instead, only those patients with significant bleeding should be treated. 
However, exceptions may include very high-risk procedures in which bleeding is unlikely 
to be detected in time to intervene before irreversible damage occurs (e.g., intracranial 
pressure monitor placement in patients with acute liver failure). Under these circumstances, 
it seems reasonable to (partially) correct prolonged coagulation times with FFP in spite of 
limited clinical data to support this practice. Because highly elevated levels of VWF appear to 
balance thrombocytopenia in patients with liver disease, and given the potential side effects, 
prophylactic platelet transfusion should also not be administered routinely. However, it has 
been suggested that correcting a platelet count below 50,000 or 60,000/ml may be advisable 
for high-risk procedures [14]. For example, the Society of Interventional Radiology guidelines 
advises to correct a platelet count <50,000/ml [68]. However, there is little clinical evidence 
to suggest that the bleeding risk indeed increased with platelets counts below a certain 
threshold. A single observational study demonstrated an increased bleeding risk following 
invasive procedures in patients with a platelet count below 75,000/ml [69]. Additional studies 




to investigate whether such a threshold for correction of thrombocytopenia exists, and 
whether administration of platelet concentrates prior to invasive procedures has a beneficial 
risk/benefit ratio at platelet counts below such a threshold are required.
In contrast to the discussed transfusion products, administration of low-volume prohemostatics, 
such as prothrombin complex concentrates, that contain both procoagulant and anticoagulant 
proteins, may be useful in the prevention of bleeding during liver transplantation. The safety 
and efficacy of this preoperative administration of prothrombin complex concentrate in 
patients undergoing liver transplantation is currently under investigation [70].
Treatment strategies for bleeding complications
In summary, the occurrence of hemorrhage in patients with liver disease is frequently 
unrelated to hemostasis and depends more on portal hypertension, endothelial dysfunction, 
bacterial infection or renal failure. These risk factors should therefore also be addressed when 
preventing (re)bleeding. Moreover, excessive transfusion of red blood cells or large volumes 
of plasma should be avoided due to the increase in portal vein pressure and resultant 
increased (re)bleeding risk [14]. Indeed, in a recent randomized controlled trial in patients 
with acute upper gastrointestinal bleeding (a frequent complication in chronic liver disease) 
survival was improved and rebleeding risk reduced by the use of a restrictive red blood cells 
transfusion policy [71].
Instead of administration of blood products, treatment of coagulation abnormalities in 
liver disease patients may be addressed by the following drugs: Desmopressin (DDAVP, 
1-deamino-8-D-arginine vasopressin), antifibrinolytics such as aprotinin and tranexamic acid 
and recombinant tissue factor VIIa (rFVIIa). DDAVP has been shown to correct the bleeding 
time [72]; however, several studies have shown that administration to patients with an acute 
variceal bleeding, undergoing hepatectomy or liver transplantation, has no effect on blood 
loss [73,74]. Therefore, the hemostatic effect of DDAVP in patients with liver disease is 
questionable. During liver transplantation, the usage of antifibrinolytics seems justified as 
it resulted in substantial reduction of blood loss in randomized studies [75,76]. In addition, 
in a recent Cochrane review [77], it was confirmed that antifibrinolytics may potentially 
reduce blood loss and transfusion requirements. However, one of the most frequently used 
antifibrinolytic drug, aprotinin, has been retracted from the market due to reported side 
effects in cardiac surgery [78]. However, alternatives such as tranexamic acid and epsilon 
aminocaproic acid are still available and equally effective [76]. Currently, antifibrinolytics 
are assessed for their potential in the prevention of gastrointestinal bleeding in the HALT-
IT trial [79]. Finally, the use of rFVIIa during liver transplantation resulted in reduced blood 
loss in one pilot study [80], which was, however, not confirmed by larger randomized trials 
[81,82] and also not shown during liver resection. An effect of rFVIIa on variceal bleeding has 
recently been reported, but its use was associated with an elevated risk of thrombosis [83]. 
Thus, the evidence of the efficacy of rFVIIa in reducing bleeding complications is limited, and 
there is considerable evidence of its thrombogenic potential. Therefore, recently published 
guidelines from the European Society of Anaesthesiology on the management of severe 
perioperative bleeding recommended against the prophylactic use of rFVIIa in patients with 
liver disease and suggested that it should be used only as a rescue therapy for uncontrollable 
bleeding [84].
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Prevention & treatment of thrombotic complications
As mentioned before, thrombotic complications do occur frequently in patients with 
liver disease and these patients may even be in a hypercoagulable state. Therefore, we 
strongly advise not to withhold thrombosis prophylaxis in patients with liver disease, even 
in the presence of abnormal routine tests of hemostasis, when risk factors for thrombotic 
complications are present. Examples of such risk factors for thrombosis prophylaxis include 
hospitalization and immobilization, undergoing invasive procedures, and the presence of 
(hepatocellular) cancer [85]. However, for general antithrombotic prophylaxis, especially 
in patients both at risk for thrombosis and bleeding, careful clinical decision making on an 
individual basis is needed. Finally, as a result of limited clinical experience, the choice and 
dosage of anticoagulant drugs for the various indications is still unknown.
Different anticoagulant drugs & their pros & cons in patients with liver disease
Vitamin K antagonists have been used for decades for the long-term prevention and 
treatment of thromboembolic events, and they are the most prescribed anticoagulants in the 
general medical population worldwide. A major drawback of vitamin K antagonist therapy 
in patients with liver disease is the monitoring of the drug by the INR because INR levels are 
already abnormal in these patients. Therefore, target ranges of the INR for patients with liver 
disease are unclear and an optimal anticoagulant efficacy will be difficult to achieve. Indeed, 
studies investigating vitamin K antagonists in patients with chronic liver disease have shown 
an unacceptably high level of bleeding complications [86,87]. 
The use of low-molecular-weight heparin in selected patients with cirrhosis has shown to 
be both safe and effective in the prevention and treatment of PVT [45,88]. Anticoagulant 
therapy may even be beneficial in these patients by preventing progression of cirrhosis [45]. 
In addition, the prevention of venous thrombosis with heparins appears safe and effective 
[89]. However, also heparins have drawbacks, especially long-term use of these drugs 
may be limited by the mode of administration as well as the concern for heparin-induced 
thrombocytopenia. Furthermore, we [90, Chapter 8 of this thesis] and Senzolo et al. [91] 
have recently shown that heparin and low-molecular-weight heparin have a more profound 
anticoagulant effect in plasma from patients with cirrhosis compared with healthy individuals. 
In addition, monitoring of heparins is complicated because the anti-Xa assay underestimates 
drug levels of LMWH in patients with cirrhosis [92,93]. This is most probably related to the 
reduced AT levels in patients with liver disease. Indeed, we have recently shown that the 
anti-Xa assay not only underestimates the LMWH mass, but the test also underestimates the 
masses of other AT-dependent anticoagulant drugs in plasma from patients with cirrhosis [94, 
Chapter 9 of this thesis]. However, when excess AT is added to the anti-Xa assay, the assay can 
be used in the monitoring of heparins in patients with cirrhosis [94], but this modification of 
the test is not readily available in many routine diagnostic laboratories.
New-generation antithrombotic drugs
Newer anticoagulant drugs, such as the direct factor Xa inhibitor rivaroxaban and the 
thrombin inhibitor dabigatran, have several theoretical advantages over the currently used 
anticoagulant drugs. The advantages include an oral mode of administration, rapid onset of 
action, fewer drug to drug interactions, lack of need for monitoring and no need for titration or 
dose adjustments [95]. However, the major advantage of no need for laboratory monitoring is 
at the same time also a disadvantage as it may increase the risk for noncompliance. Previously, 




one of the major concerns for these drugs was the absence of an established reversal agent. 
However, this may be addressed in the future, as specific reversal agents for direct Xa and IIa 
inhibitors are in clinical development.
Both drugs may be applicable in the prevention and treatment of thrombotic complications in 
patients with liver disease. They may be advantageous especially in long-term anticoagulant 
strategies given the oral mode of administration. However, clinical data on the use of these 
drugs in patients with chronic liver disease are still lacking, as these patients have been excluded 
from clinical trials. According to the package insert, rivaroxaban is even contraindicated in 
patients with Child B and Child C cirrhosis due to a perceived bleeding risk. Since these new 
drugs are cleared by the liver and kidneys, the pharmacokinetics may potentially be altered 
in patients with liver disease. Nevertheless, in a recent case report, 6 months of therapy with 
rivaroxaban resulted in complete resolution of acute PVT in a patient with Child A cirrhosis, 
without any adverse effect [96]. Furthermore, in another study, five patients with cirrhosis and 
PVT safely received oral factor Xa inhibitor anticoagulants (rivaroxaban or apixaban) and in 
two patients repermeation of the portal vein occurred after 6 months of therapy [97]. We 
recently studied the potency of old and new anticoagulant drugs in plasma from patients with 
cirrhosis [90, Chapter 8 of this thesis] and observed a substantially increased anticoagulant 
response to dabigatran. In contrast, rivaroxaban resulted in a reduced response in plasma from 
patients with cirrhosis. Thus, the new oral anticoagulants may work differently in liver disease 
patients compared with patients with intact liver function, which is a potential caveat. Drug-
specific dose adjustments, taking both the pharmacokinetics and the altered anticoagulant 
potency of the drug into account, may be required for patients with liver disease. Laboratory 
tests meeting these specific needs need to be developed.
Thus, antithrombotic treatment is frequently required in patients with liver disease and 
thrombosis prophylaxis should not be withheld from these patients. Clinical studies on efficacy 
and safety of the available anticoagulant drugs in patients with liver disease are urgently 
needed in order to better recommend the appropriate choice and dosage of anticoagulant 
drug for the prevention and treatment of the various thrombotic complications.
Conclusion
The concept of a rebalanced but more precarious hemostatic system in patients with liver 
disease, with the risk of both bleeding and thrombotic complications, is increasingly accepted. 
Routine laboratory tests, such as the platelet count, PT and APTT, are poor in predicting the 
bleeding risk in these patients, and more sophisticated tests of hemostasis, such as thrombin 
generation testing, are not available for routine use in diagnostic laboratories yet. Therefore, 
it is currently impossible for clinicians to identify individual patients with an increased risk 
for bleeding, except when risk factors, such as portal hypertension, endothelial dysfunction, 
bacterial infection or renal failure, are present. Future research should focus on developing a 
method that can reliably predict the bleeding risk of an individual liver disease patient.
In this paper, we have summarized the available evidence that the use of prophylactic 
transfusion products prior to invasive procedures, to correct prolonged routine coagulation 
tests, does not reduce bleeding risk. Instead, the use of blood products may paradoxically 
cause bleeding as a result of volume overload and has several other severe side effects. 
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These new insights should be established in common practice and only those patients with
an active bleed should be treated. Furthermore, clinicians should be aware of the risk factors 
for hemorrhage and these should also be addressed.
It has also been highlighted that regular thrombosis prophylaxis should not be withheld in 
patients with liver disease, especially in the presence of risk factors, such as hospitalization 
and immobilization, undergoing invasive procedures, and the presence of (hepatocellular) 
cancer. However, we also acknowledge that future clinical research focusing on the efficacy 
and safety of anticoagulant therapies in these patients is necessary as specific guidelines 
for dosing and monitoring of these drugs for the prevention or treatment of thrombosis are 
lacking.
Expert commentary
Medical research on the hemostasis in liver disease has recently begun to expand, and 
laboratory testing and clinical observations have shifted the assumption of a hypocoagulation-
based bleeding tendency in patients with liver disease toward the concept of a rebalanced 
hemostasis in these patients. However, these patients may suffer from both clinical relevant 
bleeding and thrombotic complications. Current laboratory tests fail to accurately predict 
bleeding and thrombosis risk in patients with liver diseases, and we therefore discourage 
using these tests in the prevention of procedural-related bleeding. Thrombin generation 
assays may be promising in assessing hemostatic imbalance in patients with liver diseases, as 
it is a good marker of global hemostasis. However, future studies are needed to further asses 
the clinical value of the test in predicting hemostatic abnormalities and to standardize it for 
routine use. 
Current knowledge on the occurrence of bleeding complications in patients with liver disease 
has shown that its etiopathophysiology is frequently unrelated to a coagulopathy and depends 
more on risk factors, such as portal hypertension, renal failure or infections. This suggests that 
prophylactic transfusion of blood products prior to invasive procedures is not helpful in the 
prevention of bleeding, and indeed research has shown no benefits of these products. Its use 
may even contribute to bleeding rather than prevent it. We therefore strongly advise against 
prophylactic transfusion of blood products prior to invasive procedures in patients with liver 
disease. Instead, only those patients with significant bleeding should be treated, and the risk 
factors for bleeding should be addressed in the prevention of (re)bleeding. 
Finally, since clinical observations have provided evidence for the occurrence of thrombotic 
complications in patients with liver diseases, we believe that these patients should not be 
withheld from thrombosis prophylaxis.
Five-year view
The occurrence of thrombotic complications and the necessity of antithrombotic therapy 
in patients with liver diseases is increasingly recognized. In the future, a further increase in 
the use of anticoagulant therapy in these patients may be expected due to the increased 
incidence of thrombotic complications over time related to increasing rates of fatty liver 
disease and generally longer survival times of patients with chronic liver disease. 




Moreover, although our knowledge on bleeding in patients with cirrhosis has tremendously 
expanded, there still are patients with severe hemostasis-related bleeding, either 
spontaneously or procedure-related. First of all, it would be useful if we could predict which 
patients are at risk for thrombosis or bleeding. Currently, two tests may be promising in the 
prediction of bleeding or thrombosis risk in these patients, thrombin generation assays and 
TEG, as they both measure global hemostasis. However, future research is necessary to further 
asses the clinical value of these tests in predicting thrombosis and bleeding risk and their use 
in routine laboratories. 
Furthermore, as the incidence of thrombotic complications may increase in patients with 
liver disease, both thrombosis prophylaxis and treatment should be used more frequently in 
these patients. Currently, specific guidelines on the choice and dose of anticoagulant drugs 
in patients with liver disease are lacking, and the available drugs have various advantages 
and disadvantages. Therefore, future clinical studies focusing on the efficacy and safety of 
anticoagulant therapies in these patients are urgently needed.
By far the most exciting advance in the field is the accumulating data showing that 
antithrombotic treatment may slow down progression of liver disease. If confirmed, this 
finding may cause a revolution in the management of patients with cirrhosis. If antithrombotic 
treatment truly prevents progression of disease and substantially delays decompensation, 
the need for liver transplant, or death, this will profoundly impact the clinical management 
of patients with (early) cirrhosis. However, future clinical studies on the benefits and safety 
of such treatment strategies in different patient groups are required to further apply this in 
clinical practice. 
Finally, in the field of bleeding management in patients with liver disease prophylactic use 
of transfusion products prior to invasive procedures is not recommended because there is 
no evidence that this will reduce the bleeding risk. However, in the future it may be useful 
to investigate whether administration of low-volume prohemostatics can prevent bleeding 
during invasive procedures.
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Abstract
Protein S acts as a cofactor for tissue factor pathway inhibitor (TFPI) in down regulation of 
thrombin generation, and acquired and congenital protein S deficiencies are associated with 
a concomitant TFPI deficiency.  In contrast, in patients with liver diseases, decreased protein 
S, but normal or increased levels of TFPI have been reported. We compared TFPI and protein 
S  plasma levels between 26 patients with cirrhosis and 20 healthy controls and found that 
TFPI levels were comparable between patients (111 ± 38%) and controls (108 ± 27%), despite 
reduced protein S levels (74 ± 23% in patients vs. 98 ± 10% in controls). Subsequently, we 
quantified the activity of the TFPI-protein S system by measuring thrombin generation in the 
absence and presence of neutralizing antibodies to protein S or TFPI. Ratios of peak thrombin 
generation in the absence and presence of these antibodies were calculated. Both the protein 
S and the TFPI ratios were increased in patients with cirrhosis compared to controls. Protein 
S ratios were 0.62 [0.08-0.93] in patients vs. 0.32 [0.20-0.54] in controls; TFPI ratios were 0.50 
[0.05-0.90] in patients vs. 0.18 [0.11-0.49] in controls. Thus, although the acquired protein 
S deficiency in patients with cirrhosis is not associated with decreased TFPI levels, the TFPI/
protein S anticoagulant system is functionally impaired.





Protein S is a vitamin K-dependent plasma protein that is synthesized in the liver and by 
endothelial cells. It is well known that protein S acts as a cofactor for activated protein C (APC) 
in the proteolytic inactivation of coagulation factors Va and VIIIa [1]. It has been shown that 
protein S also effectively inhibits thrombin generation in plasma in the absence of APC [2,3]. 
This APC-independent anticoagulant property of protein S was especially observed at low 
TF concentrations. These observations led to the identification of a new role of protein S as a 
cofactor for tissue factor pathway inhibitor (TFPI) in the inhibition of factor Xa (FXa) [4]. Based 
on these findings, it has been proposed that protein S deficiency not only increases the risk 
of thrombosis by impairing the protein C system, but also by reducing the ability of TFPI to 
down-regulate the coagulation pathway. In fact, it has been shown that TFPI plasma levels 
are reduced in both congenital and acquired protein S deficiency [5], which is most probably 
due to the existence of a complex between protein S and TFPI in plasma. Deficiency of either 
protein is associated with an increased risk of venous thrombosis [6,7]
Castoldi et al. [5] assessed the functional consequences of combined (partial) protein S 
and TFPI deficiency by comparing thrombin generation in plasma from heterozygous type I 
protein S-deficient individuals with age- and sex-matched controls. At a low TF concentration, 
thrombin generation in plasma from patients with a protein S deficiency was 3-fold higher than 
in plasma from healthy individuals. Furthermore, simultaneous normalization of both protein 
S and TFPI levels completely corrected the elevated thrombin generation, while normalization 
of the protein S level alone hardly affected thrombin generation and normalization of the TFPI 
level alone reduced the peak height of thrombin generation by half.  
 In addition, Maurissen et al. [8] quantified the activity of the TFPI-protein S system 
in plasma by measuring thrombin generation in the absence and presence of neutralizing 
antibodies to protein S or TFPI. These studies showed that protein S and TFPI ratios, determined 
as the ratio of thrombin peaks in the absence and presence of neutralizing antibodies, were 
elevated in protein S-deficient individuals, indicating an impairment of the TFPI-protein 
S system. Furthermore, both ratios correlated well with full-length TFPI levels, which were 
significantly lower in protein S-deficient patients compared to family members with normal 
levels of protein S. This decrease in TFPI levels in conjunction with protein S deficiency was 
proposed to exacerbate the hypercoagulable phenotype of protein S deficiency [5]. 
We recently reported that plasma levels of protein S are markedly reduced, with median 
levels of only 16% of normal, in patients with acute liver failure [9]. Also, protein S levels 
were reported to be decreased in plasma from patients with cirrhosis [10,11]. Whether this 
decrease can be fully attributed to decreased synthesis, or whether protein S consumption 
also contributes is at present unclear. TFPI is not produced by the liver, but the microvascular 
endothelium is thought to be the principal source of TFPI [12]. Therefore, it has previously 
been proposed that patients with liver disease have normal plasma levels of TFPI. However, 
the literature is scarce and also conflicting. Increased TFPI levels have been described in 
patients with hepatic inflammatory diseases [13,14]. Also in those patients with acute liver 
failure, in whom we reported substantially decreased protein S levels, plasma levels of TFPI 
were substantially increased, by more than 2-fold, as compared to healthy controls [15]. In 
contrast, another study reported normal levels of the inhibitor in patients with advanced 
chronic hepatocellular disease [16]. In yet another study, patients with chronic hepatocellular 
disease appeared to have normal or elevated levels of TFPI, but patients with fatal hepatic 
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dysfunction had either low, normal, or high levels of TFPI [17]. Finally, one study has shown 
that the TFPI concentration decreases in advanced liver disease [18].
Although the literature is not consistent, several studies have shown normal or even increased 
levels of TFPI in patients with liver disease, despite a reduced plasma level of protein S. Thus, 
liver disease may be an exception to the rule that protein S deficiency is accompanied by TFPI 
deficiency. Here we studied protein S and TFPI levels in a well characterized cohort of patients 
with cirrhosis. In addition, we studied the functionality of the TFPI/protein S system in these 
patients by comparing thrombin generation profiles generated in plasma of cirrhotic patients 
to profiles generated in plasma from healthy individuals in the presence and absence of 
inhibitory antibodies to protein S or TFPI.
Patients and methods
Patients
Twenty-six adult patients with a previous clinical diagnosis of liver cirrhosis, who were under 
routine control for their disease by the Department of Hepatology of the University Medical 
Center Groningen (UMCG) or who were admitted to the Hepatology ward of the UMCG, were 
included in the study. The patients were classified according to the Child-Pugh classification 
[19]. Ten patients with Child’s A cirrhosis, ten patients with Child’s B cirrhosis, and six patients 
with Child’s C cirrhosis were studied. Exclusion criteria were documented history of congenital 
coagulation disorders, presence of active infection (<2 weeks), presence of acute liver failure, 
use of anticoagulant drugs in the past 10 days, pregnancy, human immunodeficiency virus 
(HIV) positivity, and recent (<7 days) transfusion with blood products.
The control group consisted of twenty adult healthy volunteers working at our institution. 
Exclusion criteria for the control group were documented history of congenital coagulation 
disorders, documented history of hepatic disease, recent viral infection (<2 weeks), use of 
anticoagulant drugs in the past 10 days, pregnancy, use of oral contraceptives, and HIV 
positivity.
This study was approved by the local medical ethical committee and informed consent was 
obtained from each subject before inclusion in the study.
Plasma samples
Blood samples from each patient and control were drawn by clean venepuncture and 
collected into vacuum tubes containing 0.129 mol/l trisodium citrate as an anticoagulant, at 
a blood to anticoagulant ratio of 9:1, and was stored at room temperature for a maximum of 
1 hour. Platelet-poor plasma (PPP) was prepared by double centrifugation at 2000 and 10 
000 g, respectively for 10 min at 18°C. Plasma was aliquoted, snap-frozen and stored at -80°C 
until use.
Thrombin generation-based assays for measurement 
of the activity of the TFPI-protein S system
Thrombin generation was determined using calibrated automated thrombography. Methods 
were based on the thrombin generation-based assays to measure the activity of the TFPI-
protein S system described by Maurissen et al. [8]. Plasma (68 µl) was incubated for 15 min 
at 37°C with 4 µl of corn trypsin inhibitor (CTI, 33 µg/ml final concentration; Hematologic 
Technologies, Essex Junction, VT, USA) and 8 µl of either HEPES-NaCl buffer (25 mmol/l 




HEPES, pH 7.4, 175 mmol/l NaCl), polyclonal antibodies to protein S (to a final concentration 
of 2.80 µmol/l; DakoCytomation, Glostrup, Denmark), or monoclonal antibodies to TFPI 
(to a final concentration of 0.66 µmol/l, MW1848; Sanquin, Amsterdam, The Netherlands). 
Coagulation was initiated with 20 µl PPP 5 pmol/l reagent (Thrombinoscope B.V., Maastricht, 
The Netherlands) diluted with 0.9% NaCl, to obtain a final concentration of 2.0 pmol/l TF 
and 1.6 µmol/l phospholipids in the reaction mixture. After addition of 20 µl of CaCl2 and 
fluorogenic substrate (Thrombinoscope B.V.), substrate conversion by thrombin was followed 
in a Fluoroskan Ascent reader (Thermo Labsystems, Helsinki, Finland) with 390 nm excitation 
and 460 nm emission filter sets. Peak heights of thrombin generation were calculated using 
software obtained from Thrombinoscope B.V. [20]. The TFPI cofactor activity of protein S was 
expressed as the ratio of thrombin peaks determined in the absence and presence of anti-
protein S antibodies (protein S ratio). Furthermore, the activity of the TFPI-protein S system 
was expressed as the ratio of thrombin peaks determined in the absence and presence of 
anti-TFPI antibodies (TFPI ratio).
Determination of factor levels in plasma
Total protein S antigen was assayed by enzyme-linked immunosorbent assay (ELISA) using 
antibodies from DAKO (Glostrup, Denmark). Free protein S was measured by precipitating 
the C4b-binding protein-bound fraction with polyethylene glycol 8000 and measuring the 
concentration of free protein S in the supernatant. Plasma TFPI levels were measured by ELISA 
as previously described [8]. Levels of protein S and TFPI were expressed as percentages of 
pooled normal plasma, which was obtained by combining plasma samples from >200 healthy 
volunteers.
Statistical analysis
Data are expressed as means (with standard deviations [SDs]), medians (with ranges), or 
numbers (with percentages) as appropriate. Means of two groups were compared by 
Student’s t-test or Mann–Whitney U-test as appropriate. Multiple groups were compared 
using one-way analysis of variance (ANOVA; with the Bonferroni post-test) or Kruskal–Wallis 
H-test (with Dunn’s post-test) as appropriate. Spearman’s correlation coefficient was used to 
assess correlation between continuous variables and Pearson chi-square or Fisher’s exact test 
with Pearson Correlation Coefficient for dichotomous variables. P-values of 0.05 or less were 
considered statistically significant. GRAPHPAD PRISM (San Diego, CA, USA) and IBM SPSS 
STATISTICS 20 (New York, NY, USA) were used for analyses.
Results
Patient characteristics
The main characteristics of the study population are reported in Table 1. Twenty-six patients 
with cirrhosis (14 males and 12 females; mean age 55 ± 11 years) were included and 
categorized according to the severity of liver disease as expressed by the Child Pugh score 
[19]. The most common aetiologies of cirrhosis were alcoholic disease and non-alcoholic 
steatohepatitis (NASH). Twenty healthy subjects (10 males and 10 females; mean age 35 ± 11 
years) were included as controls. None of the patients or controls used oral contraceptives or 
hormone replacement therapy.
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Plasma protein S and TFPI levels
Plasma TFPI levels were comparable between patients and controls (108 ± 27% in patients 
vs. 111 ± 38% in controls, P = 0.815; Table 2). In contrast, protein S levels were substantially 
decreased in patients (total Protein S: 74 ± 23% in patients vs. 98 ± 10% in controls, P < 0.001; 
free protein S: 83 ± 23% in patients vs. 103 ± 12% in controls, P = 0.0006), and the decrease 
in protein S levels was proportional to the severity of the disease (Table 2).
Table 1. Demographic and clinical characteristics of the study population
Data are expressed as number (%), mean [SD], or median [range]. 
HCV: Hepatitis C virus, NASH: Non-alcoholic steatohepatitis, PBC: Primary biliary cirrhosis, PSC: Primary sclerosing 
cholangitis, DM: Diabetes Mellitus, INR: International Normalized Ratio.
Thrombin generation
Plasma from cirrhotic patients and controls were incubated with CTI in the absence or 
presence of neutralizing antibodies to protein S or TFPI for 15 min at 37°C. Thrombin 
generation was then initiated with a low TF concentration (2.0 pmol/l). The median peak 
heights in the absence of antibodies were 25.7 [9.6–66.5] nmol/l (median [range]) in plasma 
from controls and 61.4 [3.2–132.7] nmol/l in plasma from patients (P = 0.01). Peak heights 
of thrombin generation without antibodies were significantly higher in Child class B (81.1 




	 Child	A	 Child	B	 Child	C	 	
	 n=10	 n=10	 n=6	 	
Characteristic	
Age	(yrs)	 55	[20-72]	 54	[41-61]	 58	[53-68]	 .497	
Sex	(male)	 5	(50)	 5	(50)	 4	(67)	 .781	
BMI	 26.0	[5.3]	 28.9	[6.0]	 30.5	[6.9]	 .320	
Smoking	 4	(40)	 2	(20)	 2	(33.3)	 .668	
Alcohol	(U	per	week)	 0	[0-10]	 0	[0-7]	 0	[0-130]	 .408	
Aetiology	of	liver	disease:	
		Alcoholic	 3	(30)	 2	(20)	 6	(100)	 .005	
		HCV	 0	(0)	 1	(10)	 0	(0)	 1.000	
		NASH	 2	(20)	 2	(20)	 0	(0)	 .639	
		Hemochromatosis	 0	(0)	 2	(20)	 0	(0)	 .323	
		PBC	 1	(10)	 0	(0)	 0	(0)	 1.000	
		PSC	 0	(0)	 1	(10)	 0	(0)	 1.000	
		Auto-immune	 1	(10)	 1	(10)	 0	(0)	 1.000	
		Wilson’s	disease	 1	(10)	 0	(0)	 0	(0)	 1.000	
		Alcoholic	+	NASH	 0	(0)	 1	(10)	 0	(0)	 1.000	
		Alcoholic	+	HCV	 1	(10)	 0	(0)	 0	(0)	 1.000	
		Hemochromatosis	+	NASH	 1	(10)	 0	(0)	 0	(0)	 1.000	
Co-morbidity:	
		Cardiovascular	 4	(40)	 2	(20)	 0	(0)	 .258	
		DM	 4	(40)	 1	(10)	 0	(0)	 .227	
Plasma	levels:	
		Serum	bilirubin	(µmol/L)	 10	[4-26]	 40	[18-121]	 93	[63-255]	 .0001	
		Serum	albumin	(g/L)	 42.7	[3.9]	 33.1	[4.8]	 27.2	[2.6]	 <.0001	
		Serum	creatinin	(µmol/L)	 62.4	[19.2]	 72.8	[32.3]	 86.7	[18.5]	 .193	
		Haemoglobin	(mmol/L)	 8.7	[0.6]	 7.2	[0.9]	 6.3	[0.8]	 <.0001	
		Leukocytes	(109/L)	 6.9	[2.7]	 4.9	[2.1]	 6.5	[3.7]	 .238	
		Platelets	(109/L)	 134	[49-321]	 71	[28-471]	 73	[48-114]	 .084	
INR	 1.1	[0.1]	 1.3	[0.2]	 1.6	[0.2]	 <.0001	
Data	are	expressed	as	number	(%),	mean	[SD],	or	median	[range].		
HCV:	Hepatitis	C	virus,	NASH:	Non-al oholic	steatohepatiti ,	PBC:	Prim ry	biliary	cirrhosis,	PSC:	Primary	
sclerosing	cholangitis,	DM:	Diabetes	Mellitus,	INR:	International	Normalized	Ratio.	
	 	




to healthy controls (P = 0.04 and P = 0.007 respectively). Addition of antibodies to protein 
S increased the thrombin peaks to 78.1 [41.2–147.4] nmol/l in controls and to 97.7 [34.8–
188.6] nmol/l in patients (P = 0.203; Table 2; Fig 1). Furthermore, in the presence of protein 
S antibodies, average peak heights were no longer significantly higher in the Child class B 
and C cirrhotic patients compared to controls (Table 2), suggesting that decreased protein 
S levels in cirrhotic patients explain the difference in thrombin generation between cirrhotic 
Child class B and C patients and healthy controls. Complete inhibition of the TFPI-protein 
S system was achieved through addition of inhibitory antibodies against TFPI, resulting in 
further increases of peak heights to 128.2 [90.4–202.2] nmol/l in controls and 116.2 [59.4–
197.7] nmol/l in patients (Table 2; Fig 1).
Figure 1. Effects of anti-protein S and anti-tissue factor pathway inhibitor (TFPI) antibodies on thrombin generation at a 
low tissue factor concentration (2.0 pmol/l). Average of (A) 20 separate thrombin generation curves in plasma of healthy 
controls and (B) 26 separate thrombin generation curves in plasma of patients with cirrhosis, without addition of antibodies 
(dotted line), with anti-protein S antibodies (dashed line) or with anti-TFPI antibodies (solid line).
The anticoagulant activities of protein S and TFPI were expressed as the ratio of peak heights 
obtained in the absence and presence of the respective inhibitory antibodies. The median 
protein S ratios were 0.32 and 0.62 in controls and patients respectively. In other words, 
protein S, via its TFPI cofactor activity, reduced thrombin generation by approximately 68% 
in controls and by 38% in patients. The median TFPI ratios were 0.18 and 0.55, respectively, 
indicating that the TFPI-protein S system as a whole reduced thrombin generation by 
approximately 82% in controls and by 45% in patients. Both protein S and TFPI ratios were 
significantly increased in patients compared to controls, P = 0.03 and P = 0.009, respectively 
(Fig 2). In particular in Child class B and C patients, both ratios were markedly increased 
compared to controls (Table 2).
Figure 2. Functional tissue factor pathway inhibitor (TFPI)–protein S assays in controls and in patients with Child A, B, or 
C cirrhosis. (A) Protein S ratio in plasma from controls and patients. (B) TFPI ratio in plasma from controls and patients.
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Interestingly, peak thrombin generation in the absence of inhibitory antibodies (basal peak 
thrombin generation) was strongly correlated to protein S ratios, both in patients and controls 
(r = 0.88; P < 0.0001 and r = 0.82, P < 0.0001 respectively). This positive correlation was also 
observed between basal peak thrombin generation in plasma and TFPI ratios (r = 0.92; P < 
0.0001 and r = 0.87, P < 0.0001, respectively; Fig 3).
Figure 3. Correlation between basal peak thrombin generation (nmol/l) and (A) protein S ratio and (B) TFPI ratio, in plasma 
from 20 healthy individuals (●) and 26 patients with cirrhosis (●).
Furthermore, plasma protein S levels strongly correlated with the protein S ratio in patients 
(r = -0.66, P = 0.0002; Fig 4). Plasma protein S levels were also correlated with the TFPI ratio 
in both patients (r = -0.76, P < 0.0001) and controls (r = -0.51, P = 0.02; Fig 4). Free plasma 
protein S levels also correlated with both the protein S ratio (r = -0.41, P = 0.04) and the TFPI 
ratio (r = -0.48, P = 0.01) in patients. In addition, plasma TFPI levels strongly correlated with 
the TFPI ratios in both patients (r = -0.67, P < 0.0001) and controls (r = -0.75, P = 0.0001; Fig 5). 
No correlation between plasma TFPI levels and protein S ratios was observed in both patients 
and controls.
Figure 4. Correlations between total protein S levels and (A) protein S ratio and (B) TFPI ratio, in plasma from 20 healthy 
individuals (●) and 26 patients with cirrhosis (●).
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Figure 5. Correlations between tissue factor pathway inhibitor 
(TFPI) levels and TFPI ratio in plasma from 20 healthy individuals 
(●) and 26 patients with cirrhosis (●).
Table 2. Tissue factor pathway inhibitor (TFPI)–protein S parameters in cirrhotic patients and controls. Data are expressed 
as mean [SD] or median [range]. *P < 0.05; **P < 0.01.







Peak	height	(nmol/l)	 25.7	[9.6-66.5]	 26.2	[5.0-77.1]	 81.1	[3.2-132.7]*	 81.0	[48.8-116.5]**	
Peak	height	
	+	α-protein	S	(nmol/l)	
78.1	[41.2-147.4]	 76.5	[34.8-116.2]	 112.5	[36.9-188.6]	 116.9	[78.6-152.5]	
Peak	height		
+	α-TFPI	(nmol/l)	
128.2	[90.4-202.2]	 108.7	[82.9-146.5]	 119.6	[59.4-197.7]	 122.6	[83.4-177.0]	
Protein	S	ratio	 0.32	[0.20-0.54]	 0.28	[0.13-0.66]	 0.69	[0.08-0.90]	 0.82	[0.32-0.93]*	
TFPI	ratio	 0.18	[0.11-0.49]	 0.19	[0.06-0.58]	 0.68	[0.05-0.84]	 0.79	[0.28-0.90]**	
TFPI	(%)	 108.1	[27.1]	 121.5	[32.1]	 96.2	[46.2]	 116.0	[26.5]	
Protein	S	total	(%)	 98.4	[9.9]	 90.2	[24.9]	 65.9	[19.1]**	 62.2	[12.3]**	
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Discussion
Protein S and TFPI act together in down-regulating thrombin formation [4] and it has been 
shown that both hereditary and acquired protein S deficiency states are accompanied by 
a partial deficiency of full-length TFPI [5]. However, we show that in patients with cirrhosis 
the acquired protein S deficiency is not accompanied by a decrease in TFPI plasma levels. 
Furthermore, patients with cirrhosis showed a reduced activity of the TFPI-protein S system 
when compared to healthy controls.
Despite the substantial decrease in protein S plasma levels in cirrhotic patients, TFPI levels are 
comparable between patients and controls. In addition, we have previously shown increased 
TFPI levels despite substantially decreased protein S levels in patients with acute liver failure 
[15]. This indicates that the decrease in TFPI levels in conjunction with acquired protein S 
deficiency as described previously [5] does not occur in patients with liver diseases.
A possible explanation for normal TFPI levels in patients with liver diseases despite decreased 
plasma levels of protein S may be that TFPI release in these patients is substantially increased 
compared to that in healthy individuals, but that this increased TFPI release is masked, in part, 
by the protein S deficiency. In both chronic and acute liver diseases, continuous activation 
of the endothelium is common, resulting in increased plasma levels of endothelial-derived 
proteins, such as von Willebrand factor [21,22]. The combination of continuous endothelial 
cell activation and protein S deficiency may thus result in normal to slightly elevated TFPI 
levels. Endothelial activation was probably absent in the acquired protein S deficiencies 
studied by Castoldi et al (use of oral contraceptives or vitamin K antagonists) [5], explaining 
the divergent results between our study and the published data.
Protein S and TFPI levels are significantly lower in females than in males [8,23]. In this study 
there were slightly more males in the patient group (14 males and 12 females) than in the 
control group (10 males and 10 females). However, this could not explain the differences in 
protein S levels between patients (with lower protein S levels) and controls observed here. 
Furthermore, the mean age in the patient group was substantially higher than in the control 
group. However, levels of TFPI are hardly influenced by age [7] and only in females does total 
protein S levels increase with increasing age [23] which is unlikely to explain the decreased 
protein S levels in the (older) patients compared to the (younger) controls observed here.
The decreased TFPI-dependent anticoagulant capacity in patients with cirrhosis resulted in 
an increased thrombin generation as compared to controls. The difference in peak thrombin 
generation between patients and controls largely disappeared upon addition of anti-protein 
S antibodies, indicating that the low protein S levels were responsible for the impairment of 
the TFPI–protein S system in the patients with cirrhosis.
We have previously proposed that the haemostatic system in patients with liver disease 
is in a ‘rebalanced’ status due to a concomitant decrease in pro- and anticoagulants [24]. 
Furthermore, we proposed the rebalanced haemostatic status of patients with liver disease to 
be unstable, resulting in a propensity to switch to both a hypo- and hypercoagulable status. 
The experiments performed in this study suggest that the haemostatic status of a patient 
with liver disease also depends on the strength of the initiating trigger. At the suboptimal 
concentrations of TF and lipids used in this study, thrombin generation profiles in healthy 
individuals are clearly marginal (Fig 1A), and plasma from patients with cirrhosis clearly 




generate more thrombin compared to that in healthy volunteers (Fig 1B). This hypercoagulable 
phenotype was much less pronounced when thrombin generation in the same patients was 
tested using a high TF trigger (data not shown).
The observed increased peak thrombin generation in this study is in line with the clinical 
observation of thrombotic complications in patients with cirrhosis. Several studies have 
shown an increased risk of venous thromboembolism (VTE) in patients with cirrhosis [25-27]. 
Portal vein thrombosis forms another frequently occurring venous thrombosis in patients with 
cirrhosis [28]. These thrombotic complications cause increasing morbidity and mortality. The 
increase in factor VIII in combination with decreased protein C is proposed to be responsible 
for the hypercoagulable status in patients with chronic liver disease [29]. However, in the 
current study we have shown that the impaired activity of the TFPI-protein S system in 
patients with cirrhosis may also contribute to this hypercoagulable state, especially at a 
low TF concentration. Thus, the increased risk of thrombotic complications, such as venous 
thrombosis and portal vein thrombosis, which are probably not associated with massive 
exposure of TF, may be explained by the decreased TFPI-dependent anticoagulant capacity 
in patients with cirrhosis.
In conclusion, the acquired protein S deficiency in patients with cirrhosis is not associated 
with a decrease in TFPI plasma levels. Despite normal TFPI plasma levels, the TFPI/protein S 
anticoagulant system is functionally impaired in patients with cirrhosis, which may contribute 
to thrombotic complications.
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Abstract
Introduction: Patients with cirrhosis have substantial alterations in their hemostatic 
system, which are paradoxically associated with the risk of both bleeding and thrombotic 
complications. However, it still remains difficult to predict those risks, because results from 
conventional coagulation tests, such as the prothrombin time (PT) and activated partial 
thromboplastin time (APTT), do not reflect the complex hemostatic changes in these patients. 
More sophisticated global hemostasis tests, such as thrombin generation assays, are not 
standardized for routine use yet. Here we examined the spatial clot growth in plasma from 
patients with cirrhosis using the novel Thrombodynamics assay, which uses a fundamentally 
new approach to test plasma hemostatic capacity.
Materials and Methods: Thrombodynamics assays were performed in plasma from thirty-one 
patients with cirrhosis and twenty-five healthy controls. Results were compared to results with 
thrombin generation testing and PT/APTT test results.
Results: Rates of clot growth, clot size, and clot density from the Thrombodynamics assay 
were comparable between patients and controls. Thrombin generation in the presence of 
thrombomodulin was increased in the patients, despite prolonged PT and APTT test results. 
There was little correlation between parameters derived from the Thrombodynamics assay 
and the PT, APTT, or thrombin generation data.
Conclusions: The Thrombodynamics assay showed preserved clot formation in plasma from 
patients with cirrhosis, which is in line with the results of the thrombin generation assay in this 
study and previously reported by others.





Conventional coagulations tests, such as the prothrombin time (PT) and activated partial 
thromboplastin time (APTT), are frequently prolonged in patients with cirrhosis suggesting 
a hypocoagulable state [1]. Traditionally, these findings have been considered as pointing 
towards a bleeding tendency in patients with a chronic liver disease. However, these 
coagulation tests are only sensitive for selected procoagulant factors and do not take the 
reduction in anticoagulant factors, which also occurs in these patients, into account. In fact, 
the hemostatic system in patients with a chronic liver disease is nowadays considered to be 
rebalanced [2]. However, this balance is more unstable compared to that in healthy individuals 
and there is thus a frequent clinical need for predicting the risk of bleeding or thrombosis in 
patients with a liver disease [2,3].
In contrast to the conventional coagulation tests, the thrombin generation test in the presence 
of thrombomodulin, the main activator of protein C, is sensitive to all anticoagulant systems 
in plasma and thus measures the true balance between the pro- and anticoagulant proteins. 
This test has shown normal to even increased thrombin generation in patients with a chronic 
liver disease [4–8]. However, the thrombin generation assay is not widely available yet. The 
test is currently too complicated for routine use in diagnostics laboratories, and the addition 
of thrombomodulin is not yet standardized.
Recently a new plasma-based global hemostasis assay, Thrombodynamics, has been 
developed that allows a continuous monitoring of clot growth in non-stirred plasma initiated 
by a thin layer of immobilized tissue factor (TF) [9,10]. This assay was designed to better 
mimic the in vivo conditions of clot formation by taking into account both the biochemical 
reactions of the coagulation cascade and the spatial aspects of clot formation. Indeed, while 
in other coagulation tests (e.g. PT and thrombin generation) clotting is activated by TF that 
is homogenously distributed over the plasma sample, in this test only a thin layer of plasma 
is exposed to TF and clot formation starts on this surface and propagates into the bulk of 
plasma. This spatial clot growth assay previously showed defective clot formation (with 
lower rate of clot growth and thinner clots) in both patients with hemophilia A and B [11]. In 
addition, another study showed that spatial clot growth in plasma can be used to predict an 
increase in D-dimer levels in sepsis patients [9]. Furthermore, the test was useful for detecting 
procoagulant changes caused by an aptamer antagonist of tissue factor pathway inhibitor 
[10], recombinant factor VIIa [12], or platelet microparticles [13].
Here we aimed to examine the spatial clot growth in plasma from patients with a chronic 
liver disease using the novel Thrombodynamics assay and compared results with thrombin 
generation testing and PT/APTT test results.
Materials and Methods
Patients
Thirty-one adult patients with cirrhosis, who were seen on an outpatient basis or were 
admitted to the department of Hepatology of the University Medical Center Groningen, were 
included in the study. Patients were classified according to the Child-Pugh classification [14]. 
Eleven patients were classified as Child A, ten patients as Child B, and ten patients as Child 
C cirrhosis. Exclusion criteria were documented history of congenital coagulation disorders, 
presence of active infection (<2 weeks), presence of acute liver failure, use of anticoagulant 
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drugs in the past 10 days, pregnancy, human immunodeficiency virus (HIV) positivity, and 
recent (<7 days) transfusion with blood products.
Twenty-five healthy volunteers working at our institute were included as controls. Exclusion 
criteria for the control group were a documented history of congenital coagulation disorders, 
documented history of hepatic disease, recent viral infection (<2 weeks), use of anticoagulant 
drugs in the past 10 days, pregnancy, and HIV positivity.
The study protocol was approved by the medical ethical committee of the University Medical 
Center Groningen, Groningen, The Netherlands and written informed consent was obtained 
from each subject before inclusion in the study.
Plasma Samples
Blood samples from each patient and control were drawn by venipuncture and collected 
into vacuum tubes containing 3.8% trisodium citrate as an anticoagulant, at a blood to 
anticoagulant ratio of 9:1. Platelet poor plasma was prepared by double centrifugation at 
2000 g and 10.000 g respectively for 10 min. Plasma was snap-frozen in liquid nitrogen and 
stored at -80 °C until use.
Thrombodynamics Assay
The general concept of the Thrombodynamics test was previously described by others 
[9,10,15,16]. Briefly, in a thin layer of plasma coagulation is activated when it is brought in 
contact with tissue factor (TF) immobilized on a plastic surface. The clot formation starts on 
the activator and propagates into the bulk of plasma in which no TF is present. Light scattering 
by fibrin allows observation of spatial clot formation in real time by using time lapse imaging 
[17].
In this study, the Thrombodynamics assay was performed using an experimental device 
provided by HemaCore LLC (Moscow, Russia). Reagents (Thrombodynamics kit, Hemacore 
LLC, Mosow, Russia) and protocols from the manufacturer were used. According to these 
instructions, plasma was pre-treated with Corn Trypsin Inhibitor for 10minutes at 37 degrees 
Celcius prior to initiation of the assay. The following parameters were analyzed: lag time, 
initial and stationary rates of cloth growth, clot density, and clot size at 30minutes. The lag 
time is defined as the time between clotting initiation and actual appearance of the fibrin clot. 
The initial rate of clot growth (Vi) is the slope of the curve on a clot vs. time graph during the 
first 2-6 minutes of cloth growth. Stationary rate of clot growth (Vst) is measured as a slope 
of the curve on a clot size vs. time graph within the interval 15–25 minutes after clot growth 
begins.
Coagulation Tests
Thrombin generation testing was performed using platelet-poor plasma (PPP) with the 
fluorimetric method described by Hemker, Calibrated Automated Thrombography® (CAT) 
[18]. Reagents and protocols were purchased from Thrombinoscope BV, Maastricht, The 
Netherlands. Coagulation was activated using commercially available reagents containing 
recombinant TF (final concentration 5 pM), phospholipids (final concentration 4 mM), in 
absence or presence of soluble thrombomodulin. To calibrate the thrombin generation 
curves, Thrombin Calibrator (Thrombinoscope BV) was added, and a fluorogenic substrate 




with CaCl2 (FluCa-kit, Thrombinoscope BV, Maastricht, The Netherlands) was used to allow 
a continuous registration of thrombin generation. Fluorescence was read in time by a 
fluorometer, Fluoroskan Ascent® (ThermoFisher Scientific, Helsinki, Finland).
The PT, APTT, and fibrinogen levels were assessed on an automated coagulation analyzer 
(ACL 500 TOP) with reagents (Recombiplastin 2G for PT, SynthaSil for APTT, and QFA thrombin 
(Hemosil) for fibrinogen) and protocols from the manufacturer (Instrumentation Laboratory, 
Breda, the Netherlands).
Statistical Analysis
Data are expressed as means (with standard deviations (SDs)), medians (with interquartile 
ranges), or numbers (with percentages) as appropriate. Means of two groups were compared 
by Student’s t-test or distributions in the two groups by Mann-Whitney U test as appropriate. 
Multiple groups were compared using one-way ANOVA (with the Bonferroni post test) or 
Kruskal-Wallis H test (with Dunn’s post test) as appropriate. Spearman’s correlation coefficient 
was used to assess correlation between continuous variables. P values of 0.05 or less were 
considered statistically significant. GraphPad Prism (San Diego, USA) and IBM SPSS Statistics 
20 (New York, USA)) were used for analyses.
Results
Patient Characteristics
The main characteristics of the study population are presented in Table 1. Thirty-one patients 
with cirrhosis (20 males and 11 females) were included, and they were categorized according 
to the severity of liver disease as expressed by the Child Pugh classes (11 Child A, 10 Child 
B and 10 Child C patients). Twenty-five healthy subjects (10 males and 15 females) with a 
mean age of 33.9 ± 11.1 (mean ± SD) were included as controls. The most common etiology 
of liver disease was alcoholic, especially in the Child class C patients. Three healthy subjects 
and none of the patients used oral contraceptives (P=0.08).None of the healthy subjects and 
three patients used antiplatelet agents or nonsteroidal anti-inflammatory drugs (two used 
carbasalate calcium and one used naproxen) (P= 0.25).
Thrombodynamics Assay
The results of the Thrombodynamics test in the plasma from patients and controls are 
presented in Table 2 and Figure 1. The lag time was slightly, but significantly prolonged in the 
patients compared to the controls (P = 0.025). Vi was significantly increased in the Child class 
C patients (63.7 μm/min (59.4-68.6) (median with range)) compared to controls (57.0 μm/min 
(50.0-63.4); P < 0.01). However, the Vst was comparable between patients and controls. Clot 
size was also comparable between patients and controls. Finally, clot density was decreased 
in the Child class C patients (8093 arbitrary units (a.u.) (4712-10923)) compared to controls 
(11228 a.u. (6181-20868); P < 0.01).
Correlations Between Thrombodynamics Results and Other Coagulation Tests
There was no significant correlation between the Thrombodynamics data and the PT, APTT, or 
thrombin generation data in the controls. The PT was significantly prolonged in the patients 
(12.8 s (9.8-23.8)) compared to the controls (10.8 s (9.9-12.1); P < 0.0001), especially in the 
Child class B and C patients (Table 2). There was a significant negative correlation between 
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the PT and the clot density of the Thrombodynamics test in the patients (r = -0.72; P < 0.001). 
Furthermore, the Vi of the Thrombodynamics test showed a positive correlation with the 
PT (r = 0.53; P = 0.002). The APTT was also significantly prolonged in the patients (38.7 s 
(33.3-48.7)) compared to the controls (33.4 s (27.6-39.1), P < 0.0001). There was a significant 
negative correlation between the APTT and the clot density of the Thrombodynamics test in 
the patients (r= -0.51; P = 0.004).
The endogenous thrombin potential (ETP) was decreased in the patients compared to the 
controls (Table 2). However, in the presence of thrombomodulin, the ETP was increased 
in the patients (616.4 nM*min (144.6-1046.7)) compared to the controls (355.4 nM*min 
(168.3-1251.4); P = 0.003), especially in the Child class C patients (Table 2). Peak thrombin 
generation was also increased in the patients compared to the controls in the presence of 
thrombomodulin (Table 2). In the patients, both ETP and peak thrombin generation showed 
a significant negative correlation with clot density (r= -0.61; P=0.0002 for ETP and r=-0.46; 
P=0.01 for peak) and a positive correlation with Vi of the Thrombodynamics test (r= 0.48; P = 
0.006 for ETP and r = 0.43; P = 0.02 for peak). 
Table 1. Clinical and demographic characteristics of the study population.
Data are expressed as number (%), mean [SD], or median [range]. NSAIDs: Nonsteroidal anti-inflammatory 




	 Child	A	 Child	B	 Child	C	
	 n=11	 n=10	 n=10	 	
Characteristics	
MELD	score	 7	[6-10]	 11	[7-18]	 17	[13-25]	 <.0001	
Age	(years)	 61.0	[11.4]	 49.0	[12.5]	 52.2	[7.5]	 .042	








Smoking	 4	(36.4)	 2	(20)	 4	(40)	 .705	
Alcohol	(U	per	week)	 0	[0-1]	 0	[0-7]	 0	[0-490]	 .638	
History	of	variceal	bleeding	
(number	of	patients)	
3	(27.3)	 2	(20)	 1	(10)	 .849	
History	of	portal	vein	thrombosis	
(number	of	patients)	
0	(0)	 0	(0)	 2	(20)	 .194	
Etiology	of	liver	disease	
		Alcoholic	 4	(36.4)	 2	(20)	 9	(90)	 .005	
		HCV	 1	(9.1)	 1	(10)	 0	(0)	 1.000	
		NASH	 2	(18.2)	 2	(20)	 0	(0)	 .511	
		Hemochromatosis	 0	(0)	 1	(10)	 0	(0)	 0.645	
		PSC	 1	(9.1)	 2	(20)	 0	(0)	 .511	
		Auto-immune	 2	(18.2)	 0	(0)	 0	(0)	 .312	
		Alcoholic	+	NASH	 0	(0)	 1	(10)	 0	(0)	 0.645	
		Alcoholic	+	HCV	 1	(9.1)	 0	(0)	 0	(0)	 1.000	
		Unknown	 0	(0)	 1	(10)	 1	(10)	 .527	
Plasma	levels	
		Serum	bilirubin	(µmol/L)	 13	[4-26]	 29	[18-61]	 82	[36-121]	 <.0001	
		Serum	albumin	(g/L)	 42	[28-58]	 33	[29-63]	 26	[24-29]	 <.0001	
		Serum	creatinin	(µmol/L)	 67	[25]	 77	[30]	 69	[28]	 .655	
		Hemoglobin	(mmol/L)	 8.4	[1.1]	 7.3	[0.9]	 6.4	[0.9]	 .0005	
		Leukocytes	(109/L)	 4.6	[3.4-10.4]	 5.1	[2.1-8.7]	 6.0	[3.4-19.1]	 .601	
		Platelets	(109/L)	 128	[77-274]	 90	[28-471]	 79	[44-165]	 .118	










In addition, the lag time of the thrombin generation assay showed a significant positive 
correlation with the clot density of the Thrombodynamics assay (r = 0.47; P = 0.007), and the 
velocity index of the thrombin generation correlated with the clot density (r = -0.45; P = 0.01) 
as well as the Vi of the Thrombodynamics test (r= 0.45; P = 0.01). Finally, fibrinogen levels 
strongly correlated with the clot density of the Thrombodynamics test in the patients (r= 0.97; 
P < 0.0001).
Discussion
This study shows preserved clot formation in plasma from patients with cirrhosis using the 
novel Thrombodynamics assay. These results are in line with the results of previous studies 
using the thrombin generation in the presence of thrombomodulin, which demonstrated 
normal to increased thrombin generation in patients with a chronic liver disease [4,6,7]. Also 
in this study we observed increased thrombin generation in patients with cirrhosis when 
thrombomodulin was added to the plasma. 
Although overall the Thrombodynamics assay showed comparable test results between 
patients and controls, in patients with Child C cirrhosis both hyper- and hypocoagulable 
features were present, with an increase in initial rate of clot growth and decrease in clot 
density, respectively. The decrease in clot density might be partially explained by a decrease 
in fibrinogen in patients with severe cirrhosis [19,20]. Patients with, especially severe, cirrhosis 
may thus have a precarious rebalanced hemostasis, explaining the risk of both bleeding and 
thrombotic complications [3,21].
Despite the fact that both the Thrombodynamics assay and the thrombomodulin-modified 
thrombin generation assay showed similar results in patients with cirrhosis, correlation 
between test results was poor. Especially in the controls, we observed no significant correlation 
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    Figure 1. Thrombodynamics 
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C: stationary rate of clot growth 
(Vst), D: clot size, and E: clot 
density. *P < 0.05 compared to 
controls.
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between any of the Thrombodynamics data and the PT, APTT, or thrombin generation data. This 
may be explained by the fact that this novel Thrombodynamics assay uses a fundamentally 
different principle to assess the coagulation cascade than both the thrombin generation 
assay and the conventional coagulation tests. Whereas in these tests clotting is activated by 
homogeneously dissolved TF, in the Thrombodynamics test clotting is activated by a surface 
with immobilized TF, which better resembles in vivo clot formation. The correlations observed 
between Thrombodynamics test results and PT, APTT, or thrombin generation test results in 
patients were confusing and conflicting. For example, the negative correlation between the PT 
and clot density is not in line with the negative correlation between the ETP and clot density. Also 
the positive correlation between the PT and the initial rate of clot growth is difficult to explain.
The preserved clot formation in plasma from patients with cirrhosis observed with the 
novel Thrombodynamics assay in this study together with similar conclusions drawn from 
thrombomodulin-modified thrombin generation tests supports the notion that hemostasis 
in cirrhosis is rebalanced and even has hypercoagulable features [2,19,21]. The clinical 
consequences of this include a restrictive use of prophylactic prohemostatic agents in patients 
undergoing invasive procedures [3,22]. Furthermore, routine thrombosis prophylaxis should 
Table 2. PT, APTT, Thrombodynamics, and thrombin generation data in patients with cirrhosis and 
healthy subjects. Data are expressed as mean [SD] or median [range]. *P<0.05; **P<0.01; ***P<0.001 
versus controls. PT: prothrombin time, APTT: activated partial thromboplastin time, Vi: initial rate of clot 




































Vst	(umol/min)	 33.6	[5.0]	 33.3	[5.6]	 32.9	[4.3]	 30.2	[5.1]	 36.8	[6.5]	














































































Lag	time	 1.7	[1.3-2.7]	 1.4	[1.1-3.7]	 1.8	[1.4-3.7]	 1.5	[1.3-2.0]	 1.3	[1.1-
1.6]***	












not be withheld in these patients, even though routine coagulation tests are abnormal and 
prolonged [3,23].
Since patients with cirrhosis can suffer from both thrombotic and bleeding complications, 
there is a frequent clinical need for predicting the risk of bleeding or thrombotic events before, 
during, or after procedures in these patients. Currently, two tests may be useful in assessing 
overall hemostasis, thrombin generation assays and thromboelastography. However, the 
thrombin generation test is not widely available, the addition of thrombomodulin is not 
standardized yet, and currently the test is too complicated for routine use in diagnostic 
laboratories [3,24]. Thromboelastography also has some major drawbacks, including its 
unique set of pre-analytic and analytic variables that impact test reliability and reproducibility. In 
addition, thromboelastography does not allow quantification of the contribution of individual 
components of the hemostatic system to abnormalities in the thromboelastographic tracing. 
Finally, there are various methods to perform the test and these results poorly correlate [25–
27]. 
The Thrombodynamics assay is a global coagulation assay with a fundamentally new test 
principle. Given the stability of the assay, provided a strict blood processing protocol 
is followed, this test may have merit in the clinical setting [17]. It may hold promise in the 
prediction of bleeding or thrombotic risk in patients with a chronic liver disease, which awaits 
clinical validation studies.
In conclusion, we observed preserved clot formation in plasma from patients with cirrhosis using 
the novel Thrombodynamics assay, which is in line with the results of the thrombin generation 
assay in this study and previously reported by others [4,6,7]. The Thrombodynamics assay may 
be promising in assessing the hemostatic imbalance in patients with liver diseases, as it uses a 
fundamentally different principle to measure the coagulation than the other coagulation tests, 
which may better resemble the in vivo clot formation. However, future studies are needed 
to assess the clinical value of the test in predicting hemostatic abnormalities and to further 
standardize it for routine use.
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Abstract
Background: Conventional coagulation tests are frequently prolonged after liver surgery, 
suggesting a post-operative hypocoagulability. However, these tests are unreliable for 
assessment of the haemostatic status in these patients. In contrast, thrombin generation 
testing measures the true balance between pro- and anti-coagulant factors.
Aim: To study the perioperative coagulation status in patients undergoing hemi-hepatectomy 
using thrombin generation assays.
Methods: We examined thrombin generation profiles in serial plasma samples taken from 
seventeen patients undergoing right hemi-hepatectomy. Results were compared to ten 
patients undergoing pancreatic resection and twenty-four healthy volunteers. In addition, we 
measured conventional coagulation tests and plasma levels of several haemostatic proteins.
Results: Following liver resection, the endogenous thrombin potential (ETP) slightly decreased 
until post-operative day 7. However, in the presence of thrombomodulin, the ETP increased 
[from 542 nM*min (417–694) at baseline to 845 nM*min (789–1050) on post-operative day 
3] to values higher than that in healthy subjects (558 nM*min (390–680); P < 0.001), which 
contrasts with substantially prolonged PT levels. Normal to decreased thrombin generation 
was observed following pancreatic resection. Thrombin generation was only slightly affected 
by thrombomodulin after hemi-hepatectomy, while thrombin generation in healthy subjects 
decreased profoundly upon addition of thrombomodulin. This hypercoagulability following 
liver resection may be explained by decreased levels of protein C, S, and antithrombin and 
by elevated levels of factor VIII.
Conclusions: Thrombin generation in the presence of thrombomodulin revealed 
hypercoagulability in patients following liver resection. These results support the recently 
advocated restrictive use of plasma during liver resection and the exploration of more 
extensive use of post-operative thrombosis prophylaxis.





Major abdominal surgery is associated with a post-operative hypercoagulable state and this 
hypercoagulability has been recognised as a factor that contributes to the occurrence of 
thromboembolic complications, such as deep vein thrombosis and pulmonary embolism [1]. 
The underlying mechanisms include increased activation of platelets, reduced concentrations 
of anti-coagulants, and impaired fibrinolysis [2], as well as more general risk factors for 
thrombosis, such as immobilisation, tissue damage and the presence of cancer.
Conventional coagulation tests, such as the activated partial thromboplastin time (APTT), and 
the prothrombin time (PT) and related international normalised ratio (INR), are frequently 
elevated after liver surgery [3–6], suggesting a post-operative hypocoagulability. These tests 
are, however, not reliable for assessment of the overall haemostatic status in these patients, 
because they only evaluate narrow aspects of haemostasis. Specifically these tests are only 
sensitive for circulating levels of pro-coagulant factors, and do not test functionality of the 
natural anti-coagulant systems. Indeed, venous thromboembolism also occurs after liver 
surgery and, in fact, the risk increases with the extent of hepatectomy [7, 8]. The thrombotic 
risk after liver resection may result from a hypercoagulable state induced by extensive tissue 
injury or reduction in anti-coagulant factors determined by increased consumption, blood 
loss or haemodilution [9–13]. Despite this, elevation of routine coagulation tests (PT, APTT) 
following liver resection frequently leads to transfusion of fresh frozen plasma (FFP) [14–16]. 
However, several serious side effects of blood product transfusion may occur, including 
the risk of infection and the risk of transfusion-related acute lung injury [17]. In addition, 
elevation of routine coagulation tests often leads clinicians to delay thrombosis prophylaxis, 
based on the assumption that the patient is ‘auto-anticoagulated’. This potentially increases 
the risk of deep vein thrombosis and pulmonary embolism in these patients [7, 18]. Using 
thromboelastography (TEG), which analyses all components of the haemostatic system, it was 
shown that after living donor liver transplantation the majority of donors were hypercoagulable 
in spite of elevated routine coagulation tests [10]. Also patients undergoing partial liver 
resection for malignant disease demonstrated a brief hypercoagulable state, followed by 
normal clot formation as shown byTEG [5, 19], and yet another study using TEG reported 
normocoagulability after liver resection [6].
Thromboelastography is routinely used for guiding transfusion of blood products during 
massive bleeding and liver transplantation by many centres [20, 21]. However, it is still 
uncertain if thromboelastography-guided transfusion strategies improve outcome in 
patients with massive bleeding [22], or decrease blood loss during liver transplantation [23]. 
Furthermore, although thromboelastography assesses the haemostatic status in a whole 
blood environment, the technique has three major drawbacks. (1) There are multiple ways to 
perform a thromboelastographic analysis. Specifically, tests with non-anticoagulated blood as 
well as with citrated blood are widely used, and the results from these various methods poorly 
correlate [24]. When using citrated blood, various triggers are added to initiate coagulation 
(tissue factor/kaolin). 
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Furthermore, two devices (TEG and ROTEM) are used clinically, and results from these methods 
are also not always in accordance [25,26]. (2) Quantification of the contribution of individual 
components of the haemostatic system to abnormalities in the thromboelastographic tracing 
is not possible, although it has been demonstrated that alterations in some components 
of the traces are dominated by platelets, coagulation or fibrinogen levels [25, 26]. (3) 
Thromboelastography suffers from a unique set of pre-analytic and analytic variables that 
impact test reliability and reproducibility [27].
The thrombin generation assay, which measures the total amount of thrombin generated 
during in vitro coagulation, has been successfully used to reassess the haemostatic status of 
patients with liver disease [28–31]. This global test, which takes plasma concentrations of both 
pro- and anti-coagulants into account, offers a valid alternative to the conventional coagulation 
tests which only test functionality of some of the pro-coagulant factors. Thrombin generation 
testing has demonstrated normal or even superior thrombin generation in patients with 
cirrhosis [28–31], despite a prolonged PT or APTT. It has been well established that plasma 
levels of haemostatic proteins decrease following a partial liver resection, which has been 
attributed in part to a reduced synthetic capacity of the liver remnant [6, 9, 10]. However, 
the net results of these changes in plasmatic coagulation have not been established. We 
therefore studied the perioperative coagulation status in patients undergoing right hemi-
hepatectomy using both conventional coagulation tests and thrombin generation assays. 
Furthermore, we compared results to those of patients undergoing a pancreatic resection 
which is a surgical procedure of a similar extent, but without a decrease in post-operative 
synthetic capacity of the liver.
Materials and Methods
Patients
Seventeen adult patients, who underwent a right (n = 15) or extended right (n = 2) hemi-
hepatectomy were included in the study. The control group consisted of ten patients who 
underwent a pylorus preserving pancreaticoduodenectomy (PPPD). Twenty-four adult healthy 
volunteers were included to establish reference values for the various tests performed. 
All patients were included in the University Medical Center Groningen, the Netherlands. 
Exclusion criteria were age younger than 18 years, pre-existing coagulation disorders, pre-
operative anti-coagulation, and use of non-steroidal anti-inflammatory drugs or aspirin 1 
week before surgery. Routine surgical and anaesthetic procedures were adopted.
The study protocol was approved by the local medical ethical committee and informed 
consent was obtained from each subject before inclusion in the study.
Plasma samples
Plasma samples for analyses were, for both groups, drawn at the following time points: after 
induction of anaesthesia (baseline), at the end of surgery, and on the post-operative days 
1, 3, 5, 7 and 30. Following surgery, all patients received standard thromboprophylaxis with 
(once-daily) low molecular weight heparin (LMWH) and at each post-operative day blood was 
drawn just prior to the administration of the LMWH.
Blood samples from each subject were drawn by venepuncture and collected into vacuum 
tubes containing 3.8% trisodium citrate as an anti-coagulant, at a blood to anti-coagulant 




ratio of 9:1. Platelet-poor plasma was prepared by double centrifugation at 2000 g and 10 
000 g, respectively, for 10 min. at 18 °C. Plasma was aliquoted, snap-frozen and stored at -80 
°C until use.
Thrombin generation
Thrombin generation testing was performed using platelet-poor plasma (PPP) with the 
fluorimetric method described by Hemker, Calibrated Automated Thrombography  (CAT) 
[32]. Coagulation was activated by using a commercial trigger composed of recombinant 
tissue factor (TF, final concentration 5 pM) and phospholipids (final concentration 4 µM), in 
the presence or absence of soluble thrombomodulin (TM). These reagents were purchased 
from Thrombinoscope BV, Maastricht, The Netherlands. To calibrate the thrombin generation 
curves, thrombin Calibrator (Thrombinoscope BV) was added. A fluorogenic substrate 
with CaCl2 (FluCa-kit, Thrombinoscope Thrombinoscope BV, Maastricht, the Netherlands) 
was dispensed in each well to permit a continuous registration of thrombin generation. 
Fluorescence was read in time by the fluorometer Fluoroskan Ascent (ThermoFisher Scientific, 
Helsinki, Finland). All procedures were followed according to the protocol suggested by 
Thrombinoscope B.V. Thrombin generation variables analysed were endogenous thrombin 
potential (ETP), peak thrombin generation, lag-time (time needed for thrombin concentration 
to reach 1/6th of the peak concentration) and velocity index (slope between the end of lag-
time and peak thrombin generation). Furthermore, a normalised thrombomodulin sensitivity 
ratio (TM-SR) was determined by dividing the ETP in the presence of TM divided by the ETP 
in the absence of TM of an individual, by the ETP in the presence of TM divided by the ETP in 
the absence of TM of pooled normal plasma. A TM-SR >1 reflects a decreased anti-coagulant 
response to TM in comparison to pooled normal plasma.
Conventional coagulation tests
The PT was assessed on an automated coagulation analyser (ACL 500 TOP) with reagents 
(Recombiplastin 2G) and protocols from the manufacturer (Instrumentation Laboratory, 
Breda, the Netherlands). Levels of factor (F) VIII and II, antithrombin (AT), and protein C were 
measured on an automated coagulation analyser (ACL 500 TOP) with reagents and protocols 
from the manufacturer (Recombiplastin 2G for FII, Hemosil (R) SynthASil for FVIII, Liquid 
Antithrombin reagent for AT, and IL reagent for protein C) (Instrumentation Laboratory).
Statistical analyses
Values are expressed as means (with S.D.), medians (with interquartile ranges), or numbers 
(with percentages) as appropriate. Differences between values of pre-operative coagulation 
tests and thrombin generation tests, and follow-up values were evaluated by mixed linear 
models. To calculate differences between continuous data among independent groups, 
the t-test for independent samples or the Mann–Whitney U-test, as appropriate, was used. 
Differences between patient values and levels measured in healthy controls were compared 
using one-way ANOVA (with the Bonferroni post-test) or Kruskal–Wallis H test (with Dunn’s 
post-test) as appropriate. P-values of 0.05 or less were considered statistically significant. 
GraphPad Prism (San Diego, CA, USA) and IBM SPSS Statistics 20 (New York, NY, USA) were 
used for analyses.
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Results
Patient characteristics
Seventeen patients who underwent a right (n = 15) or extended right (n = 2) hemi-
hepatectomy, ten patients who underwent a PPPD, and twenty-four controls were included in 
the study. The main characteristics of the study population are reported in Table 1. The most 
common indication for liver resection was liver metastases from colorectal cancer and the 
most common indication for PPPD was pancreatic cancer. The median estimated blood loss 
was 700 mL in the patients who underwent a hemi-hepatectomy and 400 mL in the patients 
who underwent a PPPD. None of the patients suffered from venous thrombosis within 30 days 
after surgery.
Conventional coagulation tests
Baseline PT was 10.8 s (9.9–11.2) [median (interquartile range)] in the controls, 11.5 s (10.9–
12.0) in the patients undergoing hepatectomy (P < 0.05 compared to controls), and 11.6 
s (10.6–12.2) in the patients undergoing PPPD (P > 0.05 compared to controls). The PT 
progressively increased after both liver and pancreatic surgery (Figure 1), with a peak PT of 
18.3 s (16.8–21.3) in the patients undergoing hepatectomy (P < 0.001 compared to baseline 
PT) and 14.4 s (13.5–15.1) in the patients undergoing PPPD (P = 0.002 compared to baseline 
PT) on post-operative day 1. After post-operative day 1 the PT decreased to baseline levels 
on post-operative day 3 in the patients undergoing PPPD and on post-operative day 7 in the 
patients undergoing hepatectomy.
The APTT was 34.2 s (31.1–38.5) in the controls, 37.9 s (32.3–43.5) in the patients undergoing 
hepatectomy (P > 0.05 compared to controls), and 30.2 s (25.6– 36.3) in the patients 








Sex	(male)	 6	(35)	 7	(70)	 13	(54)	 0.201	
Age	(years)	 62	[9.8]	 67	[7.9]	 27	[4.5]	 <0.001	





			Colon	cancer	metastasis	 9	(53)	 1	(10)	 	
			Hepatocellular	carcinoma	(HCC)	 2	(12)	 0	 	
			Pancreatic	cancer	 0	 7	(70)	 	
			Cholangiocarcinoma	 2	(12)	 1	(10)	 	
			Neuroendocrine	tumor		 1	(5.9)	 1	(10)	 	
			Leiomyosarcoma		 1	(5.9)	 0	 	
			Adrenocortical	Carcinoma	metastasis	 1	(5.9)	 0	 	
			Benign	lesion	 1	(5.9)		 0	 	
Length	of	surgery	(min)	 616	(480-650)	 631	(551-739)	 	 0.414	
Estimated	blood	loss	(ml)	 700	(200-1000)	 400	(300-1125)	 	 0.980	
Amount	of	fluids	administered	(ml)	 4441	[1580]	 5225	[1239]	 	 0.192	
RBC	transfusion	(units)	 0	(0-0)	 0	(0-0)	 	 0.902	
FFP	transfusion	(units)	 0	 0	 	 1.000	
Length	of	hospital	stay	(days)	 14	(9-21)	 15	(11-21)	 	 0.863	
Hemoglobin	before	surgery	(mmol/L)	 8.6	[1.2]	 8.2	[1.1]	 	 0.407	






Table 1. Patient characteristics. 
PPPD: pylorus preserving pancreaticoduodenectomy
Data are expressed as number (%), mean [SD], or median (interquartile range). 
* To convert values for hemoglobin to g/dL, multiply by 1.650.




following hepatectomy [reaching 31.8 s (28.8– 34.6) on post-operative day 3; P = 0.009], but 
increased following PPPD [reaching 39.6 s (36.4–43.2) on post-operative day 1; P < 0.001; 
Figure 1].
At baseline, AT levels were slightly lower in patients undergoing hepatectomy [85.0% (78.0–
92.0), P < 0.001)] and patients undergoing PPPD [83.0% (71.3–85.8), P < 0.001] compared 
to the controls [109.0% (99.3– 117.0)]. Levels of AT substantially and significantly decreased 
at the end of surgery after both the hepatectomy [52.0% (40.0–63.5), P < 0.001 compared 
to baseline value] and PPPD [61.0% (35.3–68.5), P < 0.001 compared to baseline value]. AT 
levels further decreased in the patients undergoing hepatectomy until post-operative day 
3, after which levels slowly increased towards baseline levels which were reached on post-
operative day 30. In the patients undergoing PPPD, levels of AT progressively increased after 
post-operative day 1, reaching levels exceeding baseline levels on post-operative day 30 (P 
= 0.002; Figure 1).
Baseline levels of protein C were comparable between patients undergoing hepatectomy, 
patients undergoing PPPD, and controls [96.0% (82.0–111.0), 94.5% (80.0– 118.8) and 104.0% 
(93.0–112.3), respectively]. Protein C levels decreased until post-operative day 1 in both the 
patients undergoing hepatectomy [44.0% (31.0–51.5), P < 0.001 compared to baseline value] 
and the patients undergoing PPPD [53.0% (45.0–75.5), P < 0.001 compared to baseline 
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Figure 1. Changes in 
laboratory measurements 
(A) prothrombin time 
(PT), (B) activated partial 
thromboplastin time 
(APTT), (C) anti-thrombin 
(AT), (D) Protein C (PC), 
(E) factor II (FII), and (F) 
factor VIII (FVIII) after 
hepatectomy and PPPD. 
*P < 0.05 between the 
hepatectomy and PPPD 
group. ⁰P < 0.05 vs. 
baseline levels in the 
hepatectomy group. §P 
< 0.05 vs. baseline levels 
in the PPPD group. ●P < 
0.05 in the hepatectomy 
group vs. controls. ∞P< 
0.05 in the PPPD group vs. 
controls. 
End-OK, end of surgery; 
POD, post-operative day.
WilmaPotze_Proefschrift2017_170x240_Binnen_FINAL.indd   75 21-03-17   19:20
76
Hemostasis and 
Anticoagulant Therapy in 
Liver Diseases  
value]. Protein C levels decreased significantly more after hepatectomy compared to PPPD 
(P = 0.03), and the time to reach baseline levels was substantially longer after hepatectomy 
(levels returned to baseline on post-operative day 30 after hepatectomy, compared to post-
operative day 3 after PPPD) (Fig. 1).
Levels of FII at baseline were comparable between the groups, with 99.0% (91.0–110.0) of 
FII in the controls, 102.0% (86.8–107.4) in the patients undergoing hepatectomy, and 93.5% 
(83.5–105.5) in the patients undergoing pancreatic surgery. FII levels decreased following 
surgery to 55.8% (50.9–67.0) (P < 0.001 compared to baseline value) in patients undergoing 
hepatectomy and 55.0% (47.5–71.0) (P < 0.001 compared to baseline value) in patients 
undergoing PPPD on post-operative day 1. Baseline levels of FII were reached again on post-
operative day 4 after PPPD, but not until post-operative day 30 after hepatectomy (Figure 1).
FVIII levels were, at baseline, significantly higher in both the patients undergoing hepatectomy 
[135.6% (109.0–165.8), P < 0.05] and the patients undergoing PPPD [162.5% (112.5–203.5), P 
< 0.01] compared to the controls [92.5% (85.5–114.8)]. Levels of FVIII increased in both groups 
following surgery, with the highest levels of FVIII on post-operative day 5 after hepatectomy 
[251.1% (227.8–264.4), P < 0.001 compared to baseline value], and on post-operative day 7 
after PPPD [250.0% (234.0–261.0), P = 0.03 compared to baseline value]. After post-operative 
day 7 the levels of FVIII substantially decreased in both groups although levels remained 
elevated compared to the healthy controls (Fig. 1).
Thrombin generation
At the start of surgery, the ETP measured in the absence of TM, was comparable between 
the patients undergoing hepatectomy, the patients undergoing PPPD and healthy volunteers 
(Table 2). In the patients undergoing hepatectomy, the ETP decreased until post-operative 
day 7 (P < 0.001 compared to baseline value), and recovered until baseline values on day 30. 
In the patients undergoing PPPD, the decrease in ETP was more pronounced as compared to 
the decrease in the patients undergoing hepatectomy (P = 0.01 compared to baseline value, 
and P = 0.045 compared to hepatectomy on post-operative day 3). The ETP in the patients 
undergoing PPPD also recovered to baseline values on post-operative day 30 (Figure 2).
Despite the decrease in thrombin generation in the absence of TM, in the presence of TM 
thrombin generation increased following hepatectomy (Table 2; Figure 2). The ETP increased 
from 542 nM*min (417–694) at baseline (P > 0.05 compared to controls) to 845 nM*min 
(789–1050) on post-operative day 3 (P < 0.001 compared to baseline; P < 0.001 compared 
to controls). In comparison, total thrombin generation only slightly increased in the patients 
following PPPD (Figure 2). When these data were recalculated to a normalised thrombomodulin 
sensitivity ratio (TM-SR), it became evident that after hepatectomy thrombomodulin was less 
effective at regulating thrombin generation in these patients compared to controls (Figure 2). 
The TM-SR increased from 1.2 ± 0.4 (mean ± S.D.) at baseline to 2.1 ± 0.2 on post-operative 
day 3 in the patients undergoing hepatectomy (P < 0.001 compared to baseline; P < 0.001 
compared to controls). In comparison, the TM-SR only slightly increased in the patients 
following PPPD.




Figure 2. Changes in the thrombin generation assay [(A) endogenous thrombin potential (ETP) without thrombomodulin 
(TM), (B) endogenous thrombin potential (ETP) with TM, (C) thrombomodulin sensitivity ratio (TMSR)] after hepatectomy 
and PPPD. 
*P < 0.05 between the hepatectomy and PPPD group. ⁰P < 0.05 vs. baseline levels in the hepatectomy group. §P < 0.05 
vs. baseline levels in the PPPD group. ●P < 0.05 in the hepatectomy group vs. controls. ∞P < 0.05 in the PPPD group vs. 
controls. End-OK, end of surgery; POD, post-operative day.
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Table 2. Parameters derived from the thrombin generation test in patients following hepatectomy, patients 
following PPPD, and healthy controls.
Data are expressed as mean [SD] or median [range]. *P<0.05; **P<0.01; ***P<0.001 versus controls. 
PT: prothrombin time, APTT: activated partial thromboplastin time, Vi: initial rate of clot growth, Vst: 
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Table 2 shows the other parameters derived from the thrombin generation test. In the 
absence of TM, also peak thrombin generation levels remained comparable to baseline 
values following hepatectomy, and slightly decreased in the patients following PPPD on post-
operative day 1. Following surgery, the lag-time remained comparable to baseline values 
for both patient groups. The velocity index increased until post-operative day 30 following 
hepatectomy, but only slightly increased on post-operative day 3 and declined again 
thereafter following PPPD. In the presence of TM, peak thrombin generation also gradually 
increased following hepatectomy, compared to only an increase on post-operative day 3 
following PPPD. Following surgery, the lag-time remained the same in both patient groups. 
The velocity index, however, increased in both groups following surgery, with a maximum on 
post-operative day 3.
Discussion
In the present study, we observed a hypercoagulable status in samples taken from patients 
following a right hemi-hepatectomy, despite substantially prolonged conventional coagulation 
tests. Our results using thrombomodulin-modified thrombin generation testing are in line with 
several recent studies that found a normal to hypercoagulable state following liver surgery 
[5,6,10,19]. In contrast to previous work, our study provides a mechanistic explanation for the 
hypercoagulable state, i.e. a profound and sustained post-operative deficiency of the natural 
anti-coagulants AT and protein C.
Samples taken after liver resection were profoundly resistant to the anti-coagulant action of 
thrombomodulin, the physiological activator of the natural anti-coagulant protein C. While 
thrombin generation substantially decreased in healthy volunteers when thrombomodulin 
was added to the plasma, thrombin generation only slightly decreased by the addition of 
thrombomodulin in plasma from patients following hemi-hepatectomy. Consequently, 
thrombin generation in the presence of thrombomodulin was higher than that of healthy 
volunteers. The thrombomodulin resistance following liver surgery is in part explained by the 
decreased levels of protein C and elevated levels of FVIII [28]. Combined with the low levels 
of AT, the net effect is a normal or even supranormal thrombin generation when tested in 
the presence of thrombomodulin after hemi-hepatectomy, despite decreased levels of pro-
coagulant proteins.
The decrease in coagulation factors following hemi-hepatectomy is in part explained by the 
decreased synthetic capacity of the liver remnant. However, we also observed a transient 
decrease in FII, AT, and protein C following pancreatic surgery. Therefore, it is likely that 
consumption of coagulation proteins as a result of surgical damage may also play a role. 
Finally, haemodilution may also partly explain the decrease in coagulation factor levels, and 
the decrease in haemoglobin following surgery combined with the limited blood loss indeed 
suggests our patients to be slightly haemodiluted.
Despite similar effects of both liver and pancreas surgery on levels of coagulation factors, 
we observed a difference in thrombin generation following hemi-hepatectomy and PPPD. 
Although thrombin generation tested in the presence of thrombomodulin was increased 
following liver surgery, thrombin generation under these experimental conditions was 
normal in patients following pancreatic surgery. Furthermore, when thrombin generation was 
tested in the absence of thrombomodulin, we observed a decrease in thrombin generation in 
both groups, but this decrease was much more pronounced following pancreatic surgery. De 




Pietri et al. [6] have also shown signs of hypocoagulability in patients undergoing pancreatic 
surgery using TEG. As the decrease in protein C and AT were more extensive following hemi-
hepatectomy compared to the decrease in patients following PPPD, this may in part explain 
the difference in thrombin generation between both groups.
As reported before [5,6,19,28], we also observed a substantial prolongation of conventional 
coagulation tests in patients following liver surgery. However, these tests cannot reflect the 
true haemostatic status of patients undergoing liver surgery, as they are only sensitive for 
levels of pro-coagulant factors and do not take the reduction in anti-coagulant factors, which 
also occur following liver surgery, into account. The thrombomodulin-modified thrombin 
generation test is, however, sensitive to all anti-coagulant proteins in the plasma. Therefore, 
this test measures the true balance between the pro- and anti-coagulant factors. Thrombin 
generation testing in the presence of thrombomodulin has demonstrated normal or even 
superior thrombin generation in patients with chronic liver disease, despite prolonged 
conventional coagulation tests [28,29,31]. These findings have challenged the long held 
dogma of chronic liver disease being associated with a bleeding tendency due to changes 
in the plasmatic coagulation system [33]. Our present findings show comparable findings in 
patients that underwent liver resections, which may have important clinical consequences. 
First, we strongly advise not to correct routine coagulation tests by using blood product 
transfusion during or after hepatectomy. In fact, several serious side effects of blood 
product transfusion may occur, including the risk of infection and the risk of transfusion-
related acute lung injury [17]. Furthermore, routine thrombosis prophylaxis should not be 
withheld in patients undergoing liver resection, as this may result in higher rates of venous 
thromboembolism in post-operative liver disease patients. More extensive prophylaxis may 
even be required as VTE rates are still substantial in those patients receiving optimal routine 
thromboprophylaxis [34].
In conclusion, although conventional coagulation tests point to hypocoagulability in patients 
undergoing liver resection, thrombin generation in the presence of thrombomodulin 
revealed hypercoagulability following liver resection. This hypercoagulability was associated 
to a profound thrombomodulin resistance which was likely attributable to decreased levels of 
protein C and elevated levels of FVIII. Therefore, clinicians should be aware of the limitations 
of the use of conventional coagulation tests to guide haemostatic management during liver 
surgery. Furthermore, the results of our study support the exploration of more extensive use 
of anti-coagulant medication in the post-operative period, as was previously suggested by 
others [7,18,34].
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Abstract
Nonalcoholic fatty liver disease (NAFLD) is increasingly being diagnosed and is considered to be 
the most frequent chronic liver disorder in Western countries. It represents a histopathological 
spectrum ranging from simple hepatic steatosis to steatohepatitis and finally cirrhosis. NAFLD 
is considered as the hepatic manifestation of the metabolic syndrome and is associated with 
increased mortality. Increasing evidence now suggests that NAFLD is also associated with 
higher cardiovascular disease (CVD) morbidity and mortality independent of conventional 
cardio metabolic risk factors (such as obesity, insulin resistance, and diabetes mellitus). The 
exact mechanisms linking NAFLD to increased CVD risk are still incompletely understood and 
likely reflect multiple coexisting pathways. Recent evidence suggests a contributive effect of 
an altered hemostasis in patients with NAFLD. For example, patients with NAFLD have higher 
levels of pro-thrombotic factors (e.g., von Willebrand factor, fibrinogen, factor VII activity, and 
plasminogen activator inhibitor-1), which correlate with underlying histological severity of the 
disease. The current review focuses on these hemostatic abnormalities in NAFLD and the link 
with increased CVD risk.





Nonalcoholic fatty liver disease (NAFLD) is the most common cause of abnormally elevated 
aminotransferases [1,2] with an estimated prevalence ranging from 6.3 to 33% with a median 
of 20% in the general population [2]. Its prevalence increases from 70 to 90% among those 
with diabetes or obesity [1,2]. NAFLD is characterized by fat accumulation in the liver in 
the absence of excessive alcohol consumption (less than 20 g/day in women and less 
than 40 g/day in men) and exclusion of other secondary causes of hepatic steatosis [3–6]. 
NAFLD represents a histopathological spectrum ranging from simple hepatic steatosis 
to steatohepatitis (NASH), characterized by necroinflammatory changes which increase 
the risk for progression to advanced fibrosis and cirrhosis [6–8]. NAFLD is considered the 
hepatic manifestation of the metabolic syndrome and is associated with increased mortality, 
particularly cardiovascular disease (CVD)-related mortality [7–9]. The metabolic syndrome 
is a cluster of metabolic abnormalities that predicts the risk of developing diabetes and 
CVD better than any of its individual components [10]. The metabolic syndrome predicts 
the development of NAFLD, and the risk of having NAFLD increases significantly with the 
addition of each of the component of the metabolic syndrome [11,12].
Cardiovascular Disease and Nonalcoholic Fatty Liver Disease
Patients with NAFLD have multiple traditional and nontraditional risk factors for CVD, and CVD-
related mortality is the leading cause of death in those with NAFLD [7,8,13] Although NAFLD 
is commonly seen with other features of the metabolic syndrome, the increased CVD risk in 
NAFLD is independent of obesity, diabetes, and other features of the metabolic syndrome 
[14,15]. Accumulating evidence implicates NAFLD as a risk factor not only for CVD events but 
also for subclinical and premature CVD [16] Presence of NAFLD is associated with increased 
carotid artery intimal medial thickness (IMT), a validated marker of subclinical atherosclerosis 
[14]. These findings were corroborated in a larger meta-analysis that clearly showed that the 
presence of NAFLD was associated with carotid artery IMT and prevalence of carotid artery 
atherosclerotic disease [17]. The IMT was the greatest in those with steatohepatitis, then in 
those with simple hepatic steatosis, and the lowest in healthy individuals [14]. In addition, the 
association between NAFLD and the increased risk of coronary artery disease (as measured by 
coronary artery calcium score or CAC) is independent of conventional risk factors, metabolic 
syndrome features, insulin resistance, and even preexisting CVD [18].
The risk of clinically evident CVD is also much higher in those with NAFLD and is independent 
of classical CVD risk factors, features of metabolic syndrome, and insulin resistance [15,19]. 
In addition, the presence of NAFLD was associated with lower remodeling lesions or lipid 
core plaques of coronary arteries, thereby implicating NAFLD as a risk factor for vulnerable 
coronary artery plaques [20]. In a community-based cohort those with NAFLD had a much 
higher 10-year FraminghamRisk Score (FRS) than matched controls [21]. In fact, in a recent 
meta-analysis, presence of NAFLD was associated with increased overall mortality (odds ratio 
[OR]: 1.57; confidence interval [CI]: 1.18–2.10) deriving from liver related and cardiovascular-
related mortality [22]. The exact mechanisms linking NAFLD to increased CVD risk are 
incompletely understood and likely reflect multiple coexisting pathways, one of which is 
altered hemostasis in those with NAFLD. The current review focuses on these hemostatic 
abnormalities in NAFLD.
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Hemostasis in Nonalcoholic Fatty Liver Disease
A link between NAFLD and CVD is their close association with pro-inflammatory markers, 
such as high sensitivity C-reactive protein (hs-CRP), interleukin-6 (IL-6), tumor necrosis factor-a 
(TNF-a), and other acute phase reactants [23–26]. In addition to these pro-inflammatory 
markers, NASH is also considered to be associated with a pro-thrombotic state and the 
studies investigating this association are summarized in Table 1.
Nonalcoholic Fatty Liver Disease and Platelets
It is well known that platelet activation is increased in the metabolic syndrome and obesity 
[46–51], likely reflecting the altered biophysical state of the platelet membrane component 
in these patients. Platelets of these individuals have an enhanced expression of the platelet 
surface of adhesive receptors, such as P-selectin, αIIbβ3, and the glycoprotein (GP)Ib/IX/V 
complex. The increased expression of the latter two receptors most probably causes more 
frequent episodes of platelet activation and degranulation [52]. Patients with metabolic 
syndrome also have concurrent endothelial dysfunction which may trigger platelet activation. 
Finally, hypertriglyceridemia, a key clinical feature of NASH, is a known trigger for platelet 
activation and may contribute to the underlying thrombotic risk [53,54]. Studies have also 
shown an increase in mean platelet volume, a reliable indicator of platelet activation, in 
patients with NAFLD [27–29]. In fact, in a cohort of 100 consecutive patients undergoing liver 
biopsy for NAFLD, the mean platelet volume increased in a stepwise fashion from those with 
no steatosis to those with simple steatosis to those with NASH [30]. Furthermore, in a group 
of 44 NASH patients, an increase in platelet count was observed [55]. However, the increase in 
platelet count is followed by a steady decrease in platelet count when the disease progresses 
to fibrosis/cirrhosis [56]. Finally, von Willebrand factor (VWF), a mediator of platelet adhesion 
and aggregation, was found to be significantly elevated in patients with NAFLD and this may 
be a consequence of endothelial injury [31,34,43].
Nonalcoholic Fatty Liver Disease and Hemostatic Abnormalities
In addition to the increased platelet activation, patients with NAFLD also have higher 
levels of pro-thrombotic factors (e.g., VWF, fibrinogen, factor VII activity, and plasminogen 
activator inhibitor-1 [PAI-1]) and this directly correlates with underlying histology [57–59] 
For example, Kotronen et al observed that the plasma levels of factors VIII, IX, XI, and XII 
were increased in 54 patients with NAFLD compared with 44 controls [32]. The associations 
between NAFLD and these coagulation factors were independent of age, gender, and body 
mass index, suggesting that the presence of hepatic steatosis independently contributes to 
the thrombosis risk. More recently, Verrijken et al found significantly higher levels of PAI-1 in 
patients with NASH than controls and this association correlated with underlying histological 
parameters [31]. However, in patients with NAFLD plasma levels of fibrinogen, factor VIII, 
VWF, and antithrombin did not correlate with liver histology, but did correlate with features 
of the metabolic syndrome. Elevated levels of PAI-1 might, therefore, partly explain the 
increased cardiovascular risk seen in patients with NAFLD. Indeed, increased levels of PAI-
1, with resultant reduction in fibrinolysis, have been extensively reported as a risk factor for 
thrombosis and cardiovascular events [60], although some studies suggest PAI-1 merely to 
be a reflection of general cardiovascular risk factors [61]. The liver is the site of synthesis for 
a majority of pro-coagulant proteins. Several studies have now documented an increased 
intrahepatic expression of these proteins in patients with NAFLD [35,36], suggesting that this 
increase may be because of increased hepatic synthesis [58,59]. These findings are further 




corroborated by previous studies that have shown dysregulation of several candidate genes 
responsible for accelerated atherogenesis in the liver of those with NASH [62–64]. Despite 
the initial findings between NAFLD and hemostatic abnormalities, the data should be 
interpreted with caution as most of these studies are limited by their relatively small sample 
size and cross-sectional design. In addition, patients with cirrhosis were excluded from most 
of these studies, so it is not clear how progression to cirrhosis impacts these parameters. 
Nevertheless, some evidence does suggest that patients with NASH-related compensated 
cirrhosis have an increased risk of atherothrombotic events [65]. In a prospective study, it was 
demonstrated that, while patients with compensated cirrhosis because of NASH have a lower 
overall mortality rate than patients with hepatitis C virus-associated cirrhosis, cardiovascular 
mortality is increased in patients with NASH related cirrhosis than those with hepatitis C virus-
associated cirrhosis [66].
To date, only one recent study has examined the coagulation status in patients with NASH-
related cirrhosis [33]. The authors observed a pro-coagulant imbalance characterized by 
increased levels of factor VIII and a reduction in protein C in patients with NAFLD and these 
differences were more pronounced in those with NASH and NASH-cirrhosis than those with 
simple steatosis. However, they found no differences in alcoholic/viral-related cirrhosis, in 
which a pro-coagulant imbalance was also observed, as has been previously noted [67–69]. 
This observation, therefore, does not explain the increased risk of cardiovascular disease in 
NASH cirrhosis compared with alcoholic/viral cirrhosis. Furthermore, the authors only show 
the endogenous thrombin potential (ETP) ratio, which represents the resistance of the plasma 
to the anticoagulant action of thrombomodulin, and do not depict the original thrombin-
generation data. More specifically, they do not compare original thrombin-generation 
data, for example, ETP in the presence of thrombomodulin between patients with NAFLD 
and controls. If the original ETP values are indeed significantly increased in patients with 
NAFLD compared with controls, this implies a hypercoagulable status in plasma of patients 
with NAFLD. Thus, to confirm these findings, further studies are needed to investigate the 
hemostatic abnormalities in patients with advanced NAFLD. 
Table 1. Summary of studies on the changes in all phases of the hemostasis in patients with nonalcoholic fatty liver 
disease.
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Risk of Venous Thrombosis in Nonalcoholic Fatty Liver Disease
Recent epidemiological studies have challenged the notion that patients with a chronic 
liver disease are auto-anticoagulated, and, hence, are protected against venous thrombosis 
(including deep vein thrombosis [DVT] and pulmonary embolism) [70–74]. Rather, there 
is evolving evidence to suggest a higher propensity for developing venous thrombosis in 
patients with a liver disease [75–77].
While there are multiple case-control studies that have shown an increase in circulating levels 
of various pro-thrombotic proteins in plasma of patients with NAFLD (see previous section 
and Table 1), there is currently little published research that assessed the association between 
NAFLD/NASH and the risk of venous thrombosis. Although there is lack of data in NAFLD 
patients, there are numerous studies that implicate obesity, a common feature of NAFLD, as 
a risk factor for the development of venous thromboembolism (VTE) [78–80]. In the limited 
data available, an independent association between NAFLD and idiopathic VTE was noted 
and the prevalence of NAFLD increased nearly threefold in those with VTE [81]. A possible 
cause of the increased risk of venous thrombosis in NAFLD patients might be the elevated 
levels of PAI-1 resulting in hypofibrinolysis in these patients. However, there is currently little 
known about the incidence of venous thrombosis in NASH-related cirrhosis. In addition, a 
recent retrospective study reported an increased prevalence of portal vein thrombosis (PVT) 
in patients with NASH related cirrhosis, and the presence of NASH was an independent risk 
factor for the diagnosis of PVT [82]. Because of the limited number of studies, these data 
should be interpreted with caution and well-designed prospective studies are needed to 
further explore the relationship between NAFLD/NASH fibrosis stage and the risk of venous 
thrombosis.
Role of Hypercoagulability in Liver Fibrogenesis
The progression from chronic liver injury to advanced hepatic fibrosis or cirrhosis is a 
complex process, mediated through the interaction between genetic and environmental 
factors. Recent evidence suggests a role for the activity of the coagulation cascade in hepatic 
fibrogenesis [75,83]. For example, epidemiological evidence has shown an association 
between congenital coagulation abnormalities (e.g., increased expression of factor VIII, 
protein C deficiency, and factor V Leiden mutation) and accelerated progression to cirrhosis 
in patients with a chronic hepatitis C infection [84–87]. Furthermore, Assy et al observed a 
correlation between the presence of thrombotic risk factors and the extent of hepatic fibrosis 
in patients with NASH [45] Based on recent evidence, there may be two hypotheses that 
could explain the involvement of the coagulation cascade in the rate of liver fibrogenesis: 
tissue ischemia because of intrahepatic thrombi (also referred to as parenchymal extinction) 
and the activation of stellate cells by coagulation proteases [83].
Accumulating animal data suggest that antithrombotic treatment may retard the progression 
of fibrosis by inhibiting the coagulation or the platelet function [88–92]. Fujita et al have shown 
that antiplatelet therapy reduces hepatic steatosis, inflammation, and hepatic fibrosis in rats 
[93]. Also, anticoagulant therapy decreased fatty liver disease in an experimental animal 
model [94]. If antithrombotic treatment truly prevents progression of disease and substantially 
delays decompensation, the need for liver transplantation, or death, this will profoundly 
impact the clinical management of patients with a chronic liver disease. Nevertheless, several 
recent experimental animal studies suggest that platelets and fibrin 




may, on the contrary, have beneficial effects on liver injury [95–98]. Future clinical studies on 
the benefits and safety of antithrombotic treatment in different patient groups are, therefore, 
required before this may be considered in routine practice. NAFLD might be a reasonable 
disease state to further investigate these treatment strategies in human trials, because of 
the suggested hypercoagulable state and the relative slow course of the disease. A major 
limitation to evaluating coagulation defects clinically is the lack of readily available laboratory 
tests to measure hypercoagulability in patients with a chronic liver disease.
Conclusion
NAFLD, the most common cause of liver disease globally, is associated with higher CVD 
morbidity and mortality. Multiple processes probably contribute to this increased risk of CVD, 
including abnormal glucose, fatty acid, and lipoprotein metabolism, chronic inflammation, 
increased oxidative stress, deranged adipokine function, endothelial dysfunction, 
atherosclerosis, and cardiac lipotoxicity. Several studies have also suggested a role for the 
presence of a hypercoagulable state in the increased risk of CVD in patients with NAFLD.
The present evidence strongly highlights the importance of evaluating the risk of CVD and 
related pro-inflammatory/pro-thrombotic state in patients with NAFLD. Clinicians should 
recognize the increased risk of CVD among patients with NAFLD, which warrants evaluation 
and treatment as much as the liver disease itself.
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Abstract
Background & Aims: Non-alcoholic fatty liver disease (NAFLD) is associated with an increased 
risk of thrombosis. However, it remains unclear if hypercoagulability contributes to this risk. 
We, therefore, determined an in-depth hemostatic profile in a cohort of well-defined patients 
with NAFLD. 
Methods: We drew blood samples from 68 patients with biopsy-proven NAFLD (simple 
steatosis n = 24, NASH n = 22, and NASH cirrhosis n = 22), 30 lean controls, 30 overweight 
controls (body mass index (BMI) >25 kg/m2 ), and 15 patients with alcoholic (ASH) cirrhosis, 
and performed in-depth hemostatic profiling. 
Results: Basal and agonist-induced platelet activation, plasma levels of markers of platelet 
activation, and plasma levels of the platelet adhesion regulators von Willebrand factor 
and ADAMTS13 were comparable between patients with non-cirrhotic NAFLD and 
controls. Agonist-induced platelet activation was decreased in patients with cirrhosis. 
Thrombomodulin-modified thrombin generation was comparable between all patients 
and controls, although patients with cirrhosis had a reduced anticoagulant response to 
thrombomodulin. Thromboelastography test results were comparable between controls and 
non-cirrhotic NAFLD patients, but revealed moderate hypocoagulability in cirrhosis. Plasma 
fibrinolytic potential was decreased in overweight controls and non-cirrhotic NAFLD, but 
accelerated fibrinolysis was observed in ASH cirrhosis. Clot permeability was decreased in 
overweight controls and patients with NAFLD. 
Conclusions: The overall hemostatic profile is comparable between patients with non-
cirrhotic NAFLD and controls. Additionally, pro-thrombotic features (hypofibrinolysis and a 
prothrombotic structure of fibrin clot) in patients with NAFLD are likely driven by obesity. Our 
study suggests a limited role for hyperactive hemostasis in the increased thrombotic risk in 
NAFLD. 
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Introduction
Non-alcoholic fatty liver disease (NAFLD) is associated with an increased risk of cardiovascular 
disease (CVD). Increasing evidence suggests that the higher incidence of cardiovascular 
disease (CVD) morbidity and mortality in patients with NAFLD is independent of conventional 
cardiometabolic risk factors (such as obesity, insulin resistance, and diabetes mellitus) [1–3]. 
However, the exact mechanisms linking NAFLD to increased risk of CVD are incompletely 
understood and likely reflect multiple coexisting pathways [3]. Furthermore, rates of venous 
thromboembolism (VTE) and portal vein thrombosis (PVT) appear also increased in patients 
with NAFLD [4,5]. Recent studies have suggested a role for a hypercoagulable state in the 
increased risk of thrombosis in patients with NAFLD. Increased plasma levels of various pro-
thrombotic factors (e.g., fibrinogen, factor VIII, and plasminogen activator inhibitor 1 (PAI-
1)) have been described in patients with NAFLD [6–9]. Furthermore, studies have shown 
hypercoagulable features in patients with NAFLD detected with either thromboelastography 
(TEG) [10] or thrombin generation testing [11]. Platelet hyperactivity has also been implicated 
as a contributor of the increased risk of cardiovascular disease in patients with the metabolic 
syndrome [12–14], but its role in NAFLD remains unclear [3]. 
Nevertheless, results on the hemostatic status in NAFLD are inconsistent [3]. Furthermore, most 
studies have reported plasma levels of individual hemostatic proteins rather than functional 
tests of hemostasis. In addition, no study has profiled all components of the hemostatic 
system simultaneously, and patients with cirrhosis were excluded from most of these studies. 
The hemostatic status across the spectrum of NAFLD stages thus remains unclear. Whether 
the hemostatic status might explain the increased risk of thrombosis in these patients also 
remains to be firmly established. We, therefore, determined an in-depth hemostatic profile 
by performing functional hemostatic tests of platelets, coagulation, fibrinolysis, and fibrin clot 
structure in a cohort of well-defined patients with NAFLD. Furthermore, we compared the 
hemostatic status of patients with NASH-related cirrhosis to that of patients with alcoholic-
(ASH) related cirrhosis. This is the first study that comprehensively investigated all components 
of the hemostatic system (i.e., platelets, coagulation, and fibrinolysis) using both biomarkers 
and functional tests in patients with various histological severities of NAFLD. 
Patients and methods 
Patients
All subjects (healthy controls, patients with various severity of NAFLD, and patients with ASH 
cirrhosis) were enrolled through the NASH Clinic at the Virginia Commonwealth University 
(Richmond, VA). The study protocol was IRB approved and written informed consent 
was obtained from each subject before inclusion in the study. NAFLD was defined by the 
evidence of hepatic steatosis on liver biopsy and the absence of causes for secondary hepatic 
fat accumulation (such as significant alcohol consumption) [15]. The liver biopsy was graded 
according to the NASH Clinical Research Network (NASH-CRN) scoring system, and the NAFLD 
activity score (NAS) was based on the unweighted sum of steatosis, lobular inflammation, and 
hepatocellular ballooning scores [16]. The NAFLD cohort was further subdivided into patients 
with simple hepatic steatosis (defined as the presence of hepatic steatosis with no evidence of 
hepatocellular injury (ballooning), n = 24), patients with non-alcoholic steatohepatitis (NASH; 
defined as the presence of hepatic steatosis and inflammation with hepatocyte injury with or 
without fibrosis, n = 22), and patients with NASH-related cirrhosis (defined as the presence of 




cirrhosis with current or previous histological evidence of steatosis or steatohepatitis, n = 22) 
[15]. Two control groups of lean (BMI <25 kg/m2; n = 30) and overweight (BMI >25 kg/m2; n 
= 30) subjects with no evidence of chronic liver disease were included to establish reference 
values for the various tests performed. The absence of liver disease was established by normal 
liver enzymes and a normal liver sonogram. Furthermore, fifteen patients with alcoholic 
(ASH) cirrhosis were included as a control group for the patients with NASH-related cirrhosis. 
Exclusion criteria were documented history of congenital coagulation disorders, presence 
of active infection (<2 weeks), use of anticoagulant or anti-platelet drugs, pregnancy, human 
immunodeficiency virus positivity, and recent (<7 days) transfusion with blood products.
Figure 1. Schematic representation of the hemostatic system. Upon vessel wall injury, subendothelial collagen is 
exposed (A). Plasma VWF, which is a globular protein in circulation, unwinds over the collagen surface and becomes 
adhesive to platelets. The multimeric size of VWF is regulated by the protease ADAMTS13. Platelets lose velocity by rolling 
over collagen-bound VWF (B), and eventually stably adhere by multiple receptors (C). Platelets become activated by 
multiple triggers including collagen and thrombin, which results in a conformational change in αIIbβ3. This conformational 
change allows platelet-platelet interactions mediated by VWF and fibrinogen. During platelet activation, proteins within 
platelet α- granules (among which PF4) are excreted. In addition, the α-granule transmembrane protein P-selectin is 
translocated to the outer membrane during α-granule secretion. Part of this P-selectin is shed from the platelet surface 
and soluble P-selectin can be found in plasma. Simultaneously, vessel wall injury exposes tissue factor (TF), which initiates 
coagulation (D, left section). Thrombin (coagulation factor IIa) is the terminal enzyme of the coagulation system, and is 
responsible for cleavage of fibrinogen to fibrin. Thrombin generation is the net result of the work of pro- and anticoagulant 
systems. The anticoagulant systems are indicated by the interrupted line. The fibrin clot is degraded by the fibrinolytic 
system, which is activated by release of tPA from endothelial cells, resulting in conversion of plasminogen to plasmin (D, 
right section). Multiple regulatory steps in fibrinolysis are depicted with interrupted lines. Importantly, thrombin not only 
cleaves fibrinogen to fibrin, but also activates two major inhibitors of fibrinolysis (FXIII and thrombin activatable fibrinolysis 
inhibitor; TAFI).
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Blood samples
Blood was drawn by venapuncture in 3.8% citrate tubes. A sample was processed directly 
for flow cytometry and thromboelastography. The remainder of the blood was processed to 
platelet-poor plasma (PPP) by double centrifugation at 2000g and 10.000g respectively for 
10 min. Plasma was snap-frozen and stored at -80 C until use. 
Figure 1 shows an overview of hemostasis and all tests performed are indicated in this 
schematic.
Platelet activation status
The platelet activation status was assessed using flow cytometry in whole blood. Details of 
sample processing have been described previously [17]. Platelets were kept in a resting state 
or activated by either adenosine diphosphate (ADP, 15 μM, Sigma-Aldrich, St. Louis, USA) 
or thrombin receptor activating peptide (TRAP6, 15 μM, Bachem, Bubendorf, Switserland). 
Samples were analyzed within six hours after processing using a BD LSRFortessa™ X-20 cell 
analyzer (BD Biosciences, Franklin Lakes, NJ, USA). Samples were gated on the basis of their 
forward and sideward scatter properties. The percentage of platelets expressing P-selectin 
and the geometric mean fluorescence intensity (MFI) of the platelet population were 
recorded. The percentage of platelets positive for P-selectin after activation was corrected for 
the percentage of platelets positive for P-selectin in the non-activated sample of each patient 
and control. The increase in the percentage of P-selectin positive platelets obtained in this 
manner represents the extent to which platelets in a given sample can be activated by a given 
activator (i.e., the platelet activatability).
Thromboelastography
Thromboelastography (TEG) was performed using the Thrombelastograph Hemostasis 
Analyzer 5000 (Haemonetics Corp., Haemoscope Division, Niles, IL, USA) as described 
previously [18]. Briefly, 1 ml of citrated whole blood (3.2% citrate) was subjected to kaolin-
activated TEG within two hours of the blood draw. Kinetic changes in clot formation and clot 
dissolution were measured for 30 minutes after reaching maximal clot firmness. The following 
parameters were recorded: reaction time (R-time: the time taken for a clot to begin forming), 
kinetics time (K-time: the time from initial clot formation required to reach a specific clot 
firmness, α-Angle (the kinetics of clot formation), Maximum amplitude (MA: the maximal clot 
strength), and lysis at 30 minutes (Lysis-30 the percentage of clot lysis 30 minutes after MA is 
established).
Thrombin generation, PT, APTT
Thrombin generation testing was performed in platelet-poor plasma (PPP) with the fluorimetric 
method described by Hemker, Calibrated Automated Thrombography® (CAT) [19]. Reagents 
and protocols were purchased from Thrombinoscope BV, Maastricht, the Netherlands. 
Details of thrombin generation testing have been described previously [20]. The following 
parameters were recorded: endogenous thrombin potential (ETP; which represents the total 
enzymatic work performed by thrombin during the time that it was active), peak, velocity 
index (slope between the end of lag time and peak thrombin), and lag time (time needed for 
thrombin concentration to reach 1/6th of the peak concentration). In addition, a normalized 
thrombomodulin sensitivity ratio (TM-SR) was determined by dividing the ETP in the presence 




of TM divided by the ETP in the absence of TM of an individual, by the ETP in the presence of 
TM divided by the ETP in the absence of TM of pooled normal plasma. A TM-SR > 1 reflects a 
decreased anticoagulant response to TM in comparison to pooled normal plasma.
The prothrombin time (PT) and activated partial thrombin time (APTT) were assessed on an 
automated coagulation analyzer (ACL 300 TOP) with reagents (Recombiplastin 2G for PT and 
SynthaSil for APTT) and protocols from the manufacturer (Instrumentation Laboratory, Breda, 
the Netherlands).
Clot lysis
Lysis of a tissue factor–induced clot by exogenous tPA was studied by monitoring changes in 
turbidity during clot formation and subsequent lysis as described previously [21]. Clot lysis 
time was determined as the time from the midpoint of the clear to maximum turbid transition, 
which characterizes clot formation, to the midpoint of the maximum turbid to clear transition, 
which represents clot lysis.
Fibrin structure
The average pore size of the fibrin clot (expressed as the Darcy constant Ks) was determined 
in permeation studies as described previously [22,23]. 
 
Fibrin density was assessed by laser-scanning confocal microscopy of clots supplemented 
with fluorescently labeled fibrinogen. Plasma clots were generated as described previously 
[24]. Clots were visualized with a Leica TCS SP8 confocal laser scanning microscope using a 
63X/1.40 NA oil objective (Leica Microsystems, Eindhoven, The Netherlands). Alexa Fluor-488 
fibrinogen was excited at 488 nm with an argon laser. Optical sections were taken at three 
randomly chosen areas throughout the clot to visualize the fibrin network.  Fiber density was 
determined by counting the number of fibers crossing 100 µm lines placed in the image 
using the Image J plug-in grid (Fiji, National Institute of Health, Bethesda, Maryland, USA).
 
Fibrinogen was isolated from plasma samples as described previously [25]. Carbonylation of 
purified fibrinogen samples was quantified using a commercially available ELISA kit (Enzo Life 
Sciences, Farmingdale, NY) following the manufacturer’s instructions.
Plasma markers of primary hemostasis 
Soluble P-selectin (sP-selectin) and platelet factor 4 (PF4) levels were determined using a 
commercially available sP-selectin or PF4 enzyme-linked immunosorbent assay (ELISA) (R&D 
Systems, Abingdon, UK). Levels of von Willebrand Factor antigen (VWF) were assessed with 
an in-house ELISA using commercially available polyclonal antibodies against VWF (DAKO, 
Glostrup, Denmark). Plasma a disintegrin and metalloproteinase with a thrombospondin 
type 1 motif, member 13 (ADAMTS13) activity was measured using the FRETS-VWF73 assay 
(Peptanova, Sandhausen, Germany). Levels of VWF and ADAMTS13 in pooled normal plasma 
were set at 100%, and values obtained in test plasmas were expressed as a percentage of 
pooled normal plasma.
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Plasma markers of coagulation
Levels of fibrinogen, factor (F) VII, FVIII, antithrombin, protein C, and D-dimer were assessed 
on an automated coagulation analyzer (ACL 300 TOP) with reagents (QFA thrombin (Hemosil) 
for fibrinogen, Factor VII deficient plasma and Recombiplastin for FVII, Factor VIII deficient 
plasma and Hemosil (R) SynthASil for FVIII, Liquid Antithrombin reagent for antithrombin, IL 
reagent for protein C, and Ddimer 500 HS for D-dimer) and protocols from the manufacturer 
(Instrumentation Laboratory, Breda, the Netherlands). 
Plasma markers of fibrinolysis
PAI-1 levels were determined with an ELISA kit from R&D systems (Abingdon, UK). Levels of 
tissue plasminogen activator (tPA) were measured using an ELISA kit from Sekisui (Lexington, 
USA).
Statistical analysis
Data are expressed as means (with standard deviations (SDs)), medians (with ranges), or 
numbers (with percentages) as appropriate. Means of two groups were compared by 
Student’s t-test or distributions in the two groups by Mann-Whitney U test as appropriate. 
Multiple groups were compared using one-way ANOVA (with the Bonferroni posttest) or 
Kruskal-Wallis H test (with Dunn’s posttest) as appropriate. Spearman’s correlation coefficient 
was used to assess correlation between continuous variables. P values of 0.05 or less were 
considered statistically significant. GraphPad Prism (San Diego, USA) and IBM SPSS Statistics 
20 (New York, USA) were used for analyses.






Patient characteristics are reported in Table 1. Sixty-eighth patients with biopsy-proven NAFLD 
(simple steatosis n = 24, NASH n = 22, and NASH cirrhosis n = 22), thirty lean controls (BMI 25 
kg/m2), and fifteen patients with alcoholic (ASH) cirrhosis were included. None of the patients 
were diagnosed with another form of liver disease (e.g., hepatitis B, hepatitis C, autoimmune 
hepatitis, hereditary haemochromatosis etc.). The NAS score increased from patients with 
simple steatosis to patients with NASH and patients with NASH-related cirrhosis. 
Data from all hemostasis tests performed are summarized in Table 2; parts of these data are 
also graphically represented herein.
Table 1. Patient characteristics
NASH: Non-alcoholic steatohepatitis, ASH cirrhosis: alcoholic cirrhosis, OAC: oral contraceptive, AST: aspartate 
transaminase, ALT: alanine transaminase, Alk phos: alkaline phosphatase, LDL: low-density lipoprotein, HDL: high-density 
lipoprotein, NAS: NAFLD activity score, MELD: model for end-stage liver disease. *P<0.05, **P<0.01, ***P<0.001 compared 
to lean controls. #P<0.05, #P<0.01, #P<0.001 compared to overweight controls. Data are expressed as number (%), mean 






















Age	(years)	 43	[13]	 42	[11]	 50	[15]	 53	[12]#	 61	[10]***###	 54	[8]#	 <0.0001	
Gender	(male)	 10	(33)	 5	(17)	 10	(42)	 8	(36)	 9	(41)	 12	(80)*	 0.003	
BMI	(kg/m2)	 22.6	[1.4]	 30.4	[3.8]***	 33.6	[6.5]***	 34.6	[9.2]***	 35.2	[5.4]***	 27.2	[5.7]	 <0.0001	
Alcohol	(units/week)	 1	[0-8]	 1	[0-42]	 0	[0-7]	 0	[0-3]	 0	[0-3]	 0	[0-130]	 0.032	
Race	
		Caucasian	 18	(60)	 23	(77)	 19	(79)	 22	(100)*	 21	(95.5)	 10	(67)	 	
<0.001			African	American	 4	(13)	 6	(20)	 4	(17)	 0	 1	(4.5)	 5	(33)	
		Asian	 8	(27)	 1	(3)	 1	(4)	 0	 0	 0	
OAC	use	 4	(13)	 3	(10)	 0	 0	 0	 0	 0.076	
Diabetes	mellitus	 0	 0	 6	(25)	 12	(54.5)*#	 15	(68.2)*#	 1	(6.7)	 <0.001	
Insulin	dependent	 0	 0	 1	(4.2)	 4	(18.2)	 3	(13.6)	 0	 0.008	
Hemoglobin	(g/dL)	 	 	 14.0	[1.4]	 14.5	[1.6]	 13.3	[1.2]	 12.2	[2.2]	 0.0003	



























































		Total	(mg/dL)	 155	[31]	 164	[17]	 180	[46]	 159	[37]	 163	[39]	 134	[31]	 0.004	
		LDL	(mg/dL)	 81	[23]	 85	[19]	 110	[36]**##	 88	[35]	 89	[29]	 73	[19]	 0.0006	
		HDL	(mg/dL)	 48	[15]	 42	[14]	 53	[14]	 49	[15]	 50	[21]	 37	[11]	 0.018	
		Triglycerides	(mg/dL)	 91	[64]	 136	[95]	 121	[47]*	 154	[70]	 129	[54]	 72	[38]#	 0.001	
NAS	score	 	 	 3	[1-4]	 5	[4-6]	 5	[4-8]	 	 <0.0001	
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Platelet activation status
The basal platelet activation status and the agonist-induced platelet activatability in patients 
and controls are reported in Figure 2. There was no statistically significant difference in the 
number of P-selectin positive platelets at baseline between patients with NAFLD, patients with 
ASH cirrhosis, and lean controls, although few individual patients appeared to have a slightly 
increased basal platelet activation status. Also the MFI of the P-selectin signal was comparable 
between all patients and controls. When platelets were activated in vitro using either TRAP 
or ADP, the percentage of platelets expressing P-selectin were decreased in patients with 
cirrhosis compared to controls when corrected for baseline values, although the difference 
did not reach statistical significance. Furthermore, the MFI after activation with TRAP or ADP 
was also decreased in patients with cirrhosis, although the difference did not reach statistical 
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Figure 2. Basal and agonist-induced platelet activation. 
The basal platelet activation status (A) and the agonist-induced platelet activatability using TRAP (B) and ADP (C) as 
assessed by flow cytometry for P-selectin in lean controls, overweight controls, patients with simple steatosis, patients with 
non-alcoholic steatohepatitis (NASH), patients with NASH cirrhosis, and patients with alcoholic (ASH) cirrhosis. Shown 
are the percentage of P-selectin positive platelets (left panels) and the mean fluorescent intensity (MFI) of the same flow 
cytometry experiments (right panels). Agonist-induced platelet activatability values were corrected for baseline values. 
Horizontal lines represent medians. Bars indicate medians with the error bars representing ranges.




significance compared to controls. Neither basal platelet activation status nor platelet 
activatability in patients with NAFLD correlated with BMI, lipid levels (high density lipoprotein 
(HDL)-C, low density lipoprotein (LDL)-C, total cholesterol, and triglycerides (TGs)), NAS score 
or individual histological parameters (steatosis, inflammation, and ballooning), aspartate 
aminotransferase (AST), alanine aminotransferase (ALT), bilirubin, or c-reactive protein (CRP).
Thromboelastography
TEG test results were comparable between lean and overweight controls, patients with simple 
steatosis, and patients with NASH. However, TEG revealed moderate hypocoagulability 
in both NASH and ASH cirrhosis as demonstrated by a prolonged K-time (NASH cirrhosis 
vs. overweight controls p <0.01) and a decreased a-angle (NASH cirrhosis vs. overweight 
controls p <0.01) and MA (ASH cirrhosis vs. overweight controls p <0.05).
Thrombin generation, PT, APTT
Compared to lean controls, there was a trend towards increased thrombin generation 
in overweight controls but this did not reach statistical significance. In the absence of TM, 
thrombin generation was decreased in patients with cirrhosis, as demonstrated by a decrease 
in ETP and peak. However, in the presence of TM, thrombin generation was comparable 
between all patient groups and controls (Fig. 3). When these data were recalculated to a 
normalized thrombomodulin sensitivity ratio (TM-SR), it became evident that TM was less 
effective at regulating thrombin generation in patients with cirrhosis compared to controls 
(Fig. 3). There was a strong negative correlation between TM-SR and levels of protein C (r = 
-0.60; p <0.0001) and levels of antithrombin (r = -0.57; p <0.0001). In addition, the TM-SR 
correlated with the ratio of factor VIII to protein C (r = 0.50; p <0.0001). However, TM-SR 
values did not correlate with BMI, lipid levels, or NAS score.
None of the thrombin generation parameters within the patients with NAFLD correlated 
with BMI, lipid levels (HDL-C, LDL-C, total cholesterol, and TGs), NAS score or individual 
histological parameters (steatosis, inflammation, and ballooning), AST, ALT, bilirubin, or CRP.
Both PT and APTT were comparable between patients with non-cirrhotic NAFLD and controls. 
However, in patients with cirrhosis the PT (p <0.001 compared to lean controls) and APTT (p 
<0.01 compared to lean controls) were prolonged.
Figure 3. Results from the thrombin generation test. 
Endogenous thrombin potential (ETP) (A), ETP in the presence of thrombomodulin (TM+ ) (B), and the thrombomodulin 
sensitivity ratios (TM-SR) (C) in lean controls, overweight controls, patients with simple steatosis, patients with non-
alcoholic steatohepatitis (NASH), patients with NASH cirrhosis, and patients with alcoholic (ASH) cirrhosis. 
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Fibrinolysis
The clot lysis time was higher in overweight controls and in patients with non-cirrhotic NAFLD 
compared to lean controls, although differences did not reach statistical significance. The clot 
lysis time was comparable between patients with NASH-related cirrhosis and lean controls, 
but was decreased in patients with ASH-related cirrhosis (Fig. 4).
Figure 4. Fibrinolytic potential. 
Clot lysis time (A) and levels of plasminogen activator inhibitor-1 (PAI-1) (B) in lean controls, overweight controls, patients 
with simple steatosis, patients with non-alcoholic steatohepatitis (NASH), patients with NASH cirrhosis, and patients with 
alcoholic (ASH) cirrhosis. Horizontal lines represent medians. 
* P <0.05, ** P <0.01 compared to lean controls. # P <0.01, ## P <0.01 compared to overweight controls.
Fibrin structure
Clot permeability was decreased in overweight controls and patients with NAFLD, indicating 
more dense clots compared to lean controls, although differences did not reach statistical 
significance (Fig. 5). Clot permeability was similar in patients with ASH-related cirrhosis 
compared to lean controls, whereas clots generated in NASH-related cirrhosis had 
substantially reduced permeability.
Confocal microscopy revealed a stepwise increase in fiber density from lean controls to 
overweight controls and patients with simple steatosis to patients with NASH and NASH 
cirrhosis (Fig. 5). Fiber density was also increased in patients with ASH-related cirrhosis 
compared to lean controls (p <0.001). 
The protein carbonyl content of fibrinogen purified from patients with simple steatosis, 
NASH, and NASH cirrhosis was increased compared to lean controls, although differences 
did not reach statistical significance. However, the carbonyl content of fibrinogen purified 
from patients with ASH-related cirrhosis was significantly elevated (p <0.01 compared to lean 
controls).
We observed a negative correlation between fibrinogen levels and clot permeability (r = 
-0.66, p <0.0001). Furthermore, fiber density correlated with the BMI (r = 0.35, p <0.0001). 
However, within patients with NAFLD, values of clot permeability or fiber density did not 
correlate with lipid levels, NAS score, AST, ALT, bilirubin, or CRP.
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Figure 5. Fibrin structure. 
The permeability coefficient (Ks, calculated following Darcy’s Law) (A) and fibrin fiber density assessed by laser-scanning 
confocal microscopy (expressed as the number of fibers per 100 µm) (B) in plasma clots of lean controls, overweight 
controls, patients with simple steatosis, patients with non-alcoholic steatohepatitis (NASH), patients with NASH cirrhosis, 
and patients with alcoholic (ASH) cirrhosis. Horizontal lines represent medians. * P <0.05, ** P <0.01 compared to lean 
controls.
Plasma levels of proteins involved in primary hemostasis
Levels of sP-selectin were slightly, but non-significantly increased in patients with NASH, NASH 
cirrhosis, and ASH cirrhosis compared to lean and overweight controls. In contrast, levels of 
PF4 were comparable between all patient groups and controls. Plasma levels of VWF were 
comparable between controls and patients with non-cirrhotic NAFLD. However, VWF levels 
were increased in patients with cirrhosis compared to patients with non-cirrhotic NAFLD and 
controls (p <0.001). In contrast, ADAMTS13 activity was comparable between all cohorts.
Plasma levels of proteins involved in coagulation
Although fibrinogen levels were higher in overweight controls and patients with NAFLD 
compared to lean controls, this did not reach statistical significance. Patients with cirrhosis 
and lean controls had comparable fibrinogen levels. In NAFLD patients, levels of fibrinogen 
modestly correlated with BMI (r = 0.21; p = 0.02). Furthermore, fibrinogen levels increased 
with increasing severity of steatosis on liver biopsy (2.24 mg/ml [2.08–2.65] (median [range]) in 
steatosis <5%, 3.38 mg/ml [2.21–5.91] in steatosis 5–33%, 3.09 mg/ml [1.49–5.07] in steatosis 
34–66%, and 3.80 mg/ml [3.44–4.43] in steatosis >66%; p <0.007). However, fibrinogen levels 
did not correlate with other individual histological parameters (inflammation or ballooning) or 
with lipid levels. Plasma levels of FVII were slightly, but non-significantly increased in patients 
with non-cirrhotic NAFLD compared to lean controls. In contrast, in patients with cirrhosis 
levels were decreased (NASH cirrhosis p <0.05; ASH cirrhosis p <0.001 compared to lean 
controls). Levels of FVIII were increased in patients with NASH-related cirrhosis compared 
to lean controls (p <0.05). In contrast, levels were similar between patients with ASH-related 
cirrhosis and controls. Both protein C and antithrombin levels were decreased in patients with 
NASH- and ASH-related cirrhosis (p <0.001 for both protein C and antithrombin compared 
to lean controls). Levels of D-dimer were non-significantly increased in patients with non-
cirrhotic NAFLD, but levels were significantly increased in patients with cirrhosis compared to 
lean controls (p <0.001).
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FVII	(%)	 105	[27]	 127	[32]	 113	[29]	 114	[34]	 79	[32]*###	 62	[25]***###	 <0.0001	
FVIII	(%)	 144	[37]	 149	[39]	 141	[46]	 142	[35]	 182	[55]*	 154	[48]	 0.016	
Protein	C	(%)	 114	 118	 120	 125	 76##	 63***###	 <0.0001	
















































































































































1.57	[0.23]	 1.79	[0.36]	 1.73	[0.33]	 1.96	[0.38]**	 1.88	[0.39]*	 1.77	[0.41]	 0.003	
Lag	time	TM+	
(min)	
1.54	[0.26]	 1.75	[0.29]	 1.69	[0.35]	 1.90	[0.34]**	 1.91	[0.36]***	 1.80	[0.38]	 0.0004	
















































































Table 2. Data from all 
hemostatic tests. NASH: Non-
alcoholic steatohepatitis, ASH 
cirrhosis: alcoholic cirrhosis, MFI: 
mean fluorescence intensity, 
sP-selectin: soluble P-selectin, 
PF4: platelet factor 4, VWF: von 
Willebrand Factor, ADAMTS13: a 
disintegrin and metalloproteinase 
with a thrombospondin type 1 
motif member 13, PT: prothrombin 
time, APTT: activated partial 
thromboplastin time, F: factor, 
tPA: tissue plasminogen activator, 
PAI: plasminogen activator 
inhibitor, ETP: endogenous 
thrombin potential, Velindex: 
velocity index, TM+: in presence 
of thrombomodulin, TM-SR: 
thrombomodulin sensitivity 
ratio, R-time: reaction time, 
K-time: kinetics time, MA: 
maximum amplitude, LY30: lysis 
at 30 minutes. *P<0.05, **P<0.01, 
***P<0.001 compared to lean 
controls. #P<0.05, #P<0.01, 
#P<0.001 compared to overweight 
controls. Data are expressed 
as number (%), mean [SD], or 
median [range]. 




Plasma levels of proteins involved in fibrinolysis
Levels of PAI-1 stepwise increased from lean controls to overweight controls to patients with 
simple steatosis, and were still increased in patients with NASH and NASH cirrhosis (Fig. 4), 
although levels were only significantly increased in patients with NASH compared to lean 
controls. Levels of tPA also stepwise increased from healthy controls to patients with NASH 
cirrhosis, although levels were only significantly increased in patients with NASH cirrhosis 
compared to lean controls.
The clot lysis time correlated with PAI-1 levels (r = 0.68; p <0.0001) and fibrinogen levels (r 
= 0.25; p = 0.007) in patients with NAFLD. In addition, within the patients with NAFLD, clot 
lysis time slightly correlated with BMI (r = 0.19; p = 0.04), but not with lipid levels (HDL-C, 
LDL-C, total cholesterol, and TGs), NAS score or individual histological parameters (steatosis, 
inflammation, and ballooning). Levels of PAI-1 also correlated with BMI (r = 0.21; p = 0.02), but 
not with lipid levels. Furthermore, PAI-1 levels increased with increasing grade of NAS score 
(1.08 ng/ml [0.29–9.15] in patients with NAS <3, 1.94 ng/ml [0.58–7.70] in patients with NAS 
3-4, and 2.18 ng/ml [0.19–9.12] in patients with NAS ≥5), although these differences were 
not significant. PAI-1 levels also appeared to increase with increasing severity of steatosis, 
inflammation, and ballooning on liver biopsy, although differences did not reach statistical 
significance (data not shown). Finally, within patients with NAFLD, none of the fibrinolysis 
parameters correlated with AST, ALT, bilirubin, or CRP.
Discussion
The combined results of this study show that the overall hemostatic status is comparable 
between patients with NAFLD and controls. Our study, therefore, suggests that the role 
for hyperactive hemostasis in the increased risk of thrombosis in patients with NAFLD is 
probably limited. Furthermore, since there were no differences in the coagulation status 
between patients with NASH- or ASH-related cirrhosis, there is probably also a limited role for 
hemostasis in the increased thrombotic risk in patients with NASH-related cirrhosis compared 
to patients with cirrhosis from other etiologies. However, our data show some pro-thrombotic 
features in patients with NAFLD, including hypofibrinolysis and a pro-thrombotic structure of 
the fibrin clot, which appear driven by obesity rather than the liver disease itself. We observed 
a hypofibrinolytic state in patients with non-cirrhotic NAFLD, which appeared to resolve in 
NASH-related cirrhosis. The hypofibrinolytic state in non-cirrhotic NAFLD may contribute to 
thrombosis risk in these patients as a hypofibrinolytic state as determined with our clot lysis 
assay has been demonstrated to form a risk factor for both venous and arterial thrombosis in 
the general population [26–28]. Furthermore, we observed decreased fibrin clot permeability 
and increased clot density in patients with NAFLD indicating a pro-thrombotic structure of the 
fibrin clot in these patients.
Previous studies have shown decreased fibrin clot permeability to be associated with 
thrombotic diseases [29–31]. We have recently shown that fibrin clot permeability in patients 
with cirrhosis of varying etiology is markedly reduced despite decreased fibrinogen plasma 
levels in these patients. The pro-coagulant properties of the fibrin clot in cirrhosis was 
attributed to increased oxidation of the fibrinogen molecule [25], which is known to result 
in a more thrombogenic fibrin clot. The thrombogenic nature of fibrin clots in patients with 
NAFLD, as identified in the present study, is likely attributable to multiple factors including 
increased oxidation of the fibrinogen molecule and elevated plasma fibrinogen levels. In 
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addition, in those patients with diabetes, glycation of the fibrinogen molecule contributes to 
decreased fibrin clot permeability [32].
Previous studies have suggested an increased activity of platelets in patients with the 
metabolic syndrome [12,13] and in patients with NAFLD [14,33–35], which might contribute 
to their increased risk of thrombosis. However, results from these studies are inconsistent, 
most of these studies are limited by their relative small sample size, and use indirect markers 
of platelet activation (e.g., mean platelet volume). The results of our study show that NAFLD 
is not associated with platelet hyperactivity measured using a direct flow cytometric assay 
of platelet activation status. In addition, NAFLD was not associated with changes in pivotal 
proteins in primary hemostasis. We did observe decreased platelet activatability in patients 
with cirrhosis, which has been previously shown [17].
Although TEG and thrombin generation testing in the absence of thrombomodulin 
revealed a slight hypocoagulability in patients with cirrhosis, when tested in the presence of 
thrombomodulin thrombin generation was comparable to that of lean or overweight controls 
in patients with cirrhosis, which has been previously shown [36–38]. In extent, thrombin 
generation was also normal in patients with NAFLD. In contrast, Tripodi et al. concluded that 
NAFLD is characterized by a pro-coagulant-imbalance, as shown by an increase in ETP-ratio 
(with-to-without thrombomodulin) in these patients [11]. However, this ratio only represents 
the capacity of thrombomodulin to downregulate thrombin generation, and is by no means 
a direct indicator of hemostatic potential. An increase in the ETP-ratio in patients with 
NAFLD therefore does not explain their increased risk of thrombosis compared to patient 
with alcoholic/viral cirrhosis. We argue against the use of the ETP-ratio or TM-SR to classify 
if patient samples are normo- or hypercoagulable, but instead believe that the thrombin 
generation performed in the presence of thrombomodulin is the most accurate laboratory 
measure of the coagulant potential of a patients’ plasma.
Several studies have shown increased levels of various individual pro-thrombotic factors in 
patients with NAFLD [7–9,11,39–41]. Although results have been inconsistent, an increase in 
PAI-1, fibrinogen, and factor VIII and a decrease in antithrombin are most frequently reported. 
Levels of fibrinogen were also increased in patients with non-cirrhotic NAFLD in this study, 
although the difference with controls did not reach statistical significance. However, in patients 
with cirrhosis fibrinogen levels are mostly decreased [42], as also observed in patients with 
ASH-related cirrhosis in this study. Yet, patients with NASH-related cirrhosis in our study had 
fibrinogen levels comparable to that of the controls, which likely relates to a relative increase 
in fibrinogen production due to the fatty liver disease. Levels of factor VIII were increased 
in patients with NASH-related cirrhosis in this study. In contrast, levels of antithrombin were 
decreased in patients with cirrhosis, which is in agreement with previous studies [36,38,43]. 
Finally, we observed increased levels of PAI-1 in patients with NAFLD and levels increased 
with increasing severity of the disease and increasing severity of steatosis, which has been 
previously shown [9].
In our study, several hemostatic test results (such as platelet activity, clot lysis time, PAI-1 
levels, and fiber density) showed a higher variability in patients than in controls, suggesting 
individual patients may have a more thrombogenic hemostatic profile. We did not identify 
any characteristics of individual patients to explain the more extreme values in individual 




patients, although our study likely lacks power to identify such characteristics. We did observe 
relations between BMI and clot lysis time, PAI-1 levels, and fibrin fiber density, which in part 
have been previously described [27,44].
To conclude, the combined results of this study show that the overall hemostatic status is 
comparable between patients with NAFLD and controls, which contrasts with previously 
published results in similar populations. We did identify some pro-thrombotic features in 
patients with NAFLD, particularly a pro-thrombotic structure of the fibrin clots. Although the 
discrepancy between our study and previous ones is unclear, we included a well-defined 
cohort of patients and controls, included patients with established cirrhosis, and performed an 
exhaustive panel of hemostasis tests including functional assessment of platelets, coagulation, 
and fibrinolysis. The results of this study suggest that the role for hemostasis in the increased 
risk of thrombosis in patients with NAFLD and NASH-related cirrhosis is probably limited.
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Abstract
Background: Treatment and prevention of thrombotic complications is frequently required in 
patients with cirrhosis. However anticoagulant therapy is often withheld from these patients, 
because of the perceived bleeding diathesis. As a result of the limited clinical experience, the 
anticoagulant of choice for the various indications is still unknown.
Objectives: We evaluated the in vitro effect of clinically approved anticoagulant drugs in 
plasma from patients with cirrhosis.
Patients/Methods: Thirty patients with cirrhosis and thirty healthy controls were studied. 
Thrombin generation assays were performed before and after addition of unfractionated 
heparin, low molecular weight heparin, fondaparinux, dabigatran, and rivaroxaban, to 
estimate anticoagulant potencies of these drugs.
Results: Addition of dabigatran led to a much more pronounced reduction in endogenous 
thrombin potential in patients compared to controls (72.6% reduction in patients vs. 12.8% 
reduction in controls, P<0.0001). The enhanced effect of dabigatran was proportional to the 
severity of disease. In contrast, only a slightly increased anticoagulant response to heparin and 
low molecular weight heparin and even a reduced response to fondaparinux and rivaroxaban 
was observed in plasma from cirrhotic patients as compared to control plasma.
Conclusions: The anticoagulant potency of clinically approved drugs differs substantially 
between patients with cirrhosis and healthy individuals. Whereas dabigatran and, to a lesser 
extent, heparin and low molecular weight heparin are more potent in plasma from patients 
with cirrhosis,  fondaparinux and rivaroxaban showed a decreased anticoagulant effect. These 
results may imply that in addition to dose adjustments based on altered pharmacokinetics, 
drug-specific dose adjustments based on altered anticoagulant potency may be required in 
patients with cirrhosis.





Chronic liver disease has long been considered as the epitome of acquired bleeding 
disorders, due to clinically observed bleeding complications (e.g. variceal bleeding) in 
combination with a decreased number and function of platelets, decreased synthesis of 
coagulation factors by the diseased liver, and hyperfibrinolysis [1]. Conventional coagulation 
tests such as the prothrombin time (PT) and activated partial thromboplastin time (APTT), 
designed to assess isolated defects of pro-coagulants, but insensitive for anticoagulant 
factors, are frequently prolonged in patients with cirrhosis suggesting defective hemostasis 
and thus a bleeding tendency. Recently, more sophisticated tests of hemostasis that allow 
assessment of the true balance between pro- and anticoagulant factors, have been used 
to reassess the hemostatic capacity of patients with liver disease. In particular, thrombin 
generation testing performed in the presence of thrombomodulin (TM) has demonstrated 
normal or even superior thrombin generation compared to healthy volunteers [2–7]. These 
experiments in conjunction with clinical observations have led to the concept of ‘rebalanced 
hemostasis’, which suggests hemostatic balance by a concomitant decrease in both pro- and 
anticoagulant drivers [8,9]. Although the hemostatic system of patients with liver disease is in 
a ‘rebalanced’ status, clinical thrombotic events and bleeding complications suggest that this 
balance is more unstable as compared to the balance in healthy individuals and can be easily 
tipped over to a hyper- or a hypocoagulable state [10].
Despite historical beliefs that patients with liver disease are ‘auto-anticoagulated’, thrombotic 
complications do occur in cirrhotic patients and form evidence for hypercoagulability in these 
patients [11,12]. Because of the perceived bleeding diathesis of liver disease, prophylactic 
anticoagulant therapy is presumably underused in patients with cirrhosis. Furthermore, 
treatment of thrombotic complications is frequently required, as patients with liver disease 
can suffer from deep vein thrombosis or pulmonary embolism, and portal vein thrombosis 
[11,12]. Moreover, patients may require anticoagulation for systemic arterial events [12].
Nowadays, there is increasing recognition of various thrombotic complications that may occur 
in patients with chronic liver disease and therefore an increase in the use of anticoagulant 
therapy in these patients may be expected. Due to the limited clinical experience, the 
anticoagulant of choice for the various indications is still unclear. Vitamin K antagonists have 
major drawbacks when used in cirrhotic patients, as vitamin K antagonist therapy requires 
monitoring by the international normalized ratio (INR) which is frequently already abnormal 
in cirrhotic patients. Clinical data on the use of low molecular weight heparin (LMWH) 
indicate that the drug is safe and effective in both the treatment and prevention of portal vein 
thrombosis [13,14]. In addition heparins appear safe and effective in prevention of venous 
thrombosis [15]. However, the mode of administration of these agents as well as the concern 
for heparin-induced thrombocytopenia (HIT) may limit long-term use. In addition, monitoring 
of heparins is complicated by the substantial underestimation of heparin levels when tested 
by an anti-Xa assay [16–18]. Finally, LMWH accumulation is known to occur in patients with 
renal failure, and thus patients with chronic liver disease and decreased renal function likely 
require dose adjustments based on altered pharmacokinetics.
There is little published clinical experience with the new oral anticoagulants (NOACs) such 
as the direct factor Xa and thrombin inhibitors Rivaroxaban and Dabigatran in patients with 
a chronic liver disease. However, these new agents would be potentially applicable in both 
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long- and short term anticoagulant strategies in patients with cirrhosis, and such agents have 
(theoretical) advantages over currently used strategies [19]. Nevertheless, since currently 
available NOACs such as Rivaroxaban and Dabigatran are cleared by liver and kidneys, it 
is conceivable that the pharmacokinetics of these drugs is also altered in patients with 
(advanced) liver disease.
In vitro studies have demonstrated that LMWH has a more profound anticoagulant effect 
in plasma from patients with cirrhosis as compared to plasma from healthy controls [17]. 
Possible increased responses to anticoagulant drugs may have important consequences for 
the dosing regiments in these patients. In this study, we aimed to investigate the efficacy of 
currently approved and widely used anticoagulant drugs by performing in vitro thrombin 
generation tests in plasma of patients with cirrhosis.
Patients and Methods
Patients
Thirty adult patients with a previous clinical diagnosis of cirrhosis, who were under routine 
control for their disease by the department of Hepatology of the UMCG or who were 
admitted at the Hepatology ward of the UMCG, were included in the study. The patients were 
classified according to the Child-Pugh classification [20]. Ten patients with Child’s A cirrhosis, 
10 patients with Child’s B cirrhosis, and 10 patients with Child’s C cirrhosis were studied. 
Exclusion criteria were documented history of congenital coagulation disorders, presence of 
active infection (<2 weeks), presence of acute liver failure, use of anticoagulant drugs in the 
past 10 days, pregnancy, HIV positivity, and recent (<7 days) transfusion with blood products.
The control group consisted of thirty adult healthy volunteers working at our institution. 
Exclusion criteria for the control group were documented history of congenital coagulation 
disorders, documented history of hepatic disease, recent viral infection (<2 weeks), use of 
anticoagulant drugs in the past 10 days, pregnancy, and HIV positivity.
Ethics statement
This study protocol was approved by the medical ethical committee of the University Medical 
Center Groningen, Groningen, The Netherlands and written informed consent was obtained 
from each subject before inclusion in the study. The study was conducted according to the 
principles expressed in the Declaration of Helsinki.
Plasma samples
Blood samples from each patient and control were drawn by clean vena-puncture and 
collected into vacuum tubes containing 3.8% trisodium citrate as an anticoagulant, at a blood 
to anticoagulant ratio of 9:1. Platelet poor plasma was prepared by double centrifugation at 
2000 g and 10.000 g respectively for 10 min. Plasma was snap-frozen and stored at 280uC 
until use.




Addition of anticoagulants to plasma samples
The following anticoagulants were added to plasma samples of every cirrhotic patient and 
control. The mentioned concentrations represent final concentrations in plasma.
– Unfractionated heparin (Leo Pharma, Denmark), 0.1 U/ml
– The LMWH Clexane (Sanofi-Aventis BV, Gouda, the Netherlands), 0.2 U/ml
– Fondaparinux (Arixtra) (GlaxoSmithKline BV, Zeist, the Netherlands), 0.5 mg/ml
– Dabigatran (Alsachim, Illkirch Graffenstaden, France), 300 ng/ml
– Rivaroxaban (Alsachim, Illkirch Graffenstaden France), 25 ng/ml
The final concentrations of the various drugs were based on initial experiments in which 
drugs were added in various concentrations to pooled normal plasma after which thrombin 
generation was performed as described in the next paragraph. Those drugs concentrations 
which gave appreciable (but not maximal) inhibition of thrombin generation in pooled normal 
plasma were selected so it would be possible to detect both increased and decreased drug 
effects in patients compared to controls.
Thrombin generation
The thrombin generation test was performed using platelet-poor plasma (PPP) with the 
fluorimetric method described by Hemker, Calibrated Automated ThrombographyH 
(CAT) [21]. Coagulation was activated using commercially available reagents containing 
recombinant tissue factor (TF, final concentration 5 pM), phospholipids (final concentration 4 
mM), in the presence or absence of soluble thrombomodulin (TM, the concentration of which 
is not revealed by the manufacturer). These reagents were purchased from Thrombinoscope 
BV, Maastricht, The Netherlands. Thrombin Calibrator (Thrombinoscope BV) was added 
to calibrate the thrombin generation curves. A fluorogenic substrate with CaCl2 (FluCa-
kit, Thrombinoscope BV, Maastricht, The Netherlands) was dispensed in each well to allow 
a continuous registration of thrombin generation. Fluorescence was read in time by a 
fluorometer, Fluoroskan AscentH (ThermoFisher Scientific, Helsinki, Finland). All procedures 
were according to the protocol suggested by Thrombinoscope B.V.
The anticoagulant potency of the different drugs was expressed as the percentual reduction 
of endogenous thrombin potential (ETP), peak, or velocity index, and the percentual increase 
in lag time after the addition of anticoagulants. These percentages were compared between 
patients and controls.
Routine coagulation laboratory tests
The INR was assessed with commercially available methods on an automated coagulation 
analyzer (ACL 500 TOP) with reagents (Recombiplastin 2G) and protocols from the 
manufacturer (Instrumentation Laboratory, Breda, the Netherlands). Levels of factor (F) VIII, 
II, and X, and antithrombin (AT) were measured on an automated coagulation analyzer (ACL 
500 TOP) with reagents and protocols from the manufacturer (Recombiplastin 2G for FII and 
FX, Hemosil (R) SynthASil for FVIII, and Liquid Antithrombin reagent for AT) (Instrumentation 
Laboratory). Total protein S antigen was assayed by enzyme-linked immunosorbent assay 
(ELISA) using antibodies from DAKO (Glostrup, Denmark). Free protein S was measured by 
precipitating the C4b-binding protein-bound fraction with polyethylene glycol 8000 and 
measuring the concentration of free protein S in the supernatant. Protein C was determined 
using the Coamatic protein C activity kit from Chromogenix (Mölndal, Sweden).
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Statistical analysis
Data are expressed as means (with standard deviations (SDs)), medians (with interquartile 
ranges), or numbers (with percentages) as appropriate. Means of two groups were compared 
by Student’s t-test or Mann-Whitney U test as appropriate. Multiple groups were compared 
using One-way ANOVA (with the Bonferroni posttest) or Kruskal-Wallis H test (with Dunn’s 
posttest) as appropriate. Spearman’s correlation coefficient was used to assess correlation 
between continuous variables. P values of 0.05 or less were considered statistically significant. 





	 Child	A	 Child	B	 Child	C	
	 n=10	 n=10	 n=10	 	
Characteristics	
MELD	score	 8.0	[6.0-10.0]	 11.5	[8.0-19.0]	 15.5	[6.0-19.0]	 .002	
Age	(yrs)	 56.0	[14.2]	 50.5	[12.5]	 54.9	[8.3]	 .560	








Smoking	(number)	 4	(40)	 1	(10)	 4	(40)	 .297	
Alcohol	(U	per	week)	 0	[0-1]	 0	[0-7]	 0	[0-490]	 .670	
Etiology	of	liver	disease	
		Alcoholic	 2	(20)	 1	(10)	 10	(100)	 <.001	
		HCV	 1	(10)	 0	(0)	 0	(0)	 1.000	
		NASH	 1	(10)	 2	(20)	 0	(0)	 .754	
		Hemochromatosis	 0	(0)	 1	(10)	 0	(0)	 1.000	
		PBC	 1	(10)	 0	(0)	 0	(0)	 1.000	
		PSC	 2	(20)	 2	(20)	 0	(0)	 .507	
		Auto-immune	 3	(30)	 1	(10)	 0	(0)	 .286	
		Alcoholic	+	NASH	 0	(0)	 1	(10)	 0	(0)	 1.000	
		Unknown	 0	(0)	 2	(20)	 0	(0)	 .310	
Co-morbidity	
		Cardiovascular	 3	(30)	 2	(20)	 0	(0)	 .321	
		DM	 2	(20)	 1	(10)	 1	(10)	 1.000	
Plasma	levels	
		Serum	bilirubin	(µmol/L)	 15	[5-35]	 40	[18-61]	 82	[46-131]	 <.0001	
		Serum	albumin	(g/L)	 36	[28-44]	 33	[27-63]	 27	[25-91]	 .003	
		Serum	creatinin	(µmol/L)	 69	[23]	 72	[32]	 70	[20]	 .966	
		Hemoglobin	(mmol/L)	 8.2	[1.4]	 7.2	[0.9]	 6.5	[0.8]	 .005	
		Leukocytes	(109/L)	 6.5	[4.5]	 5.1	[2.1]	 7.4	[5.3]	 .463	






Table 1. Demographic and clinical characteristics of the study population.
HCV: Hepatitis C virus, NASH: Non-alcoholic steatohepatitis, PBC: Primary biliary cirrhosis, PSC: Primary sclerosing 
cholangitis, DM: Diabetes Mellitus.
Data are expressed as number (%), mean [SD], or median [range].






The main characteristics of the study population are reported in Table 1. Thirty patients with 
cirrhosis (18 males and 12 females) were included, and they were categorized according to 
the severity of liver disease as expressed by the Child Pugh classes (10 Child A, 10 Child B 
and 10 Child C patients). Thirty healthy subjects (14 males and 16 females) were included as 
controls. The most common etiology of liver disease was alcoholic, especially in the Child 
class C patients.
INR, FVIII, FII, FX, AT, protein S and protein C levels are shown in Table 2. Patients with 
cirrhosis showed a statistically significant prolongation of INR and a decrease in all measured 
coagulation proteins, except for FVIII (which was increased), as compared to controls. The 
reduction in levels of plasmatic factors was proportional to the severity of liver disease.
Table 2. Coagulation parameters in cirrhotic patients and controls. 
INR: International normalized ratio, AT: Antithrombin. 
Data are expressed as median [range].
Thrombin generation
When thrombin generation was performed without addition of any anticoagulant, the 
endogenous thrombin potential (ETP) and peak thrombin generation in plasma from cirrhotic 
patients were comparable to that of healthy controls, both in absence and presence of TM. 
The ETP in the presence of TM was slightly, but significantly higher in patients compared to 
controls. Values in the absence of TM were: ETP 872 ± 260 nM*min (mean ± SD), peak 169 ± 
41 nM in patients vs. ETP 945 ± 268 nM*min, peak 188 ± 49 nM in healthy controls, P =0.28 
for ETP, P =0.11 for peak; in the presence of TM: ETP 677 ± 304 nM*min, peak 146 ± 48 nM 
in patients vs. ETP 510 ± 259 nM*min, peak 131 ± 53 nM in controls, P= 0.03 for ETP, P= 0.26 
for peak.
To study the anticoagulant potency of antithrombotic drugs in plasma from cirrhotic patients, 
percentual reductions in ETP, peak, velocity index, and percentual increases in lag time after 
the addition of the different anticoagulants were calculated and compared between plasma 
from cirrhotic patients and controls. All data are shown in table 3. In figure 1, the reduction 
in ETP performed in the presence of TM after the addition of the different anticoagulants in 







	 Child	A	 Child	B	 Child	C	
INR	 1.1	[0.9-1.2]	 1.2	[1.0-2.0]	 1.5	[1.4-1.7]	 1.0	[0.9-1.1]	 <.0001	
FVIII	(%)	 132	[92-185]	 129	[91-254]	 140	[108-199]	 94	[56-138]	 <.0001	
FII	(%)	 83	[50-104]	 69	[43-98]	 42	[27-71]	 107	[88-127]	 <.0001	
FX	(%)	 90	[74-136]	 81	[41-193]	 56	[45-69]	 106	[80-147]	 <.0001	
AT	(%)	 80	[42-107]	 50	[27-113]	 40	[23-45]	 106	[87-126]	 <.0001	
Protein	C	(%)	 71	[35-105]	 53	[22-155]	 27	[12-44]	 109	[87-168]	 <.0001	
Protein	S	total	(%)	 76	[61-109]	 66	[35-200]	 57	[52-78]	 90	[68-121]	 .002	
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Figure 1. Reductions in ETP after the addition of the different anticoagulant drugs. 
Reduction in ETP after the addition of (A) dabigatran, (B) heparin, (C) LMWH, (D) Fondaparinux, and (E) rivaroxaban in 
plasma from patients with Child A, B, and C cirrhosis and healthy controls. 
Bars indicate medians with the error bars representing interquartile ranges. ** P<0.01 compared to controls.
Dabigatran
When dabigatran was added to plasma of healthy controls, the ETP was reduced by 45.4 
[39.4–47.7]% (median [IQR]) and peak thrombin generation by 29.8 [22.0–34.9]%. In contrast, 
the ETP and peak hardly decreased in the presence of TM (12.8 [210.5–23.0]% reduction in 
ETP and 0.2 [224.3–18.3]% reduction in peak). The lag time was substantially prolonged after 
addition of dabigatran both in absence and presence of TM (Table 3).
Addition of dabigatran led to a much more pronounced reduction in peak thrombin 
generation in patients compared to controls, both in absence (83.1 [64.5–96.6]% reduction in 
patients vs. 29.8 [22.0–34.9]% reduction in controls, P<0.0001) and the presence of TM (82.9 
[56.8–96.3]% reduction in patients vs. 0.2 [224.3–18.3]% reduction in controls, P<0.000001). 
The decrease in thrombin generation with dabigatran mirrored the severity of liver disease. 
Child class C patients exhibited the most pronounced reduction in peak thrombin generation, 
with a median reduction of 97.1 [92.1–97.9]% when tested in the presence of TM.
Interestingly, reductions in thrombin generation by dabigatran when tested in the presence 
of TM strongly correlated with plasma prothrombin (FII) levels (r = - 0.80, P<0.0001) (Figure 2).
Figure 2. Correlation between FII levels and reductions in 
thrombin generation after dabigatran. Correlation between 
plasmatic FII levels and percentual reduction of peak thrombin 
values when tested in the presence of TM after addition of 300 ng/
ml dabigatran in plasma from patients with cirrhosis.
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After the addition of unfractionated heparin the reduction of thrombin generation was 
more profound in plasma from cirrhotic patients compared to controls, with a median ETP 
reduction of 62.0 [54.1–76.8]% in patients vs. 46.0 [32.8–57.2]% in controls (P= 0.0003) (Table 
3). However, in the presence of TM the reductions in ETP were not significantly different 
in plasma from cirrhotic patients compared to controls. The decrease in peak thrombin 
generation was comparable between cirrhotic patients and controls (87.4 [78.6–93.0]% in 
patients vs. 87.3 [78.9–91.3]% in controls, P= 0.46, when tested in the presence of TM).
Low molecular weight heparin
After the addition of LMWH the decrease in the ETP in the absence of TM was more 
pronounced in plasma from cirrhotic patients compared to controls (42.1 [37.5–51.5]% 
reduction in patients vs. 32.8 [29.8–39.0]% reduction in controls, P<0.001) (Table 3). The 
reduction in peak thrombin generation by LMWH was not significantly different in plasma 
from cirrhotic patients (37.0 [32.4–43.5]% reduction) compared to controls (43.3 [33.1–52.1]% 
reduction) (P= 0.14). Moreover, when thrombin generation was performed in the presence of 
TM there was no difference in ETP reduction in plasma from patients compared to controls 
(52.3 [46.3–60.0]% reduction in patients vs. 48.9 [44.3–54.8]% reduction in controls, P =0.05).
Fondaparinux
Addition of fondaparinux in the absence of TM hardly affected the ETP in both patients 
and controls. The reduction in thrombin generation after the addition of fondaparinux was 
comparable between plasma from patients with Child A and B cirrhosis (49.0 [44.1–55.3]% 
and 44.2 [19.4–58.7]% reduction in peak thrombin generation in the presence of TM, 
respectively) and in plasma from healthy controls (54.4 [47.7–62.3]% reduction in peak 
thrombin generation). A reduced anticoagulant response to fondaparinux was seen in plasma 
from patients with Child C cirrhosis, with only 12.9 [8.6–22.5]% reduction in peak thrombin 
generation when tested in presence of TM (P<0.001). In addition, when tested in the presence 
of TM, the prolongation of the lag time was more extensive in plasma from Child C patients 
(25.6 [25.0–38.1]%) as compared to controls (19.8 [12.3–25.6]%; P<0.01).
Interestingly, reductions in peak thrombin generation by fondaparinux when tested in the 
presence of TM strongly correlated with both plasma antithrombin (AT) levels (r = 0.76, 
P<0.0001) and plasma factor X (FX) levels (r = 0.65, P<0.0001) (Figure 3).
Figure 3. Correlation between AT/FX levels and reductions in thrombin generation after fondaparinux. Correlation 
between the percentual reduction in ETP when tested in the presence of TM after addition of 0.5 mg/ml fondaparinux and 
(A) plasmatic AT levels and (B) plasmatic FX levels in plasma from patients with cirrhosis.
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Rivaroxaban
Addition of rivaroxaban in the absence of TM hardly affected the ETP in both patients and 
controls. In contrast, peak thrombin generation was markedly reduced by rivaroxaban in both 
patients and controls, whereas lag times were prolonged. A reduced response to rivaroxaban 
was observed in plasma from cirrhotic patients as compared to control plasma, 46.5 [27.1–
60.5]% peak reduction in patients vs. 61.8 [55.7–64.3]% peak reduction in controls in the 
presence of TM (P= 0.0005). In plasma from Child class C patients the lowest reduction in 
peak thrombin generation was observed, with a median reduction of 28.3 [21.1–39.5]%.
Interestingly, reductions in peak thrombin generation by rivaroxaban in the presence of TM 
correlated with plasma factor X (FX) levels (r = 0.61, P= 0.0004) (Figure 4).
Figure 4. Correlation between FX levels and reductions 
in thrombin generation after rivaroxaban. Correlation 
between plasmatic FX levels and the percentual reduction 
in peak thrombin generation when tested in the presence 
of TM after addition of rivaroxaban at 25 ng/ml in plasma 
from patients with cirrhosis. 
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Table 3. Inhibition of in vitro thrombin generation after addition of various anticoagulant drugs to plasma 
taken from patients with cirrhosis or plasma from healthy controls. Shown are the percentual inhibition 
of the ETP, peak, or velocity index, and the percentual increase in the lag time. 
TM: thrombomodulin, ETP: Endogenous thrombin potential, Velindex: velocity index, LMWH: low 
molecular weight heparin. Data are expressed as median percentages with interquartile range. 
* P<0.05, ** P< 0.01 compared to controls
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Discussion
We observed a profoundly increased anticoagulant response to the direct thrombin inhibitor 
dabigatran in plasma from patients with cirrhosis compared to controls. The enhanced effect 
of dabigatran on thrombin generation was proportional to the severity of liver disease. 
Furthermore, we observed a modestly increased anticoagulant response to heparin and 
low molecular weight heparin in patients compared to controls, but only when tested in 
the absence of TM. In addition, a reduced response to fondaparinux and rivaroxaban was 
observed in plasma from patients with cirrhosis, and the reduced effect was also proportional 
to the severity of disease.These data show that the anticoagulant potency of the different 
drugs differs substantially between cirrhotic patients and controls. In addition, the difference 
in anticoagulant potency between patients and controls differs substantially between the 
different drugs that were tested. The different drugs that were tested may also have an altered 
pharmacokinetics in patients with chronic liver disease, in particular in patients with advanced 
disease and in patients with concomitant renal failure. Therefore, dose adjustments based 
on both pharmacokinetics and altered anticoagulant potency of the specific drug may be 
required. Monitoring assays taking both drug level and drug potency would thus ideally be 
required for patients with liver diseases.
Although there is increasing clinical experience with heparins in patients with cirrhosis, 
clinical experience with NOACs in these patients is lacking. As we foresee that there might be 
an interest in using NOACs in patients with liver disease that require long-time anticoagulant 
treatment [19], we believe it is vital to understand the potentially altered behavior of these 
drugs in patients with liver disease, in addition to altered pharmacokinetics. We have recently 
demonstrated that, in contrast to heparins, monitoring of plasma levels of NOACs is possible 
in patients with liver disease [18], which will enable careful monitoring of these drugs. How 
altered drug potency needs to be assessed in clinical practice requires further study, but 
one could imagine that dose-adjustments based on plasma levels of FII (for Dabigatran) or 
FX (for Rivaroxaban) may be applicable given the linear relation between factor levels and 
anticoagulant potency (figures 2 and 4).
Our results extend recent observations by Senzolo et al. [17] on the increased anticoagulant 
response to LMWH in patients with cirrhosis. Our results, however, showed a more modest 
increase in anticoagulant potency of LMWH in patients with cirrhosis as compared to the 
data by Senzolo et al, and we failed to detect a difference in anticoagulant potency when 
thrombin generation was tested in the presence of TM. Indeed, clinical data on the use of 
heparins indicate that the drug is safe and effective in both the treatment and prevention of 
portal vein thrombosis [13,14,22]. The partially divergent results between our study and that 
of Senzolo et al. may be explained by the differences in LMWH dosage used, differences in 
patient characteristics, and slight differences in methodology. In fact, research has shown 
that thrombin generation is influenced substantially by pre-analytical conditions [23], among 
which the protocol for centrifugation of blood to obtain platelet poor plasma. Senzolo et al. 
prepared the platelet poor plasma by double centrifugation at 2000 g for 10 min. In our study 
the second centrifugation step was set at 10.000 g as recommended [23]. Another possible 
critical difference in the method was the type and concentration of thrombomodulin used in 
the thrombin generation experiments.
Various anticoagulant drugs show different effects on the thrombin generation curves [24]. For 




example, direct factor Xa inhibitors substantially reduce the peak thrombin generation, while 
hardly affecting the endogenous thrombin potential, which was also observed with the direct 
factor Xa inhibitor rivaroxaban in this study. Therefore it has yet to be studied which parameter 
(ETP, peak, lag time, or velocity index) forms the best representation of the anticoagulant 
effect of a specific drug. In addition, the effects of a drug on the various parameters of the 
thrombin generation curve are not per definition concordant. For example, the reductions 
in peak and ETP after addition of fondaparinux and rivaroxaban were less pronounced in 
plasma from Child C cirrhotic patients compared to controls, which may imply increase in the 
dosages. However, Child class C patients exhibited the greatest prolongation of the lag time 
after the addition of both fondaparinux and rivaroxaban, which may imply that in patients with 
cirrhosis the dosage should be decreased.
We chose the concentrations of the various drugs to obtain appreciable (but not maximal) 
inhibition of thrombin generation in controls. The drug levels therefore do not necessarily 
represent peak levels found in clinical practice, although the levels we chose are all compatible 
with drugs levels at some stage of therapy. We would like to stress that the aim of our study 
was to provide proof of concept of differential drug potency in patients with liver disease 
rather than an exact estimate of drug potencies at clinically relevant plasma levels.
In conclusion, using in vitro thrombin generation assays, we observed a substantially increased 
anticoagulant response to dabigatran and a modestly increased anticoagulant response to 
heparin and LMWH in plasma from patients with cirrhosis. In addition, a reduced response 
to fondaparinux and rivaroxaban was observed in plasma from patients with cirrhosis. These 
results may imply that drug-specific dose adjustments may be required for patients with 
cirrhosis, in particular with dabigatran. However since the pharmacokinetics of the drugs 
may also be altered in these patients, the final dosing regimen should ideally take both the 
pharmacokinetics of the drug and the altered anticoagulant potency into account. Clinical 
studies on the in vivo effect of the available anticoagulant drugs in cirrhotic patients with 
thrombosis are needed to further validate this hypothesis.
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There is increasing interest in treatment and prevention of cirrhotic portal vein thrombosis 
(PVT) with anticoagulant drugs [1]. Two recent reports in Hepatology suggested efficacy and 
safety of new-generation oral anticoagulant drugs (the direct factor Xa inhibitors, Rivaroxaban 
and Apixaban) in treatment of PVT in patients with compensated cirrhosis [2,3]. These new 
drugs have practical advantages over traditional anticoagulants [4]. We recently showed 
altered in vitro potency of different anticoagulant drugs in patients with cirrhosis, compared 
to patients with intact liver function [5]. A theoretical risk for excessive anticoagulation when 
using these drugs in patients with cirrhosis and concomitant alterations in their hemostatic 
system exists.
We previously demonstrated a decreased in vitro anticoagulant effect of Rivaroxaban in 
patients with cirrhosis. Using thrombomodulin-modified thrombin generation testing, 
we examined the in vitro anticoagulant potency of Apixaban, which we compared to the 
anticoagulant potency of Rivaroxaban. This study protocol was approved by the medical 
ethical committee of the University Medical Center Groningen (Groningen, The Netherlands), 
and written informed consent was obtained from each subject before inclusion in the study. 
We added vehicle, 25 ng/mL of Apixaban, or 50 ng/mL of Rivaroxaban to plasma samples 
of 11 healthy individuals and 14 patients with cirrhosis (9 patients with Child B cirrhosis 
and 5 with Child C cirrhosis). We performed thrombin generation tests in the presence of 
thrombomodulin and calculated the percentual decrease in total thrombin generation by 
the two anticoagulant drugs, as described previously [5]. Whereas a fixed dose of the drugs 
decreased total thrombin generation in healthy volunteers by 55 ± 6% (Rivaroxaban, mean 
± standard deviation) and 51 ± 4% (Apixaban), the mean decrease in thrombin generation 
in patients was significantly lower (30 ± 9% for Rivaroxaban, P<0.0001 [t test]; 32 ± 10% for 
Apixaban, P<0.0001).
In conclusion, the in vitro anticoagulant potency of Apixaban is substantially reduced in patients 
with moderate and advanced cirrhosis, similar to the reduced potency of Rivaroxaban, which 
we previously reported. These results suggest that anticoagulant treatment with these direct 
factor Xa inhibitors will likely not result in over-anticoagulation, with a potentially increased 
bleeding risk, provided drug levels remain in the target range. Careful monitoring of drug 
levels, for example, by anti-Xa testing [6] may be required.
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Summary
There is increasing recognition that thrombotic complications may occur in patients with 
cirrhosis, and literature on antithrombotic treatment in these patients is rapidly emerging. Due 
to extensive haemostatic changes in patients with cirrhosis, careful monitoring of anticoagulant 
therapy may be required. Recent data suggest that plasma levels of low molecular weight 
heparin (LMWH) are substantially underestimated by the anti-activated factor X (anti-Xa) assay 
in patients with cirrhosis. We studied the in vitro recovery of antithrombin (AT)-dependent and 
–independent anticoagulant drugs in plasma from 26 patients with cirrhosis and 30 healthy 
controls and found substantially reduced anti-Xa levels when AT-dependent anticoagulant 
drugs were added to the plasma of patients with cirrhosis. LMWH (0.2 U/ml) had the poorest 
recovery in plasma from patients with cirrhosis (0.13 ± 0.06 U/ml, compared to 0.23 ± 
0.03 U/ml in controls, P < 0.0001), followed by unfractionated heparin and fondaparinux. 
In contrast, the recovery of rivaroxaban and dabigatran was identical between patients and 
controls. These data suggest that the anti-Xa assay cannot be used to monitor AT-dependent 
anticoagulant drugs in patients with cirrhosis, as it substantially underestimates drug levels. 
The direct factor Xa and IIa inhibitors, however, may be monitored through the respective 
anti-Xa and anti-IIa assays in patients with cirrhosis.





In patients with chronic liver disease the haemostatic system is considered to be in a 
‘rebalanced’ status, due to a concomitant decrease in pro- and anti-haemostatic systems [1]. 
However, the relatively high incidence of thrombotic events and bleeding complications in 
these patients suggests that this balance is less stable than that in healthy individuals and 
that it can be easily tipped over to a hyper- or a hypocoagulable state [2]. In fact, treatment of 
thrombotic complications is frequently required, as patients with liver disease can suffer from 
deep vein thrombosis, pulmonary embolism or portal vein thrombosis [3,4]. Furthermore, 
patients may require anticoagulation because of concomitant cardiovascular disease[3]. 
Nowadays, there is increasing recognition of the various thrombotic complications that may 
occur in patients with chronic liver disease and therefore the increased use of anticoagulant 
therapy in these patients may be expected [5]. Due to the limited clinical experience, the 
anticoagulant of choice for the various indications is still unclear.
Vitamin K antagonists and/or heparins are widely used in the prevention or treatment of 
thrombosis, but both drug classes have drawbacks in patients with liver diseases. Vitamin K 
antagonist therapy requires monitoring by the international normalized ratio (INR). However, 
as the INR is frequently already prolonged in patients with cirrhosis in the absence of 
anticoagulant therapy, the target INR is unclear. In addition, there is major inter-laboratory 
variability in the INR measurement in patients with cirrhosis, making the test results inherently 
unreliable in these patients [6]. 
A problem with monitoring unfractionated heparin (UFH) is that the activated partial 
thromboplastin time (APTT), which is instrumental in dosing this agent, is already prolonged 
in many patients with chronic liver disease, and therefore APTT target ranges for these 
patients are unclear.
Low molecular weight heparin (LMWH) and fondaparinux do not require laboratory 
monitoring in the general population, except in patients with extreme obesity and with renal 
dysfunction. Patients with cirrhosis may also require laboratory monitoring of these agents, for 
example because of concomitant renal failure. LMWH can be monitored with anti-activated 
factor X (anti-Xa) assays, but these appear to be unreliable in patients with cirrhosis. It has 
been shown that, after the administration of a standard prophylactic or therapeutic dose 
of LMWH to patients with cirrhosis, anti-Xa levels fall below the recommended ranges for 
optimal anticoagulant control [7]. However, the decreased anti-Xa levels in these patients 
appear to be a laboratory anomaly and not a true indication of anticoagulant effect [8,9]. 
In fact, anti-Xa values have been shown to correlate positively with AT levels [7], which are 
reduced in patients with cirrhosis. Despite reduced anti-Xa values, LMWH was shown to be 
safe and effective in patients with cirrhosis [7,10,11]. Whether similar monitoring problems 
also occur with fondaparinux has not yet been assessed.
New antithrombotic agents, such as the direct factor Xa inhibitor rivaroxaban and the 
direct thrombin inhibitor dabigatran, have theoretical advantages over heparins: fewer 
(fatal) bleeding events, rapid onset of action, fewer drug-drug interactions, and oral mode 
of administration [12]. In addition, both agents do not require laboratory monitoring in the 
general population. Although patients with liver disease have been excluded from clinical trials 
on the new oral anticoagulants, they have theoretical advantages over currently used drugs, in 
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particular the oral mode of administration. Since LMWH is currently used for months or years 
to treat or prevent portal vein thrombosis, it is conceivable that the new oral anticoagulants 
will be considered in the future to avoid prolonged subcutaneous LMWH administration [5]. 
However, the current package insert for rivaroxaban indicates that it is contra-indicated for 
patients with cirrhosis, and other theoretical disadvantages of the new oral anticoagulants 
require attention [5]. Monitoring of these drugs may be required in patients with liver disease 
due to the possible altered clearance and the increased extravascular volume of patients with 
cirrhosis. No clinical studies on the efficacy and safety of these agents in cirrhotic patients 
have been performed yet. Furthermore, laboratory methodologies for monitoring these new 
drugs are still in development, and validation in patients with chronic liver disease will be 
required.
Thus, monitoring of anticoagulant drugs may be required in patients with cirrhosis, however, 
this appears to be difficult, due to the haemostatic changes associated with the underlying 
liver disease. The aim of this study was to determine whether different anticoagulant drugs 
could be reliably monitored using the anti-Xa or anti-activated factor II (anti-IIa) tests in plasma 
from patients with cirrhosis.
Patients and methods
Patients
Twenty-six adult patients with liver cirrhosis, who were seen on an out-patient basis or were 
admitted to the hospital, were included in the study. Patients were classified according to 
the Child-Pugh classification [13]. Ten patients were classified as Child A, ten as Child B, and 
six patients as Child C cirrhosis. Exclusion criteria were a documented history of congenital 
coagulation disorders, presence of active infection (<2 weeks), presence of acute liver failure, 
use of anticoagulant drugs in the past 10 d, pregnancy, human immunodeficiency virus (HIV) 
positivity and recent (<7 d) transfusion with blood products.
The control group consisted of 30 adult healthy volunteers working at our institution. Exclusion 
criteria for the control group were a documented history of congenital coagulation disorders, 
documented history of hepatic disease, recent viral infection (<2 weeks), use of anticoagulant 
drugs in the past 10 d, pregnancy and HIV positivity.
This study protocol was approved by the local medical ethical committee and informed 
consent was obtained from each subject before inclusion in the study.
Plasma samples
Blood samples were drawn by venepuncture and collected into vacuum tubes containing 
3.8% trisodium citrate as an anticoagulant, at a blood to anticoagulant ratio of 9:1. Platelet 
poor plasma was prepared by double centrifugation at 2000 g and 10 000 g respectively for 
10 min. Plasma was snap-frozen and stored at - 80°C until use.
Addition of anticoagulants to plasma samples
The following anticoagulants were added to plasma samples of cirrhotic patients and control. 
The indicated concentrations represent final concentrations in plasma.
1. UFH (Leo Pharma, Ballerup, Denmark), 0.3 U/ml
2. LMWH (Clexane; Sanofi-Aventis BV, Gouda, the Netherlands), 0.2 U/ml




3. Fondaparinux (Arixtra; GlaxoSmithKline BV, Zeist, the Netherlands), 0.5 µg/ml
4. Dabigatran (Alsachim, Illkirch Graffenstaden, France), 0.3 µg/ml
5. Rivaroxaban (Alsachim, Illkirch Graffenstaden France), 100 ng/ml
Anti-Xa/anti-IIa assay and APTT
Anti-Xa and anti-IIa values were all measured using the ACL 500 TOP analyser (Instrumentation 
Laboratory, Breda, the Netherlands). Anti-Xa values were measured in the plasma samples 
after the addition of UFH, LMWH, or fondaparinux with the Biophen Heparin (LRT) kit (Hyphen 
Biomed, Neuville Sur Oise, France), the Biophen heparin calibrator (for UFH and LMWH) or 
the Biophen arixtra calibrator (for fondaparinux), both purchased from Hyphen Biomed. No 
exogenous antithrombin is added in these assays. We repeated anti-Xa measurements in a 
limited set of plasma samples (10 patients, 10 controls), which we spiked with LMWH using 
the same kit, to which was added exogenous antithrombin (Hyphen Biomed, 75 lg/ml, final 
concentration) to assess the effect of low endogenous antithrombin levels on the outcome of 
the assay. Anti-Xa values, after the addition of rivaroxaban, were measured using the Biophen 
DiXal kit (Hyphen Biomed). A calibration curve was constructed by adding rivaroxaban to 
pooled normal plasma (obtained by combining plasma from >200 individuals). Anti-IIa values 
in the plasma samples were measured after addition of dabigatran using the Hemoclot 
thrombin inhibitors kit (Hyphen Biomed). A calibration curve was constructed by adding 
dabigatran to pooled normal plasma.
UFH activity was estimated by determination of the APTT on the ACL 500 TOP analyser, 
using reagents (HemosIL SynthASil) and protocols from the manufacturer (Instrumentation 
Laboratory, Breda, The Netherlands).
Routine coagulation laboratory tests
The INR was assessed with commercially available methods on an automated coagulation 
analyser (ACL 500 TOP) with reagents (Recombiplastin 2G) and protocols from the 
manufacturer (Instrumentation Laboratory, Breda, the Netherlands). Levels of factor (F) VIII, 
FII, FX and antithrombin (AT) were measured on an automated coagulation analyser (ACL 500 
TOP) with reagents and protocols from the manufacturer (Recombiplastin 2G for FII and FX, 
HemosIL SynthASil for FVIII, and Liquid Antithrombin reagent for AT, all from Instrumentation 
Laboratory).
Statistical analysis
Data are expressed as mean ± standard deviation (SD), medians (with ranges), or numbers 
(with percentages) as appropriate. Means of two groups were compared by Student’s t-test or 
Mann-Whitney U test as appropriate. Multiple groups were compared using One-way analysis 
of variance (ANOVA) (with the Bonferroni post-test) or Kruskal-Wallis H test (with Dunn’s 
post-test) as appropriate. Spearman’s correlation coefficient was used to assess correlation 
between continuous variables. P values of 0.05 or less were considered statistically significant. 
GraphPad Prism (San Diego, USA) and IBM SPSS Statistics 20 (New York, USA) was used for 
all analyses.
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Results
Patient characteristics
The main characteristics of the study population are reported in Table 1. Twenty-six patients 
with cirrhosis (14 males and 12 females) were included, and they were categorized according 
to the severity of liver disease as expressed by the Child Pugh score (10 Child A, 10 Child B 
and 6 Child C patients). The most common aetiology of liver disease was alcoholic, especially 
in the Child class C patients. None of the patients used pro- or anti-coagulant drugs. Thirty 
healthy subjects (14 males and 16 females) were included as normal controls.
The baseline INR and plasma levels of FVIII, FII, FX, and AT are shown in Table 2. Patients with 
cirrhosis showed a statistically significant prolongation of the INR and APTT, and a decrease 
in all measured coagulation proteins, except for FVIII (which was increased), as compared to 




	 Child	A	 Child	B	 Child	C	
	 n=10	 n=10	 n=6	 	
Characteristics	
MELD	score	 8.0	[6.0-10.0]	 11.5	[8.0-19.0]	 16.5	[12.0-
19.0]	
.0006	
Age	(yrs)	 56.0	[14.2]	 50.5	[12.5]	 59.0	[4.7]	 .367	
Sex	(male)	 4	(40)	 6	(60)	 4	(67)	 .682	
BMI	 25.4	[4.0]	 28.4	[6.0]	 28.4	[4.2]	 .337	
Smoking	(number)	 4	(40)	 1	(10)	 1	(17)	 .368	
Alcohol	(U	per	week)	 0	[0-1]	 0	[0-7]	 0	[0-0]	 .731	
Etiology	of	liver	disease	
		Alcoholic	 2	(20)	 1	(10)	 6	(100)	 .001	
		HCV	 1	(10)	 0	(0)	 0	(0)	 1.000	
		NASH	 1	(10)	 2	(20)	 0	(0)	 .769	
		Hemochromatosis	 0	(0)	 1	(10)	 0	(0)	 1.000	
		PBC	 1	(10)	 0	(0)	 0	(0)	 1.000	
		PSC	 2	(20)	 2	(20)	 0	(0)	 .639	
		Auto-immune	 3	(30)	 1	(10)	 0	(0)	 .403	
		Alcoholic	+	NASH	 0	(0)	 1	(10)	 0	(0)	 1.000	
		Unknown	 0	(0)	 2	(20)	 0	(0)	 .323	
Co-morbidity	
		Cardiovascular	 3	(30)	 2	(20)	 0	(0)	 .391	
		Diabetes	Mellitus	 2	(20)	 1	(10)	 0	(0)	 .769	
Laboratory	variables	
		Serum	bilirubin	(µmol/L)	 15	[5-35]	 40	[18-61]	 93	[63-131]	 .0001	
		Serum	albumin	(g/L)	 36	[28-44]	 33	[27-63]	 26	[25-29]	 .002	
		Serum	creatinin	(µmol/L)	 69	[23]	 72	[32]	 75	[17]	 .920	
		Hemoglobin	(mmol/L)	 8.2	[1.4]	 7.2	[0.9]	 6.2	[0.8]	 .005	
		Leukocytes	(109/L)	 6.5	[4.5]	 5.1	[2.1]	 5.4	[2.1]	 .591	







Table 1. Demographic and clinical characteristics of the study population.
HCV: Hepatitis C virus, NASH: Non-alcoholic steatohepatitis, PBC: Primary biliary cirrhosis, PSC: Primary sclerosing 
cholangitis.
Data are expressed as number (%), mean [SD], or median [range].




Figure 1. (A) Mean anti-Xa activity in plasma from healthy controls and patients with Child A, Child B, and Child C cirrhosis 
after addition of 0.3 U/ml unfractionated heparin (UFH). Error bars indicate the standard error of the mean (SEM). (B) 
Correlation between antithrombin (AT) levels and anti-Xa values after addition of 0.3 U/ml UFH in plasma from patients 
with cirrhosis. 
*P < 0.001 compared to controls.
Figure 2. (A) Mean activated partial thromboplastin time (APTT) ratios after the addition of 0.3 U/ml unfractionated 
heparin (UFH) in plasma from healthy controls and patients with Child A, Child B, and Child C cirrhosis. Error bars indicate 
the standard error of the mean (SEM). (B) Correlation between antithrombin (AT) levels and APTT ratios in plasma from 
patients with cirrhosis. 
APTT ratios were defined as (APTT in presence of UFH/APTT in absence of UFH). *P < 0.01 compared to controls.
Recovery of anticoagulant drugs assessed by anti-Xa and anti-IIa activity
UFH. When 0.3 U/ml UFH was added to the plasma of the controls, the mean anti-Xa level was 
0.29 ± 0.04 U/ml. In contrast, plasma from patients with cirrhosis spiked with the same amount 
of heparin resulted in a mean anti-Xa level of only 0.21 ±  0.05 U/ml. The reduced recovery 
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	 Child	A	 Child	B	 Child	C	
INR	 1.1	[0.9-1.2]	 1.2	[1.0-2.0]	 1.5	[1.4-1.7]	 1.0	[0.9-1.1]	 <.0001	
APTT	 40.3	[5.9]	 38.1	[4.4]	 37.0	[3.7]	 33.8	[3.8]	 .0006	
FVIII	(%)	 132	[92-185]	 129	[91-254]	 140	[108-171]	 94	[56-138]	 <.0001	
FII	(%)	 83	[50-104]	 69	[43-98]	 42	[40-71]	 107	[88-127]	 <.0001	
FX	(%)	 90	[74-136]	 81	[41-193]	 56	[49-69]	 106	[80-147]	 <.0001	







Table 2. Coagulation parameters in cirrhotic patients and normal controls. 
INR: International normalized ratio, APTT: Activated partial thromboplastin time, AT: Antithrombin. 
Data are expressed as mean [SD], or median [range].
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in the plasma of cirrhotic patients was statistically significant (P < 0.0001) and correlated 
with the severity of liver disease (Figure 1A). Furthermore, we observed a significant positive 
correlation between AT levels and anti-Xa values in plasma from cirrhotic patients (r = 0.68, P 
< 0.0001; Figure 1B).
When UFH activity was determined by the APTT, we observed a significantly greater 
prolongation of the APTT in plasma from patients compared to controls. The APTT in patients 
increased from 38.7 ± 4.9 to 104.6 ± 49.1 s after addition of 0.3 U/ml of UFH and from 33.8 ± 
3.8 to 63.8 ± 15.0 s in controls, resulting in APTT ratios (APTT with UFH/APTT without UFH) of 
2.6 ± 1.0 and 1.9 ± 0.3, respectively (P = 0.0009). The increased effect of heparin on the APTT 
became more pronounced with increasing severity of liver disease (Figure 2A). Interestingly, 
the response to heparin (expressed as the APTT ratio) negatively correlated with the AT levels 
(r = -0.73, P < 0.0001; Figure 2B).
Low molecular weight heparin. When 0.2 U/ml LMWH was added to the plasma of the 
controls, the mean anti-Xa level was 0.23 ± 0.03 U/ml (mean ± SD). In contrast, when plasma 
from patients with cirrhosis was spiked with the same amount of LMWH, the mean anti-Xa 
level detected was only 0.13 ± 0.06 U/ml. The reduced recovery in plasma from cirrhotic 
patients, compared to normal controls was statistically significant (P < 0.0001) and correlated 
with the severity of liver disease (Figure 3A).
Furthermore, we observed a significant positive correlation between AT levels and anti-Xa 
values in plasma from cirrhotic patients (r = 0.71, P = 0.0002; Figure 3B).
To assess whether the reduced recovery in patients was due to the decreased AT levels, we 
tested the effect of addition of exogenous AT (75 µg/ml, final concentration) to the plasma 
in 10 patients and 10 controls. When anti-Xa levels were set at 100% in controls, the anti-Xa 
level in the absence of exogenously added AT in patients was only 64 ± 10%, P < 0.0001. In 
contrast, when exogenously added antithrombin was present, the recovery in patients was 97 
± 8%, P = 0.56).
Figure 3. (A) Mean anti-Xa activity in plasma from healthy controls and patients with Child A, Child B, and Child C cirrhosis 
after addition of 0.2 U/ml low molecular weight heparin (LMWH). Error bars indicate the standard error of the mean (SEM). 
(B) Correlation between antithrombin (AT) levels and anti-Xa values after addition of 0.2 U/ml LMWH in plasma from 
patients with cirrhosis. *P < 0.05; **P < 0.001.
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Fondaparinux. When 0.5 µg/ml fondaparinux was added to the plasma of the controls, mean 
anti-Xa levels were 0.59 ± 0.04 µg/ml. Mean anti-Xa levels were significantly lower in plasma 
from patients with cirrhosis (0.50 ± 0.07 µg/ml, P < 0.0001). The reduced recovery in cirrhosis 
plasma correlated with the severity of liver disease (Figure 4A).
Again, we observed a significant positive correlation between AT levels and anti-Xa values in 
plasma from cirrhotic patients (r = 0.86, P < 0.0001; Figure 4B).
Figure 4. (A) Mean anti-Xa activity in plasma from healthy controls and patients with Child A, Child B, and Child C cirrhosis 
after addition of 0.5 µg/ml fondaparinux. Error bars indicate the standard error of the mean (SEM). (B) Correlation between 
antithrombin (AT) levels and anti-Xa values after addition of 0.5 µg/ml fondaparinux in plasma from patients with cirrhosis. 
*P < 0.001 compared to controls.
Rivaroxaban. When 100 ng/ml rivaroxaban was added to the plasma samples, mean anti-Xa 
levels were comparable between patients and normal controls (85.0 ± 14.2 vs. 88.0 ± 11.4 
ng/ml; P = 0.38) (Figure 5).
Figure 5. Mean anti-Xa activity in plasma from healthy 
controls and patients with Child A, Child B, and Child C 
cirrhosis after addition of 100 ng/ml rivaroxaban. Error 
bars indicate the standard error of the mean (SEM).
Dabigatran. After the addition of 0.3 µg/ml dabigatran, anti-IIa levels were 0.33 ± 0.01 µg/
ml and 0.31 ± 0.02 µg/ml in plasma from patients and normal controls, respectively. The 
observed anti-IIa levels were slightly higher in plasma from patients compared to controls (P 
= 0.0003). However, when separating patients according to the Child-Pugh classification, the 
anti-IIa levels were only significantly higher in the patients with Child C cirrhosis (0.33 ± 0.01 
µg/ml; P < 0.05), compared to controls (Figure 6).
" !   				
		  "  	 	 
		 
							 	"  
   	


WilmaPotze_Proefschrift2017_170x240_Binnen_FINAL.indd   145 21-03-17   19:20
146
Hemostasis and 
Anticoagulant Therapy in 
Liver Diseases  
Figure 6. Mean anti-IIa activity in plasma from healthy 
controls and patients with Child A, Child B, and Child C 
cirrhosis after addition of 03 lg/ml dabigatran. Shown 
are means. Error bars indicate the standard error of the 
mean (SEM). 
*P < 0.05 compared to controls.
Discussion
We observed a reduced recovery of AT-dependent anticoagulants assessed by anti-Xa levels 
when drugs were added to the plasma of patients with cirrhosis, compared to the recovery 
in plasma from healthy individuals. The addition of LMWH led to the most pronounced 
underestimation of drug levels, followed by UFH and fondaparinux. In contrast, comparable 
anti-Xa and anti-IIa levels were measured in plasma from patients and controls after the in 
vitro addition of direct FXa (rivaroxaban) and direct FIIa inhibitors (dabigatran).
We [8] and others [7,9] have previously demonstrated that the anti-Xa assay underestimates 
the LMWH mass present in plasma from patients with cirrhosis. In addition, this current 
study showed that the anti-Xa assay also underestimates the masses of other AT-dependent 
anticoagulant drugs (UFH and fondaparinux) in plasma from patients with cirrhosis.
The reduced recovery of heparins correlated with the severity of liver disease, as assessed 
by the Child-Pugh score. Accordingly, and as a potential explanation for this phenomenon, a 
positive correlation between AT levels and anti-Xa values was observed. The reduced recovery 
of AT-dependent anticoagulants thus appears to be a direct consequence of the acquired AT 
deficiency of patients with liver disease [14]. Indeed, when exogenous AT was added to the 
anti-Xa assay, the reduced recovery of the LMWH in patients compared to controls was fully 
blunted. Furthermore, other studies have also shown decreased anti-Xa values in patients 
with AT deficiency treated with UFH or LMWH [15-17]. In addition, in neonates, who have 
reduced plasma levels of AT, the anti-Xa assays have also been shown to be unreliable for 
this reason [18].
We observed a more pronounced increase in the APTT after the addition of UFH in plasma 
from patients with cirrhosis in comparison to the controls, suggesting an enhanced 
anticoagulant effect of UFH in cirrhosis. In clinical practice, the APTT would thus suggest that 
dose reductions are required in patients with cirrhosis. In contrast, recovery of UFH in the 
anti-Xa assay is reduced in cirrhosis, which, in clinical practice, may lead to dose escalations 
to reach a desired anti-Xa level. Importantly, both tests are used in clinical practice to monitor 
UFH. 
Based on the data of this study, we strongly suggest that anti-Xa levels should not be relied upon 
for monitoring heparins (that exert their effect through AT) in patients with cirrhosis, unless 
an anti-Xa test with exogenous antithrombin is available. However, many clinical laboratories 
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may not offer such a modified anti-Xa test. Novel monitoring methods (such as, for example, 
thrombin generation tests) may provide better monitoring options in patients with cirrhosis, 
but unfortunately such methods are not yet available in routine diagnostic laboratories. 
Indeed, in vitro studies using thrombin generation tests have demonstrated that LMWH has 
a more profound anticoagulant effect in plasma from patients with cirrhosis as compared to 
plasma from healthy controls [9]. Furthermore, we have also recently demonstrated that the 
anticoagulant potency of clinically approved drugs differs substantially between patients with 
cirrhosis and healthy individuals, using thrombin generation tests [19]. Whereas dabigatran 
and, to a lesser extent, heparin and LMWH are more potent in plasma from patients with 
cirrhosis, fondaparinux and rivaroxaban showed a decreased anticoagulant effect. Thus, 
although anti-Xa levels underestimate drug levels in cirrhotic patients treated with UFH or 
LMWH (which may prompt dose escalations), thrombin generation tests suggest that UFH or 
LMWH are slightly more potent in patients with cirrhosis compared to individuals with intact 
liver function. In other words, dose escalations instigated by a low anti-Xa level will potentially 
lead to a substantial bleeding risk.
Although our study shows that heparin monitoring in patients with cirrhosis may be improved 
by using anti-Xa assays to which exogenous AT is added, further studies on the performance 
of such assays in patients with cirrhosis are required. The direct FXa and FIIa inhibitors, 
however, may be monitored through the respective anti-Xa and anti-IIa assays, as comparable 
anti-Xa and anti-IIa levels were observed after the addition of rivaroxaban and dabigatran, 
respectively, in plasma from patients and controls.
Due to the limited clinical experience, the anticoagulant of choice and the dosages for the 
various indications is still unclear. Nevertheless, (theoretical) advantages and disadvantages 
of the available drugs in patients with cirrhosis have been recognized, which may facilitate a 
rational choice for a drug in a specific clinical situation [5]. The results of the present study 
will assist clinicians and clinical laboratories in interpreting anti-Xa or anti-IIa test results when 
applied in patients with cirrhosis treated with established or new anticoagulant drugs.
In conclusion, routine coagulation assays underestimate levels of antithrombin-dependent 
drugs, but not of direct anticoagulant drugs in plasma from patients with cirrhosis. This finding 
has practical consequences for monitoring heparins in these patients. Clinical (dose-finding) 
studies on the monitoring, efficacy and safety of heparins are urgently required to improve 
antithrombotic therapy in the patients with cirrhosis.
 
WilmaPotze_Proefschrift2017_170x240_Binnen_FINAL.indd   147 21-03-17   19:20
148
Hemostasis and 
Anticoagulant Therapy in 
Liver Diseases  
References
1.Lisman, T. & Porte, R.J. (2010) Rebalanced hemostasis in patients with liver disease: evidence and 
clinical consequences. Blood, 116, 878–885.
2.Lisman, T., Caldwell, S.H., Burroughs, A.K., Northup, P.G., Senzolo, M., Stravitz, R.T., Tripodi, A., Trotter, 
J.F., Valla, D.C., Porte, R.J. & Coagulation in Liver Disease Study Group. (2010) Hemostasis and 
thrombosis in patients with liver disease: the ups and downs. Journal of Hepatology, 53, 362–371.
3.Northup, P.G., Sundaram, V., Fallon, M.B., Reddy, K.R., Balogun, R.A., Sanyal, A.J., Anstee, Q.M., 
Hoffman, M.R., Ikura, Y., Caldwell, S.H. & Coagulation in Liver Disease Group. (2008) Hypercoagulation 
and thrombophilia in liver disease. Journal of Thrombosis and Haemostasis: JTH, 6, 2–9.
4.Tripodi, A., Anstee, Q.M., Sogaard, K.K., Primignani, M. & Valla, D.C. (2011) Hypercoagulability in 
cirrhosis: causes and consequences. Journal of Thrombosis and Haemostasis: JTH, 9, 1713–1723.
5.Lisman, T., Kamphuisen, P.W., Northup, P.G. & Porte, R.J. (2013) Established and new-generation 
antithrombotic drugs in patients with cirrhosis - possibilities and caveats. 
 Journal of Hepatology, 59, 358–366.
6.Porte, R.J., Lisman, T., Tripodi, A., Caldwell, S.H., Trotter, J.F. & Coagulation in Liver Disease Study 
Group. (2010) The international normalized ratio (INR) in the MELD score: problems and solutions. 
American Journal of Transplantation: Official Journal of the American Society of Transplantation and 
the American Society of Transplant Surgeons, 10, 1349–1353.
7.Bechmann, L.P., Sichau, M., Wichert, M., Gerken, G., Kroger, K. & Hilgard, P. (2011) Low-molecular-
weight heparin in patients with advanced cirrhosis. Liver International: Official Journal of the 
International Association for the Study of the Liver, 31, 75–82.
8.Lisman, T. & Porte, R.J. (2011) Towards a rational use of low-molecular-weight heparin in patients with 
cirrhosis. Liver International: Official Journal of the International Association for the 
 Study of the Liver, 31, 1063–3231.
9.Senzolo, M., Rodriguez-Castro, K.I., Rossetto, V., Radu, C., Gavasso, S., Carraro, P., Zerbinati, P., Sartori, 
M.T. & Simioni, P. (2012) Increased anticoagulant response to low-molecular-weight heparin in plasma 
from patients with advanced cirrhosis. Journal of Thrombosis and Haemostasis: JTH, 10, 1823–1829.
10.Delgado, M.G., Seijo, S., Yepes, I., Achecar, L., Catalina, M.V., Garcia-Criado, A., Abraldes, J.G., 
de la Pena, J., Banares, R., Albillos, A., Bosch, J. & Garcia-Pagan, J.C. (2012) Efficacy and safety of 
anticoagulation on patients with cirrhosis and portal vein thrombosis. Clinical Gastroenterology and 
Hepatology: The Official Clinical Practice Journal of the American Gastroenterological Association, 10, 
776–783.
11.Villa, E., Camma, C., Marietta, M., Luongo, M., Critelli, R., Colopi, S., Tata, C., Zecchini, R., Gitto, S., Petta, 
S., Lei, B., Bernabucci, V., Vukotic, R., De Maria, N., Schepis, F., Karampatou, A., Caporali, C., Simoni, 
L., Del Buono, M., Zambotto, B., Turola, E., Fornaciari, G., Schianchi, S., Ferrari, A. & Valla, D. (2012) 
Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced 
cirrhosis. Gastroenterology, 143, 1253–1260.
12.Schulman, S. & Crowther, M.A. (2012) How I treat with anticoagulants in 2012: new and old 
anticoagulants, and when and how to switch. Blood, 119, 3016–3023.
13.Durand, F. & Valla, D. (2008) Assessment of prognosis of cirrhosis. 
 Seminars in Liver Disease, 28, 110–122.
14.Tripodi, A. & Mannucci, P.M. (2011) The coagulopathy of chronic liver disease. The New England 
Journal of Medicine, 365, 147–156.
15.Holm, H.A., Abildgaard, U., Larsen, M.L. & Kalvenes, S. (1987) Monitoring of heparin therapy: should 
heparin assays also reflect the patient’s antithrombin concentration? 
 Thrombosis Research, 46, 669–675.
16.Kuhle, S., Lau, A., Bajzar, L., Vegh, P., Halton, J., Cherrick, I., Anderson, R., Desai, S., McCusker, P., Wu, 
J., Abshire, T., Mahoney, D. & Mitchell, L. (2006) Comparison of the anticoagulant effect of a direct 
thrombin inhibitor and a low molecular weight heparin in an acquired antithrombin deficiency in 
children with acute lymphoblastic leukaemia treated with L-asparaginase: an in vitro study. British 
Journal of Haematology, 134, 526–531.
17.Lehman, C.M., Rettmann, J.A., Wilson, L.W. & Markewitz, B.A. (2006) Comparative performance of 
three anti-factor xa heparin assays in patients in a medical intensive care unit receiving intravenous, 
unfractionated heparin. American Journal of Clinical Pathology, 126, 416–421.




18.Schmidt, B., Mitchell, L., Ofosu, F. & Andrew, M. (1988) Standard assays underestimate the concentration 
of heparin in neonatal plasma. The Journal of Laboratory and Clinical Medicine, 112, 641–643.
19.Potze, W., Arshad, F., Adelmeijer, J., Blokzijl, H., van den Berg, A.P., Meijers, J.C.M., Porte, R.J. & Lisman, 
T. (2013) Increased anticoagulant response to drugs targeting thrombin, but not to drugs targeting 
FXa, in plasma from patients with cirrhosis. Journal of Thrombosis and Haemostasis, 11(Suppl. 2), 57.
WilmaPotze_Proefschrift2017_170x240_Binnen_FINAL.indd   149 21-03-17   19:20
150
Hemostasis and 
Anticoagulant Therapy in 
Liver Diseases  
WilmaPotze_Proefschrift2017_170x240_Binnen_FINAL.indd   150 21-03-17   19:20
151
9
Issues With Monitoring of 
Unfractionated Heparin in 
Cirrhosis
APPENDIX TO  CHAPTER
Wilma Potze1, Ton Lisman1,2
Therapeutic Drug Monitoring 2015; 37(2):279-80
1Surgical Research Laboratory, Department of Surgery, University of Groningen, University 
Medical Centre Groningen, Groningen, The Netherlands. 
2Section of Hepatobiliary Surgery and Liver Transplantation, Department of Surgery, 
University of Groningen, University Medical Center Groningen, Groningen, The 
Netherlands.
WilmaPotze_Proefschrift2017_170x240_Binnen_FINAL.indd   151 21-03-17   19:20
152
Hemostasis and 
Anticoagulant Therapy in 
Liver Diseases  
To the Editor
Fuentes et al report a retrospective analysis on bleeding events and monitoring of 
unfractionated heparin in patients with cirrhosis compared with matched controls [1]. 
We would like to comment on a number of issues related to the results described in this 
publication. 
First, this study suggests that patients with cirrhosis are at greater risk for bleeding compared 
with matched controls when treated with unfractionated heparin. Patients with cirrhosis 
frequently have substantial alterations in their hemostatic system. The net result of these 
changes is considered to be a rebalanced hemostatic status, which is much more fragile to 
disruption compared with the hemostatic balance in healthy individuals [2]. As a consequence, 
it is of utmost importance to avoid excessive anticoagulation in patients with such a delicate 
hemostatic balance to avoid bleeding [3]. It may thus not come as a surprise that patients 
with cirrhosis seem to be at a greater risk for anticoagulant-associated bleeding as compared 
with matched controls. The findings by Fuentes et al, however, contrast with several recent 
studies, which have suggested that low-molecular-weight and unfractionated heparin to have 
a favorable safety profile in patients with cirrhosis [4–9]. Their study concluded that patients 
with cirrhosis have an increased anticoagulant-associated bleeding risk on basis of an increase 
in administered blood products. This conclusion may not be justified, as it is unclear whether 
these products were actually administered to actively bleeding patients. It is well known 
that a substantial proportion of blood products in the cirrhotic population are administered 
prophylactically [10]. As patients with cirrhosis often have abnormal routine hemostatic test 
results that are suggestive of a bleeding tendency (such as a prolonged prothrombin time 
or a decreased platelet count), prophylactic administration of fresh frozen plasma or platelet 
concentrates is still common practice, despite increasing awareness that these abnormal 
routine coagulation tests do not predict a bleeding risk [11].
Second, we wonder why these patients all received unfractionated (instead of low-molecular 
weight) heparin. Low-molecular-weight heparin is the drug of choice for at least some of 
the indications listed (e.g., treatment of acute venous thromboembolism of the leg or 
acute pulmonary embolism [12]). In addition, given the favorable published data on low-
molecular-weight heparin in patients with cirrhosis, this drug may be preferable over 
unfractionated heparin, which has a less established safety profile in patients with cirrhosis. 
We do acknowledge that concomitant renal failure, in which accumulation of low-molecular-
weight heparin is known to occur, may lead to the decision to use unfractionated and not 
low-molecular-weight heparin. 
Third, the authors note discrepancies between activated partial thromboplastin time (APTT) 
and anti-Xa monitoring of low-molecular-weight heparin. We would like to comment 
that both tests fail to accurately measure drug levels in patients with cirrhosis, as we have 
recently shown [13]. With in vitro experiments in which we added a known concentration 
of unfractionated heparin to plasma from healthy individuals or plasma from patients with 
cirrhosis, we demonstrated that the anti-Xa tests underestimate drug levels whereas the APTT 
gives an overestimation. Monitoring of heparin by APTT or anti-Xa tests is indirect. These tests 
do not assess drug levels directly but rather estimate drug levels based on the anticoagulant 
action of the drug. Heparins exert an anticoagulant effect by enhancing the anticoagulant 




effect of the endogenous anticoagulant antithrombin, and it is the heparin-enhanced 
antithrombin effect that is assessed by the APTT and anti-Xa assays. The decreased 
antithrombin levels in plasma from patients with cirrhosis lead to falsely elevated APTT 
and falsely decreased anti-Xa levels in heparin-treated patients, and both tests thus seem 
unsuitable for heparin monitoring in patients with cirrhosis [13]. 
Although the anti-Xa and APTT tests are designed to get an estimate of drug levels in plasma, 
the clinically relevant parameter is the “true” anticoagulant effect, which may, for example, 
be estimated by thrombin generation testing. We have investigated the functional effects 
of unfractionated and low-molecular-weight heparin in plasma from healthy individuals and 
plasma from patients with cirrhosis using thrombin generation testing [14]. When a known 
concentration of (low-molecular-weight) heparin was added to plasma, thrombin generation 
was inhibited to a larger extent in patients with cirrhosis compared with the decrease in healthy 
individuals, indicating that the anticoagulant potency of heparins is not necessarily equal in 
plasma from patients with cirrhosis and healthy individuals. The differences in anticoagulant 
potency, however, were not present when thrombin generation was tested in the presence of 
thrombomodulin, which allows activation of the endogenous anticoagulant protein C system. 
In other words, depending on the exact experimental conditions, heparins exert an equal 
to enhanced anticoagulant activity in plasma from patients with cirrhosis. This enhanced 
drug potency contrasts with the anti-Xa assay, which at equal drug levels gives a much lower 
value in patients with cirrhosis and thus suggests inadequate anticoagulation. The problems 
with monitoring of heparins and the altered potency of heparins in plasma from patients 
with cirrhosis are related to the antithrombin deficiency that is common in these patients, 
which is understandable because heparin exerts its anticoagulant effect by enhancing the 
anticoagulant action of endogenous antithrombin. 
Finally, we agree with the authors that studies on safety and efficacy of heparin 
anticoagulation specifically in patients with cirrhosis are warranted. These studies should also 
take improvements in laboratory monitoring in consideration. Ideally, heparin monitoring 
tests for patients with cirrhosis should take both drug levels and drug effect into account. 
Given the drawbacks of heparin use in patients with cirrhosis, there may be opportunities 
for new (antithrombin-independent) oral anticoagulants [3]. Recently, the successful use 
of rivaroxaban and apixaban in the treatment of cirrhotic portal vein thrombosis has been 
reported [15,16]. Although monitoring of these drugs in cirrhosis seems to be much more 
accurate compared with monitoring of heparins, prospective studies on efficacy and safety 
are essential before such drugs can be implemented routinely in hepatology clinics.
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The concept of a rebalanced hemostasis in patients with liver disease is increasingly gaining 
acceptance. This balance is perceived to be more unstable than in individuals with intact 
liver function, with the risk of both bleeding and thrombotic complications. However, it is 
still unclear which patients are at risk for bleeding or thrombotic complications and how we 
can predict those risks. Furthermore, the hemostatic system in patients with liver disease is 
still incompletely understood, especially in the increasing patient population with a fatty liver 
disease. Due to the increase in patients with NAFLD and aging of the patient population, 
thrombotic complications are likely to be increasingly diagnosed in patients with liver 
disease. However, little research has been done on the efficacy and safety of the available 
anticoagulant drugs in patients with liver disease. Therefore, guidelines on the anticoagulant 
drug of choice and dosing for the various indications are still lacking. The aim of this thesis 
was to gain a better understanding of the hemostatic system in patients with (fatty) liver 
disease and to study the efficacy and monitoring of anticoagulant drugs in plasma from 
patients with liver disease. Results of this thesis will contribute to better strategies to prevent 
or treat thrombosis in patients with liver disease in the future. In this chapter, the results of this 
thesis are discussed in the context of the current literature on the hemostasis in liver disease 
and the prevention or treatment of thrombotic complications.
Hemostatic changes in liver disease
As outlined in chapter 2, there are changes in all phases of the hemostatic system in patients 
with liver disease. Most important alterations of the primary hemostasis in patients with 
liver disease include a reduced platelet count [1], elevated levels of von Willebrand factor 
(VWF) [2], and low levels of ADAMTS13 [3]. In secondary hemostasis, most procoagulant and 
anticoagulant proteins are reduced. Finally, in the fibrinolytic system, levels of plasminogen, 
plasmin inhibitor, thrombin activatable fibrinolysis inhibitor (TAFI), and factor XIII are frequently 
reduced [4,5], and levels of tissue-type plasminogen activator (t-PA) and plasminogen 
activator inhibitor-1 (PAI-1) are frequently elevated [6] in patients with chronic liver disease.
If we focus on the secondary hemostasis in patients with liver disease, it is well known that 
levels of coagulation factors V, VII, IX, X, XI, and prothrombin are reduced, because the liver 
is the site of synthesis of these proteins [7]. In contrast, levels of factor VIII are often elevated 
[8]. The decreased production of procoagulant proteins is mostly counterbalanced by 
decreased production of anticoagulant proteins, such as protein C and antithrombin [9]. Also 
protein S levels are reduced in patients with cirrhosis [10,11]. Tissue factor pathway inhibitor 
(TFPI) is not produced by the liver, but the microvascular endothelium is thought to be the 
principal source of TFPI [12]. It has recently been established that protein S acts as a cofactor 
for TFPI in the down regulation of thrombin generation [13]. As a result, both acquired and 
congenital protein S deficiencies are associated with a concomitant TFPI deficiency [14]. In 
chapter 3, we studied protein S and TFPI plasma levels in patients with cirrhosis, and found 
that patients with cirrhosis have an acquired protein S deficiency, which is, however, not 
accompanied by a decrease in TFPI plasma levels. This indicates that the decrease in TFPI 
levels in conjunction with acquired protein S deficiency as described previously [14] does 
not occur in patients with chronic liver diseases. A possible explanation might be that TFPI 
release in patients with cirrhosis is substantially increased due to continuous activation of 
the endothelium, but that this increased TFPI release is masked, in part, by the protein S 
deficiency. Indeed, in both chronic and acute liver diseases, continuous activation of the 
endothelium is common, resulting in increased plasma levels of endothelial-derived proteins, 
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such as VWF [2,15]. The combination of increased TFPI release, due to continuous endothelial 
cell activation, and protein S deficiency may thus result in normal TFPI levels. Despite normal 
TFPI plasma levels, patients with cirrhosis did show a reduced activity of the TFPI-protein S 
system when compared to healthy controls. Recently, studies have proposed that the increase 
in factor VIII in combination with decreased protein C is responsible for a hypercoagulable 
state contributing to thrombotic complications in patients with cirrhosis [16]. However, in the 
study of chapter 3 we have shown that the impaired activity of the TFPI-protein S system in 
patients with cirrhosis may also contribute to this hypercoagulable state increasing the risk of 
thrombotic complications in these patients.
Laboratory tests of hemostasis in patients with liver disease
Since patients with liver disease can suffer from both thrombotic and bleeding complications, 
there is a frequent clinical need for predicting the risk of bleeding or thrombosis in individual 
patients with liver disease. However, current available clinical tests fail to accurately predict 
those risks in patients with liver disease.  
The standard coagulation profile processed in most clinical laboratories includes 
the prothrombin time (PT), international normalized ratio (INR), and activated partial 
thromboplastin time (APTT). In fact, many consider the PT the test of choice for diagnosing 
either inherited or acquired coagulopathies, in addition to the monitoring of vitamin K 
antagonists. However, these conventional coagulation tests fail to assess all the changes in 
the coagulation in patients with a liver disease. This can be explained by two considerations. 
First, the PT and APTT only measure the first 5% of thrombin being generated, since this 
is enough for plasma to start clotting [17]. Second, in the PT and APTT the anticoagulant 
factor protein C, whose activation requires thrombomodulin, cannot be properly activated 
[18]. Thrombomodulin is a protein located on the endothelial cells, and plasma and reagents 
needed to perform the PT or APTT do not contain sufficient amounts of this protein. The PT 
and APTT are, therefore, sensitive to changes in the procoagulant proteins, but not to changes 
in the anticoagulant proteins. Since in patients with liver disease both pro- and anticoagulant 
proteins are decreased, these conventional coagulation tests cannot reliably predict bleeding 
risk in these patients. Indeed, multiple studies have shown that the PT is a poor predictor of 
bleeding following liver biopsy as well as other surgical procedures, and that the PT does not 
correlate with severity of gastrointestinal bleeding in patients with cirrhosis [19-21]. 
To better resemble the hemostatic system in patients with chronic liver disease, other tests 
have been recently studied. These include thrombin generation, thromboelastography (TEG), 
and thromboelastometry. The TEG uses whole blood to measure speed and strength of clot 
formation continuously. It can, thus, theoretically analyze all components of the hemostatic 
system [22]. Both TEG and rotational thromboelastometry have been routinely used to guide 
transfusion of platelet concentrates, factor repletion, and fibrinolytic therapy during liver 
transplantation [23]. In fact, a recent randomized controlled trial reported a significant lower 
use of blood products without an increase in bleeding complications by using TEG-guided 
transfusion strategy compared to transfusion guided by INR and platelet count [24]. However, 
most parameters of the test are not standardized yet and TEG thresholds remain unclear. 
Furthermore, to date no studies have examined the use of TEG in predicting bleeding or 
thrombosis in nonsurgical patients with liver disease. Other drawbacks of TEG include pre-




analytic and analytic variables that impact test reliability and reproducibility, and the various 
methods to perform the test which results poorly correlate [25-27]. 
Another test that has been increasingly used to reassess the hemostatic capacity of patients 
with liver disease is the thrombin generation test. The thrombin generation assay evaluates 
thrombin generation (resulting from the action of the procoagulants) and decay (resulting 
from the action of the anticoagulants). In the assay, coagulation of test plasma is activated 
by small amounts of tissue factor and phospholipids, and the formation of thrombin is 
continuously monitored by means of a thrombin-specific fluorogenic substrate. There 
are several parameters that can be derived from the thrombin generation curve, but the 
endogenous thrombin potential (ETP) is the most used, which refers to the total amount of 
thrombin generated during the test. When thrombomodulin is added to the test plasma, the 
thrombin generation test is sensitive to all anticoagulant proteins in the plasma and, thus, 
measures the true balance between the pro- and anticoagulant factors. Indeed, thrombin 
generation testing in the presence of thrombomodulin has demonstrated normal or even 
superior thrombin generation in patients with liver disease [28-32]. Some studies have also 
shown that thrombin generation testing is useful in identifying patients with an increased risk 
of venous thrombosis or portal vein thrombosis [33-36]. However, the thrombin generation 
test is not widely available, the test is not standardized yet, and currently the test is too 
complicated for routine use in diagnostic laboratories.
The Thrombodynamics assay is a newly developed plasma-based global hemostasis assay, 
which continuously monitors clot growth in non-stirred plasma. Whereas in other coagulation 
tests (such as the PT or thrombin generation test) clotting is activated by homogenously 
dissolved tissue factor, in the Thrombodynamics test clotting is activated by a surface with 
immobilized tissue factor [37,38]. Therefore, this spatial clot growth assay better resembles 
in vivo clot formation. The spatial clot growth assay has been successfully used to assess the 
hemostatic system in various indications [37-40], including in patients with hemophilia [41]. In 
chapter 4, we also show preserved clot formation in plasma from patients with cirrhosis using 
the novel Thrombodynamics assay. 
Advantages of this assay include the stability of the assay (provided a strict blood processing 
protocol is followed) and the easy use and clear methods of the assay. Furthermore, the 
test provides clear reference values for the various parameters of clot growth that can be 
measured. The Thrombodynamics assay may hold promise in the prediction of bleeding or 
thrombotic risk in patients with a liver disease. However, currently the test is for research use 
only and should not be used in diagnostic procedures. Future studies to assess the clinical 
value of this novel test in predicting hemostatic abnormalities in patients with liver disease 
are needed.
Finally, it should be noticed that it may also be possible that detailed clinical assessment, 
for example by standardized bleeding scores or thrombosis risk assessment, could be able 
to identify those patients who are at risk for either bleeding or thrombosis [42]. However, 
data on the use of such clinical scores in patients with liver disease are scarce. Nevertheless, 
one recent study evaluated the Padua Predictor Score (PPS) as a risk-stratification tool for the 
development of venous thromboembolism (VTE) in patients with chronic liver disease [43]. 
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The PPS was significantly associated with risk of VTE and, thus, appears to be an effective 
assessment tool in patients with chronic liver disease. However, this was a retrospective study 
and prospective studies would be needed to confirm this finding.
Bleeding risk in surgical patients
Patients with a liver disease are not as prone to bleeding complications as clinicians formerly 
thought. As mentioned in the previous section, routine coagulations tests cannot be reliably 
used to assess a bleeding tendency in these patients. Furthermore, many patients can 
currently undergo a liver transplantation with minimal or even without transfusion of blood 
products [44-47]. Such a major surgical procedure would never be possible in a patient with a 
true coagulopathy, such as in hemophilia, without correction of the coagulopathy with factor 
concentrates or blood product transfusion. There is no evidence for the benefits of prophylactic 
blood product transfusion in perioperative medicine in patients with liver disease. Despite the 
lack of benefits, prophylactic use of blood products prior to smaller invasive procedures in 
these patients is still common practice. However, the side effects, such as risk of infection, risk 
of transfusion related acute lung injury, and transfusion associated circulatory overload with 
an increasing risk of bleeding, are increasingly acknowledged. In chapter 2 we, therefore, 
argue against routinely correcting a prolonged PT or INR with transfusion of blood products 
prior to procedures in patients with liver disease. Instead, only those patients with significant 
bleeding should be treated. Moreover, risk factors for bleeding, such as portal hypertension, 
endothelial dysfunction, bacterial infection, and renal failure, should also be addressed when 
preventing (re)bleeding.
Previously, patients following liver surgery were also perceived to be in a hypocoagulable 
state due to a prolonged PT or APTT [48-50]. However, we now know that these conventional 
coagulation tests are not reliable for the assessment of the overall hemostatic status in these 
patients. In fact, in chapter 5 we showed a hypercoagulability of plasma from patients following 
liver resection using the thrombin generation test in the presence of thrombomodulin. This 
hypercoagulable state following liver resection is also clinically evidenced by studies showing 
that the occurrence of venous thromboembolism following liver surgery is common [51] 
and, in fact, the risk increases with the extent of hepatectomy [52,53].  Furthermore, several 
recent studies also found a normal to hypercoagulable state following liver surgery using 
thromboelastography [50,54,55]. However, in chapter 5 we also provide a mechanistic 
explanation for the hypercoagulable state following liver resection. Specifically, the 
hypercoagulable state was associated to a profound thrombomodulin resistance, meaning 
that thrombin generation only slightly decreased by the addition of thrombomodulin in 
plasma from patients following liver resection compared to a substantial decrease in plasma 
from healthy controls. 
This thrombomodulin resistance was likely attributable to decreased levels of protein C and 
elevated levels of factor VIII. Combined with the decreased levels of antithrombin, the net 
effect is an increased thrombin generation when tested in the presence of thrombomodulin 
following liver resection. This decrease in coagulation factors might, in part, be explained by 
the decreased synthetic capacity of the liver remnant. Consumption of coagulation proteins 
as a result of surgical damage may also play a role. This might explain why in patients 
following pancreatic resection in our study also certain coagulation proteins decreased. 
Furthermore, this consumption theory may be supported by the finding that the risk of venous 




thromboembolism increases with the extent of the hepatectomy [52,53], and that extended 
operative time forms a risk factor for venous thromboembolism [51]. Finally, hemodilution 
may also contribute to the decrease in coagulation factors following liver resection. 
The results of chapter 5 on the hypercoagulable state following liver resection in combination 
with the discussed literature in the previous section, has important clinical implications in 
the management of patients following liver surgery. First, clinicians should be aware of the 
limitations of the use of conventional coagulation tests to guide hemostatic management. A 
prolonged PT or APTT following liver surgery should not be routinely corrected by transfusion 
of blood products. Second, patients following liver surgery should not be withheld from 
thrombosis prophylaxis. In fact, more aggressive anticoagulation may even be necessary in 
the post-operative period when certain risk factors for venous thromboembolism are present. 
Examples of such risk factors might be a history of venous thromboembolism, the presence 
of cancer, an extended operation time, or a prolonged length of stay. 
Hemostasis in NAFLD
Nonalcoholic fatty liver disease (NAFLD) is, nowadays, considered to be the most frequent 
chronic liver disorder in Western countries [56,57]. It represents a histopathological 
spectrum ranging from simple hepatic steatosis to steatohepatitis (NASH) with increasing 
risk for progression to advanced fibrosis and cirrhosis [58-60]. NAFLD is considered the 
hepatic manifestation of the metabolic syndrome, and is associated with an increased 
risk of cardiovascular disease (CVD) [61]. Furthermore, rates of venous thromboembolism 
and portal vein thrombosis (PVT) appear also increased in patients with NAFLD [62,63]. 
Multiple processes probably contribute to this increased risk of thrombosis in NAFLD, which 
have been mentioned in chapter 6. Some recent studies have also suggested a role for a 
hypercoagulable state in the increased risk of thrombosis in patients with NAFLD. However, 
in chapter 7, we show that, except for some pro-thrombotic features, the overall hemostatic 
status is comparable between patients with NAFLD and controls. Therefore, our study 
suggests a limited role for hyperactive hemostasis in the increased thrombotic risk in NAFLD. 
In this section the results found in chapter 7 in combination with the current literature on the 
hemostatic alterations in NAFLD will be further discussed.
Alterations in primary hemostasis
Previous studies have suggested an increase in platelet activation in patients with the 
metabolic syndrome [64,65] and in patients with NAFLD [66-69], which might contribute to 
their increased risk of thrombosis. However, the results of these studies are inconsistent and 
most of these studies are limited by their relative small sample size. Furthermore, most of 
these studies use indirect markers of platelet activation, such as the mean platelet volume. In 
chapter 7, we show that NAFLD is not associated with an increase in platelet activation, which 
was measured using a direct flow cytometric assay of platelet activation status. Additionally, 
NAFLD was not associated with major changes in pivotal proteins in primary hemostasis. We, 
therefore, suggest a limited role for liver disease-induced platelet activation in the perceived 
increased risk of thrombosis in patients with NAFLD.
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Alterations in coagulation & fibrinolysis
Levels of various individual pro-thrombotic factors appear to be increased in patients with 
NAFLD [70-76]. Although results of these studies on different factors have been inconsistent, 
an increase in PAI-1, fibrinogen, and factor VIII and a decrease in antithrombin are most 
frequently reported. In chapter 7, we also observed increased fibrinogen levels in patients 
with non-cirrhotic NAFLD, although the difference with controls did not reach statistical 
significance. However, levels of fibrinogen are mostly decreased in patients with cirrhosis [77], 
which we also observed in patients with alcoholic related cirrhosis. Nevertheless, patients with 
NASH-related cirrhosis had normal fibrinogen levels, which might be attributed to a relative 
increase in fibrinogen production due to the fatty liver disease. 
Furthermore, we observed increased levels of factor VIII and decreased levels of antithrombin 
in patients with cirrhosis, which is in line with previous studies [7,28,30]. Finally, in chapter 
7 we also observed increased levels of PAI-1 in patients with NAFLD. In fact, PAI-1 levels 
appeared to increase with increasing severity of the disease and increasing severity of 
steatosis. Also Verrijken et al. found significant elevated levels of PAI-1 in patients with NASH, 
which correlated with underlying histological parameters [72]. In fact, increased levels of 
PAI-1 and resultant reduction in fibrinolysis have been extensively reported as a risk factor 
for venous thrombosis [78,79]. However, levels of PAI-1 are not independently associated 
with risk of myocardial infarction, and PAI-1 levels appear to reflect other cardiovascular risk 
factors [80]. In chapter 7, we observed hypofibrinolysis using the clot lysis assay in patients 
with non-cirrhotic NAFLD. This hypofibrinolytic status might contribute to thrombosis risk in 
these patients since a hypofibrinolytic state as determined with the clot lysis assay has been 
demonstrated to form a risk factor for both venous and arterial thrombosis in the general 
population [81-83]. 
More important than to study individual hemostatic proteins, is to study if these changes 
lead to a hypercoagulability in patients with NAFLD which might explain their increased risk 
of thrombosis. We performed both TEG and thrombin generation testing in patients with 
NAFLD in chapter 7. TEG test results were comparable between non-cirrhotic NAFLD patients 
and controls. However, TEG revealed moderate hypocoagulability in cirrhotic patients. 
Furthermore, thrombin generation was also normal in patients with NAFLD. This contrasts 
with Tripodi et al., who concluded that NAFLD is characterized by a procoagulant-imbalance, 
as shown by an increase in ETP-ratio (with-to-without thrombomodulin) in these patients 
[73]. We also observed an increase in a similar ratio in patients with NASH-related cirrhosis. 
However, such ratios only represent the resistance of the plasma to the anticoagulant action 
of thrombomodulin, which is increased due to decreased levels of protein C and increased 
levels of FVIII in patients with liver disease. Furthermore, in patients with ASH-related cirrhosis 
in our study and in patients with alcoholic/viral cirrhosis in the study of Tripodi et al. the ratio 
was also increased. An increase in the ETP-ratio in patients with NAFLD, therefore, does not 
explain their increased risk of thrombosis compared to patient with alcoholic/viral cirrhosis. 
In chapter 7 we, therefore, argue against the use of this ratio to classify if patient samples are 
normo- or hypercoagulable, and instead believe that the thrombin generation performed in 
the presence of thrombomodulin is the most accurate laboratory measure of the coagulant 
potential of a patients’ plasma. 




Besides hypofibrinolysis, we did find another pro-thrombotic feature of patients with NAFLD, 
namely a pro-thrombotic structure of the fibrin clot. This was observed by decreased fibrin 
clot permeability and increased clot density in patients with NAFLD. Indeed, previous studies 
have shown decreased fibrin clot permeability to be associated with thrombotic diseases 
[84-86].
Finally, it should be mentioned that we found a higher variability of several hemostatic test 
results in patients compared to controls. This might suggest that individual patients have 
a more thrombogenic hemostatic profile. In chapter 7, we could, however, not identify any 
characteristics of individual patients to explain the more extreme values in individual patients.
Conclusion: hemostasis in NAFLD
Despite a slight hypofibrinolysis and pro-thrombotic structure of fibrin clots in patients with 
NAFLD, in chapter 7 we show that the overall hemostatic status is comparable between 
patients with NAFLD and healthy individuals. This suggests that the role for hemostasis in the 
increased risk of thrombosis in patients with NAFLD and NASH-related cirrhosis is probably 
limited.
Thrombotic complications in patients with liver disease
Various thrombotic complications do occur frequently in patients with liver disease. For 
instance, PVT is a common complication of chronic liver disease and is perceived to be 
associated with clinical deterioration [87]. However, recent studies question whether PVT truly 
affects cirrhosis outcome [88,89]. A recent systematic review and meta-analysis of multiple 
studies on anticoagulation for treatment of PVT in cirrhosis concluded that anticoagulant 
therapy could lead to a relatively high rate of portal vein recanalization [90]. However, 
further randomized controlled trials are warranted to confirm the risk-to-benefit ratio of 
anticoagulation in such patients, especially concerning anticoagulant-related bleeding. 
Recent case studies and one retrospective study have also reported both the efficacy and 
safety of new oral anticoagulants as a treatment of PVT [91-94]. Currently, there are no 
strategies available to prevent the development of PVT in cirrhosis. Nevertheless, one recent 
randomized trial reported that enoxaparin prevents PVT in patients with cirrhosis and, in 
addition, appears to delay hepatic decompensation [95]. 
Another frequent occurring thrombotic complication in patients with chronic liver disease is 
venous thrombosis (which includes deep vein thrombosis (DVT) and pulmonary embolism 
(PE)). In fact, the estimated incidence of venous thrombosis in cirrhotic patients is 0.5% to 
6.3%, compared with 0.5% to 0.9% in non-cirrhotic patients, and the incidence appears to 
increase with increasing severity of cirrhosis [96]. Current guidelines on the treatment of 
venous thrombosis in the general population recommend the use of new oral anticoagulants 
(e.g. Dabigatran, Rivaroxaban, Apixaban, or Edoxaban) over vitamin K antagonist (VKA) 
therapy [97]. Furthermore, initial parenteral anticoagulation (typically with low molecular 
weight heparin (LMWH)) is given before Dabigatran and Edoxaban, is not given before 
Rivaroxaban or Apixaban, and is overlapped with vitamin K antagonist therapy. Except in 
cancer-associated thrombosis the guidelines suggest LMWH therapy over VKAs or new oral 
anticoagulant drugs. Primary prevention of venous thrombosis in the general population 
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is achieved by LMWH, fondaparinux, low-dose unfractionated heparin, or by new oral 
anticoagulant drugs [98]. There is mounting evidence that thromboprophylactic treatment 
with LMWH is safe in patients with chronic liver disease [96]. 
Finally, arterial thrombotic events also occur in patients with liver disease and, in fact, patients 
with NAFLD have been repeatedly shown to have an increased risk for arterial disease (see 
chapter 6). For primary prevention of cardiovascular disease in the general population with 
an age of >50 years, low dose aspirin therapy is suggested. For secondary prevention of 
cardiovascular events in patients with established coronary artery disease, monotherapy 
with aspirin or clopidogrel is recommended.  Finally, following acute coronary syndromes 
with percutaneous coronary intervention and stent placement, dual antiplatelet therapy 
with aspirin in combination with ticagrelor, clopidogrel, or prasugrel is recommended [99]. 
Secondary prevention of arterial events should probably not be withheld from patients with 
liver disease, but the risk of bleeding complications may be increased [100]. This thesis 
further focuses on the use of anticoagulant drugs in patients with liver disease, the use of 
anti-platelet agents in patients with cirrhosis has been extensively reviewed elsewhere [100].
Different anticoagulant drugs in patients with liver disease
Table 1 shows the different anticoagulant drugs with their mechanisms of action, advantages 
or disadvantages, and in vitro potency (as studied in chapter 8) in patients with liver disease. 
Heparins
Heparins act by binding to antithrombin and enhancing its effect to inhibit factor Xa and/
or thrombin. They can be used for the prevention or treatment of both venous thrombosis 
and PVT. Currently, three classes of heparins are available: unfractionated heparin, LMWH, 
and fondaparinux. Several studies reported that heparins are efficacious and safe in patients 
with cirrhosis and PVT or venous thrombosis [95,101-105]. Most studies used LMWH, rather 
than unfractionated heparin or fondaparinux. Furthermore, studies suggest that the use 
of LMWH may be more favorable in terms of bleeding complications than unfractionated 
heparin for the indication of thromboprophylaxis in cirrhotic patients [105,106]. Nevertheless, 
there are important drawbacks in using heparins in both the general population and, 
specifically, in patients with liver disease. For instance, the long-term use of these drugs may 
be limited by the mode of administration (i.v. for unfractionated heparin or s.c. for LMWH 
and fondaparinux) as well as the concern for heparin-induced thrombocytopenia (HIT). The 
mode of administration may be associated with both poor compliance and skin reactions. In 
patients with renal failure LMWH accumulation is known to occur, which may require dose 
adjustments in patients with cirrhosis and decreased renal function. Furthermore, heparin 
requires antithrombin to exert its anticoagulant effect and antithrombin levels are frequently 
decreased in patients with liver disease, which theoretically leads to an unpredictable 
anticoagulant effect. Additionally, monitoring issues of heparins occur in patients with liver 
disease, which will be discussed further on. Recently, Senzolo et al. showed an increased 
anticoagulant response to LMWH in plasma from patients with cirrhosis [107]. In chapter 8, 
we also show a modestly increased anticoagulant response to both unfractionated heparin 
and LMWH in plasma from patients with cirrhosis, which was, however, only significant in the 
absence of thrombomodulin. In contrast, we observed a reduced response to fondaparinux 
in patients with, especially, advanced cirrhosis (e.g. Child-Pugh C). Dose adjustments based 
on both altered pharmacokinetics and altered drug potency might, thus, be required for 




these drugs in patients with cirrhosis. However, the limited data showing that LMWH is safe 
to use in patients with cirrhosis contradicts that dose adjustments for this drug are needed.
Vitamin K antagonists
VKAs act by decreasing vitamin K-dependent procoagulant factors II, VII, IX, X, and 
anticoagulant proteins C and S, with a reduction of hemostatic potential as a net result. A 
major advantage of VKA therapy is the oral mode of administration. However, the major 
concern with the use of VKAs in patients with liver disease is the monitoring of the drug by 
INR levels, which are already abnormal in patients with liver disease. The target INR for VKAs 
in patients with cirrhosis is, therefore, unclear. In addition, the use of VKAs in patients with 
cirrhosis has been associated with an increased risk of bleeding complications [108,109]. 
A recent retrospective study demonstrated significantly better recanalization rates of PVT 
in patients treated with warfarin therapy (with a target INR range of 2.0-3.0) compared 
to untreated patients. However, the study did report on bleeding events [110]. Given the 
reported increased bleeding risk and unclear target INR, the use of VKAs in patients with 
cirrhosis is likely associated with an unfavorable risk-to-benefit ratio.
New-generation oral anticoagulant drugs
The new-generation oral anticoagulant drugs include the direct factor Xa inhibitors 
Rivaroxaban, Apixaban, and Edoxaban and the direct thrombin inhibitor Dabigatran. Major 
advantages of these drugs include the oral mode of administration, the action independent of 
antithrombin, and the lack of need for monitoring. Although, the lack of need for monitoring 
can also be interpreted as a disadvantage of the drug as it may increase the risk for non-
compliance. Previously, one of the major concerns for these drugs was the lack of specific 
antidotes to reverse the anticoagulant effect in emergency situations. However, Idarucizumab 
is currently being used in the clinics as an antidote against Dabigatran, and Andexanet alfa 
is currently being studied in a phase IV trial as a reversal agent against factor Xa inhibitors 
[111]. Due to favorable efficacy and safety, new guidelines currently recommend the use 
of these newer drugs over VKAs and LMWH as long-term anticoagulant therapy in venous 
thrombosis in the general population (in the absence of cancer) [97]. The direct factor Xa and 
thrombin inhibitors may also be applicable in the prevention and treatment of thrombotic 
complications in patients with liver disease. Reports of success of these new-generation oral 
anticoagulant drugs in patients with cirrhosis are emerging [91,93,94], however larger clinical 
trials on efficacy and safety of these drugs in cirrhotic patients are lacking. We studied the 
efficacy of three of the new oral anticoagulant drugs in plasma from patients with cirrhosis 
in chapter 8 and the appendix to chapter 8. Addition of the direct thrombin inhibitor 
Dabigatran resulted in an increased response in plasma from patients with cirrhosis. The 
enhanced effect of Dabigatran was proportional to the severity of the disease. In contrast, 
the in vitro anticoagulant potency of both factor Xa inhibitors Rivaroxaban and Apixaban was 
substantially reduced in patients with moderate and advanced cirrhosis. Thus, the new oral 
anticoagulants may work differently in liver disease patients compared to patients with intact 
liver function, which is a potential caveat. Drug-specific dose adjustments may be required 
for these drugs in patients with liver disease. Since these drugs are cleared by the liver and 
kidneys, the pharmacokinetics may also potentially be altered in patients with liver disease. 
Dose adjustments should, thus, ideally take both the altered drug potency and the altered 
pharmacokinetics into account. Furthermore, since the in vitro anticoagulant potency of 
Dabigatran is substantially increased in patients with cirrhosis, clinicians may be cautious in 
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using this drug in patients with liver disease. The results of chapter 8 (and appendix) suggest 
that anticoagulant treatment with direct factor Xa inhibitors will likely not result in over-
anticoagulation, with a potentially increased bleeding risk, provided drug levels remain in 
the target range.  Future clinical trials should, therefore, focus on the efficacy and safety of the 
direct factor Xa inhibitors in patients with liver disease. Finally, monitoring of these new drugs 
in patients with liver disease may be advisable, which will be discussed later on.
Prevention or treatment of thrombosis in patients with liver disease
There are multiple indications for antithrombotic treatment in patients with liver disease. 
However, due to the lack of clinical data, the anticoagulant drug of choice and dosing regimens 
are in most instances unclear. In this section, some guidance on how to approach prevention 
or treatment of thrombosis in patients with liver disease will be provided. In addition, it is 
critical to evaluate each patient individually to best determine which benefits and burdens 
are most prominent in the setting of prevention or treatment of thrombosis. Finally, before 
starting thrombosis prophylaxis or treatment in patients with liver disease, pharmacologic 
(i.e. non-selective beta-blockers) or endoscopic variceal bleeding prophylaxis should be 

































































































































































Table 1. Anticoagulant drugs in the prevention or treatment of venous thrombosis and portal vein 
thrombosis in patients with liver disease. Shown are their mechanisms of action, advantages or 
disadvantages, and in vitro potency (as studied in chapter 8) in patients with liver disease.
AT: antithrombin, HIT: heparin-induced thrombocytopenia, APTT: activated partial thromboplastin time, 
LMWH: low molecular weight heparin, VKA: vitamin K antagonist, GI: gastro-intestinal.





To date, only one study reported the efficacy and safety of prevention of PVT with LMWH in 
patients with cirrhosis [95]. Since insufficient data on this topic exists, the prevention of PVT 
with anticoagulant therapy should, at present, only be considered in the context of clinical 
trials. 
In general, evidence indicates that anticoagulant therapy for PVT in carefully selected patients 
with cirrhosis is safe and effective. However, conservative dosing, in particular in patients 
with advanced disease, and in those patients with risk factors for bleeding, such as renal 
failure and severe thrombocytopenia, may be suggested. Furthermore, certain patients may 
benefit more from anticoagulant treatment of PVT, such as liver transplantation candidates 
compared to patients not suitable for liver transplantation and with an otherwise poor 
prognosis [88]. In addition, patients being considered for anticoagulation should undergo 
evaluation for esophageal varices before initiation of anticoagulation. At present, LMWH may 
be the anticoagulant drug of choice, since the available clinical data suggest LMWH to be 
safe and effective in patients with liver disease. VKAs are discouraged given the high rates of 
bleeding and the lack of suitable target INR. In the future, the new oral anticoagulants may be 
applicable in the treatment of PVT, however clinical data on this are currently lacking.
Venous thrombosis
Thrombosis prophylaxis should not be withheld in patients with a liver disease when risk 
factors for thrombotic complications are present, even in the presence of abnormal routine 
tests of hemostasis. Risk factors include hospitalization and immobilization, surgery, and 
the presence of (hepatocellular) cancer. Dosing regimens may be altered in patients with 
risk factors for bleeding, such as renal failure or profound thrombocytopenia. Mechanical 
thromboprophylaxis should be considered in those patients with clear contraindications 
for anticoagulant treatment. For the same reasons as for treatment of PVT, in prevention of 
venous thrombosis LMWH is also currently the drug of choice. 
 
While studies on prevention of venous thrombosis and prevention or treatment of PVT exist, 
no current study examined the efficacy or safety of anticoagulants for the treatment of venous 
thrombosis in cirrhotic patients. Clinicians are, therefore, left to extrapolate therapeutic 
choice and regimen for venous thrombosis in cirrhosis patients from trials and guidelines 
in medical patients [97]. This would imply that treatment of venous thrombosis should be 
initiated with LMWH, and may be continued with VKAs or new-generation oral anticoagulant 
drugs. However, the use of VKAs should be performed with great care, since dosing regimens 
are unclear. Furthermore, the use of new oral anticoagulant drugs has not been studied in 
clinical trials in patients with cirrhosis. As mentioned before, due to the unpredictable effect 
of Dabigatran observed in chapter 8, the use of direct factor Xa inhibitors may be more 
promising in patients with cirrhosis. It may, therefore, be suggested to use either prolonged 
LMWH administration or direct factor Xa inhibitors (with initial LMWH for Edoxaban) in the 
treatment of venous thrombosis in patients with liver disease. Future studies on the efficacy 
and safety of these anticoagulant drugs for treatment of venous thrombosis in patients with 
cirrhosis are urgently needed.
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Antithrombotic therapy to reduce progression of liver disease
Increasing evidence from animal models of liver disease suggests that antithrombotic 
therapy reduces progression of liver disease [112-119]. Furthermore, a single randomized 
clinical trial showed that LMWH therapy delays decompensation in patients with cirrhosis 
[95]. There may be two hypotheses that could explain the involvement of the coagulation 
cascade in the rate of liver fibrogenesis: the formation of thrombi resulting in tissue ischemia 
(also referred to as parenchymal extinction) and the activation of disease-promoting cells 
by coagulation proteases [120]. If antithrombotic therapy truly prevents progression of liver 
disease and substantially delays decompensation, this will profoundly impact the clinical 
management of patients with (early) cirrhosis. However, future clinical studies on the benefits 
and safety of antithrombotic treatment in different patient groups are required before this 
may be considered in clinical practice.
Monitoring of anticoagulant drugs
Due to the extensive hemostatic changes in patients with cirrhosis, careful monitoring of 
anticoagulant therapy may be required. For monitoring of the different heparins in the general 
population the anti-Xa assay and/or the APTT (for unfractionated heparin) can be used. 
However, recent data suggest that plasma levels of LMWH are substantially underestimated 
by the anti-Xa assay in patients with cirrhosis [104,107,121]. This is most probably related to 
the reduced antithrombin levels in these patients. Indeed, in chapter 9 we show that the anti-
Xa assay not only underestimates the LMWH mass, but the test also underestimates the plasma 
levels of other antithrombin-dependent drugs (i.e. unfractionated heparin and fondaparinux) 
in plasma from patients with cirrhosis. Furthermore, when exogenous antithrombin was 
added to the anti-Xa assay, the reduced recovery of LMWH in patients compared to controls 
was fully blunted.Based on these data, we strongly suggest that anti-Xa levels should not be 
relied upon for monitoring heparins (that exert their effect through antithrombin) in patients 
with cirrhosis, unless exogenous antithrombin is added to the test. However, this modification 
of the test is not readily available in many routine diagnostic laboratories. Since the use of 
LMWH appears safe in patients with cirrhosis, monitoring of LMWH should maybe not be 
performed at all, except in certain situations, for example in patients with severe renal failure 
in which the anti-Xa with the addition of exogenous antithrombin may be used. In contrast to 
the underestimation of levels of heparins with the anti-Xa assay, we show in chapter 9 that the 
APTT overestimates levels of unfractionated heparin in plasma from patients with cirrhosisThis 
test, therefore, also seems unsuitable for heparin monitoring in patients with cirrhosis. Since 
the different anticoagulant drugs may also have an altered anticoagulant potency in patients 
with cirrhosis (as outlined before), the ideal monitoring test for patients with cirrhosis should 
take both drug levels and drug effect into account. 
 
Monitoring of the new oral anticoagulant drugs may be required in patients with liver disease, 
since these drugs are cleared by the liver and kidneys and the anticoagulant potency of 
these drugs may be altered. The direct factor Xa and thrombin inhibitors may be monitored 
through the respective anti-Xa and anti-IIa assays, as in chapter 9 comparable anti-Xa and 
anti-IIa levels were observed after the addition of Rivaroxaban and Dabigatran, respectively, 
in plasma from patients and controls. For monitoring of Dabigatran the thrombin time (TT), 
ecarin clotting time (ECT), or APTT may also be used [122]. However, the TT and ECT are not 
widely available, and the APTT is mostly already prolonged in patients with cirrhosis.





The results of this thesis have contributed to our understanding of the hemostatic system 
and the prevention or treatment of thrombosis in patients with liver disease. However, as 
mentioned throughout this last chapter, there is still a lot of research to be done in order to 
provide better strategies to deal with hemostatic abnormalities in patients with liver disease. 
Therefore, future studies should include (but should not be restricted to) the following topics:
 • Prospective studies to assess the clinical value of promising 
 laboratory tests (thrombin generation testing, TEG, or 
 Thromboelastography) in the prediction of bleeding or thrombosis 
 risk in patients with liver disease.
 • Randomized controlled studies assessing efficacy and safety of 
 restrictive transfusion strategies during invasive procedures in patients 
 with liver disease.
 • Randomized controlled studies on reduction of bleeding 
 complications during invasive procedures in patients with small 
 volume prohemostatics, such as prothrombin complex concentrate.
 • Randomized studies on efficacy and safety of prophylaxis or 
 treatment of venous thrombosis and portal vein thrombosis in patients 
 with liver disease, specifically with the use of LMWH or new-generation 
 oral anticoagulants.
 • Prospective studies on anticoagulation in patients with NAFLD with 
 thrombotic disease.
 • Studies on the use of TEG or thrombin generation to monitor 
 anticoagulant therapy in patients with chronic liver disease.
 • Finally, prospective clinical studies on the benefits and safety of 
 antithrombotic therapy to slow down progression of liver disease.
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Hemostase is het proces wat ervoor zorgt dat een beschadiging aan een bloedvat wordt 
hersteld om zo overtollig bloedverlies te voorkomen. In normale omstandigheden is het 
hemostatische proces strikt gereguleerd. Een verstoring in de hemostatische balans kan 
aanleiding geven tot een bloeding of trombose.
Wanneer een bloedvaatwand beschadigd raakt, ontstaat er vasoconstrictie: samentrekking 
van het bloedvat om de bloeddoorstroming te verminderen. Vervolgens volgen er een aantal 
opeenvolgende processen die resulteren in afsluiting van het bloedvat. De volgende processen 
kunnen theoretisch worden onderscheiden: primaire hemostase, secundaire hemostase en 
fibrinolyse. In de primaire hemostase hechten bloedplaatjes aan blootgestelde eiwitten vlak 
onder de vaatwand, zoals collageen, en raken geactiveerd. Deze bloedplaatjes kunnen weer 
andere bloedplaatjes binden en vormen zo uiteindelijk een prop om het bloedvat af te sluiten. 
Echter voor permanente afsluiting van het bloedvat dient de plaatjesprop te worden versterkt 
door een fibrine netwerk. In de secundaire hemostase wordt fibrine gevormd met hulp van 
de stollingsfactoren. De stolling wordt in gang gezet door het vrijkomen van weefselfactor 
(tissue factor) na de weefselbeschadiging. Interactie met verschillende stollingsfactoren leidt 
uiteindelijk tot de vorming van fibrine. Daarnaast is er een actief antistollingsmechanisme, dat 
voorkomt dat teveel stolling optreedt. Ten slotte kan enige tijd nadat de vaatwand is hersteld, 
het bloedstolsel worden opgeruimd. Dit is het proces van fibrinolyse.
Hemostatische veranderingen bij leverziekte
De lever speelt een grote rol in het hemostatische systeem doordat het de meeste 
stollingsfactoren, antistollingsfactoren en eiwitten betrokken bij de fibrinolyse synthetiseert. 
Daarnaast is de lever ook betrokken bij de primaire hemostase. Acute en chronische 
leverziekten leiden daardoor tot grote veranderingen in het hemostatische systeem. In 
hoofdstuk 2 is een literatuuroverzicht van de hemostatische afwijkingen in patiënten met 
leverziekte gegeven. De belangrijkste veranderingen in de primaire hemostase omvatten 
een verminderd aantal bloedplaatjes (trombocytopenie), verhoogde waarden van von 
Willebrand factor (VWF) (betrokken bij de adhesie van bloedplaatjes) en verlaagde waarden 
van ADAMTS13 (enzym wat VWF grootte reguleert). In de secundaire hemostase zijn de 
plasma spiegels van de belangrijkste stollings- en antistollingseiwitten verlaagd, behalve van 
het stollingseiwit VIII wat verhoogd is. Tot slot zijn de plasma spiegels van eiwitten betrokken 
bij de fibrinolyse veranderd. 
De lever speelt een grote rol bij de synthese van stollingsfactoren. Daardoor zijn de spiegels 
van de stollingsfactoren V, VII, IX, X, XI en protrombine verlaagd. De plasma spiegel van 
factor VIII is echter vaak verhoogd. De verminderde productie van stollingsfactoren wordt 
echter gecompenseerd door een verminderde productie van de antistollingsfactoren, zoals 
proteïne C en antitrombine. Proteïne S plasma spiegels zijn ook verlaagd in patiënten met 
een chronische leverziekte (cirrose). Recent onderzoek heeft aangetoond dat proteïne S 
naast een cofactor voor geactiveerd proteine C ook een cofactor voor tissue factor pathway 
inhibitor (TFPI) in de remming van de stolling is. Door een directe interactie tussen proteïne 
S en TFPI zijn zowel erfelijke als verworven proteïne S deficiënties geassocieerd met een 
gelijktijdige TFPI deficiëntie. In hoofdstuk 3 laten we echter zien dat patiënten met cirrose 
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een verworven proteïne S deficiëntie hebben dat niet gepaard gaat met een verlaging in 
TFPI plasma spiegels. Patiënten met cirrose hadden vergelijkbare TFPI spiegels als gezonde 
controles. Een verklaring voor de normale TFPI spiegels kan zijn dat in patiënten met cirrose 
de TFPI afgifte is verhoogd door continue activatie van het endotheel, maar dat dit (deels) is 
gemaskeerd door de proteïne S deficiëntie. TFPI wordt inderdaad primair geproduceerd in 
het endotheel. Ondanks normale TFPI plasma spiegels, laten we in hoofdstuk 3 zien dat de 
activiteit van het TFPI/proteïne S systeem is verminderd in patiënten met cirrose in vergelijking 
met gezonde controles. De verminderde activiteit van het TFPI/proteïne S systeem in de 
remming van de stolling kan mogelijk bijdragen aan het verhoogde risico op trombotische 
complicaties in patiënten met cirrose.
Chronische leverziekten werden vroeger beschouwd als het prototype van een verworven 
coagulopathie met een verhoogde bloedingsneiging. Conventionele stollingstesten, zoals 
de protrombine tijd (PT, of afgeleide international normalised ratio (INR)) of geactiveerde 
partiële tromboplastinetijd (APTT), zijn verlengd in patiënten met een leveraandoening. Deze 
testen meten echter alleen de afname van pro-stollingsfactoren en niet de vermindering 
van de antistollingsfactoren. Recente klinische en laboratorium studies pleitten voor een 
gebalanceerde hemostase in patiënten met een chronische leverziekte door de gelijktijdige 
daling in zowel pro- als antihemostatische eiwitten. Studies die gebruik maken van trombine 
generatie testen, een meer geavanceerde test van de secundaire hemostase, laten inderdaad 
zien dat in patiënten met leverziekte de trombine generatie gelijk is (of zelfs verhoogd is) aan die 
van gezonde controles. De ‘hemostatische herbalans’ in patiënten met chronische leverziekte 
kan echter wel snel verstoord raken en aanleiding geven tot bloedingen of trombotische 
complicaties. In hoofdstuk 4 laten we zien dat de nieuwe ‘Thrombodynamics assay’, een 
globale test van de secundaire hemostase die niet trombine generatie maar vorming van 
een stolsel als eindpunt heeft, een vergelijkbare stolselvorming in plasma van patiënten met 
cirrose in vergelijking met plasma van gezonde controles meet. Toekomstig onderzoek moet 
uitwijzen of deze nieuwe hemostatische test ook kan worden gebruikt om een verhoogde 
bloedingsneiging of een verhoogd risico op trombo-embolische complicaties in patiënten te 
voorspellen. Momenteel is de test echter alleen geschikt voor onderzoeksdoeleinden en kan 
nog niet worden toegepast in de kliniek.
Hemostase na lever resectie
Men dacht vroeger dat patiënten na een leverresectie ook erg gevoelig waren voor 
bloedingscomplicaties, doordat de PT of INR ook verlengd is in deze patiënten. Echter, we 
weten nu dat deze conventionele stollingstesten niet betrouwbaar zijn in de beoordeling 
van de hemostatische status in deze patiënten. In hoofdstuk 5 is daarom gekeken naar 
de stollingsstatus van patiënten na leverresectie. Door gebruik te maken van de trombine 
generatie test laten we zien dat het plasma van patiënten na leverresectie juist een verhoogde 
stollingsneiging heeft. Ook klinische studies laten zien dat het ontstaan van veneuze trombo-
embolieën na leverresectie niet ongewoon is, het risico op trombose neemt zelfs toe met de 
omvang van de leverresectie.
De resultaten van hoofdstuk 5 in combinatie met de beschreven literatuur hebben 
belangrijke klinische implicaties in de behandeling van patiënten na leveroperaties. Allereerst 
dienen artsen zich bewust te zijn van de beperkingen van het gebruik van conventionele 
stollingstesten als leidraad voor hemostatische behandelingen. Een verlenging van de 
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PT/INR na leverresectie dient niet routine matig te worden gecorrigeerd door transfusie 
van bloedproducten. Daarnaast is trombose profylaxe geïndiceerd in patiënten na een 
leverresectie, ondanks dat de PT/INR suggereert dat patiënten ‘auto-ontstold’ zijn.
Hemostatische veranderingen in patiënten met 
niet-alcoholische leververvetting
In de westerse wereld is niet-alcoholische leververvetting (non-alcoholic fatty liver disease; 
NAFLD) de meest voorkomende oorzaak van chronische leverziekten. Het omvat een 
spectrum van steatose (leververvetting) tot niet-alcoholische steatohepatitis (NASH, een 
combinatie van vervetting en ontsteking in de lever) en uiteindelijk cirrose. Obesitas, 
voornamelijk abdominale obesitas, vormt de grootste risicofactor voor de ontwikkeling van 
NAFLD. Door de toenemende prevalentie van obesitas is er een sterke stijging in het aantal 
patiënten met NAFLD.
Uit recent onderzoek blijkt dat NAFLD is geassocieerd met een verhoogd risico op hart- en 
vaatziekten. Daarnaast lijkt er ook een verhoogd risico te zijn op veneuze trombo-embolische 
complicaties en vena porta trombose in patiënten met NAFLD. In hoofdstuk 6 gaan we in 
op de mogelijke processen die bijdragen aan een verhoogd risico op trombose in patiënten 
met NAFLD. Een aantal studies suggereert een verhoogde stollingsneiging als oorzaak van 
het verhoogd risico op trombose in patiënten met NAFLD. In hoofdstuk 7 onderzoeken 
we daarom het hemostatische systeem in patiënten met NAFLD. In dit onderzoek laten we 
zien dat de algehele hemostatische status vergelijkbaar is tussen patiënten met NAFLD 
en gezonde controles. Het plasma van patiënten met NAFLD toont echter wel enige pro-
trombotische eigenschappen, zoals een geringe hypofibrinolyse en pro-trombotische 
structuur van fibrine stolsels. Uit de resultaten van hoofdstuk 7 kunnen we concluderen dat 
er waarschijnlijk een beperkte rol is van het hemostatische systeem in het verhoogd risico op 
trombose in patiënten met NAFLD.
Behandeling van trombose in patiënten met een chronische leverziekte
Er kunnen diverse trombotische complicaties ontstaan in patiënten met een chronische 
leverziekte. Vena porta trombose is bijvoorbeeld een bekende complicatie van patiënten 
met cirrose. Andere frequent voorkomende trombotische complicaties zijn diep veneuze 
trombose en longembolieën. Behandeling en preventie van trombotische complicaties is 
dus vaak nodig. Echter, door de beperkte klinische ervaring in patiënten met cirrose, is nog 
steeds niet bekend welk antistollingsmiddel het beste is voor de verschillende indicaties. 
Veel gebruikte antistollingsmiddelen in de algemene populatie zijn vitamine K antagonisten, 
heparines en de nieuwe orale antistollingsmiddelen met een directe remming van factor X of 
trombine. Deze middelen hebben allemaal verschillende voor- en nadelen in patiënten met 
een chronische leverziekte. Heparines werken door binding aan antitrombine en versterken 
daarmee de remming van factor X en trombine. Drie klassen worden onderscheiden: 
ongefractioneerde heparine, laag moleculair gewicht heparine (LMWH) en fondaparinux. 
LMWHs lijken veilig en effectief in patiënten met cirrose en vena porta trombose of veneuze 
trombose. Echter, heparines zijn antitrombine-afhankelijke antistollingsmiddelen en 
antitrombine spiegels zijn vaak verlaagd in patiënten met een leverziekte. Een ander nadeel 
van heparines is de wijze van toediening (intraveneus voor ongefractioneerde heparine en 
subcutaan voor LMWH en fondaparinux), wat het langdurig gebruik kan beperken. Vitamine 
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K antagonisten verlagen de vitamine K afhankelijke stollingsfactoren II, VII, IX, X en de 
antistollingseiwitten proteïne C en S. Een groot voordeel van vitamine K antagonisten is hun 
orale toediening. Echter, een groot nadeel in patiënten met een leverziekte is het monitoren 
van het medicijn met de INR, want INR levels zijn al afwijkend in patiënten met een leverziekte. 
Nieuwe antistollingsmiddelen zoals de directe factor X remmers (rivaroxaban, apixaban en 
endoxaban) en de directe trombine remmer (dabigatran) worden steeds meer toegepast 
door de orale toediening en het ontbreken van de noodzaak tot monitoren van medicijn 
spiegels. Deze middelen worden, echter, (ten dele) door de lever of nieren geëlimineerd 
en worden daardoor nauwelijks gebruikt in patiënten met een leverziekte. Enkele kleine 
onderzoeken suggereren dat deze nieuwe middelen mogelijk effectief en veilig zijn in 
patiënten met cirrose, echter grote klinische trials naar de effectiviteit en veiligheid van deze 
middelen in patiënten met cirrose ontbreken. 
Doordat er weinig onderzoek is gedaan naar de effectiviteit en veiligheid van de verschillende 
antistollingsmiddelen in patiënten met cirrose, is het preferente antistollingsmiddel voor de 
verschillende indicaties onbekend. In hoofdstuk 8 hebben we daarom de in vitro effectiviteit 
van verschillende antistollingsmiddelen in patiënten met een chronische leverziekte 
onderzocht. In dit hoofdstuk tonen we aan dat het in vitro effect van de verschillende 
antistollingsmiddelen significant verschilt tussen patiënten met cirrose en gezonde controles. 
Dabigatran, en in mindere mate heparine en LMWH, toonden een versterkt antistollingseffect 
in plasma van patiënten met cirrose in vergelijking met gezonde controles. Aan de andere 
kant was er een verminderd effect van fondaparinux en rivaroxaban in patiënten met 
cirrose. Naast een veranderd effect van de middelen, kan ook de farmacokinetiek van de 
middelen anders zijn. De dosering van de verschillende antistollingsmiddelen in patiënten 
met cirrose zal dus moeten worden aangepast op basis van een veranderde farmacokinetiek 
en een veranderd effect. De resultaten van hoofdstuk 8 en appendix suggereren dat 
antistollingsbehandeling met directe factor X remmers waarschijnlijk veilig zullen zijn met het 
oog op risico op bloeding (op voorwaarde dat medicijn spiegels binnen de streefwaarden 
blijven). Toekomstige klinische trials kunnen zich daarom het beste richten op de effectiviteit 
en veiligheid van de directe factor X remmers in patiënten met een leverziekte.
Gezien de uitgebreide hemostatische veranderingen in patiënten met cirrose, kan monitoring 
van antistollingsmiddelen noodzakelijk zijn. Monitoring van heparines kan middels anti-
Xa testen of voor ongefractioneerde heparine middels de APTT. In hoofdstuk 9 laten we 
echter zien dat de anti-Xa testen niet betrouwbaar zijn in de monitoring van heparines in 
patiënten met cirrose. Er werd een substantiële afname gevonden in anti-Xa waardes 
gemeten na in vitro toevoeging van LMWH, ongefractioneerde heparine of fondaparinux 
aan plasma van patiënten met cirrose in vergelijking met gezonde controles. Deze test 
onderschat waarschijnlijk de plasma spiegels van heparines in patiënten met cirrose, omdat 
heparines antitrombine afhankelijk zijn en antitrombine spiegels verlaagd zijn in patiënten 
met cirrose. Wanneer we exogeen antitrombine toevoegen aan de test, zijn de anti-Xa 
waardes na toevoeging van de verschillende heparines inderdaad gelijk tussen patiënten 
en controles. Aangezien de anti-Xa test plasma spiegels van antitrombine-afhankelijke 
antistollingsmiddelen onderschat in patiënten met cirrose, adviseren we deze test niet te 
gebruiken in deze patiënten, tenzij exogeen antitrombine aan de test wordt toegevoegd. 
In tegenstelling tot de onderschatting van plasma spiegels met de anti-Xa test, laten we in 
hoofdstuk 9 zien dat de APTT plasma spiegels van ongefractioneerde heparine in plasma van 
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patiënten met cirrose overschat. Deze test is daarom ook niet geschikt voor de monitoring 
van ongefractioneerde heparine in patiënten met cirrose.
Monitoring van de nieuwe orale antistollingsmiddelen is mogelijk ook noodzakelijk in 
patiënten met cirrose, omdat deze middelen worden geëlimineerd door de lever en nieren en 
de antistollingspotentie van deze middelen veranderd kan zijn. De directe factor X remmers 
en directe trombine remmers kunnen echter wel betrouwbaar worden gemonitord met de 
respectievelijke anti-Xa en anti-IIa testen, aangezien we in hoofdstuk 9 vergelijkbare anti-Xa en 
anti-IIa waardes laten zien na de respectievelijke toevoeging van Rivaroxaban en Dabigatran 
in plasma van patiënten en controles. De ideale monitor test voor antistollingsmiddelen 
in patiënten met cirrose zou echter rekening moeten houden met zowel verandering in 
geneesmiddel spiegels als een veranderd effect.
Conclusie
Resultaten van dit proefschrift hebben bijgedragen aan de kennis omtrent de functionering 
van het hemostatische systeem in patiënten met een leverziekte. Daarnaast hebben we de 
effectiviteit en monitoring van antistollingsmiddelen in plasma van patiënten met cirrose 
onderzocht. De resultaten van dit proefschrift dragen bij aan een beter inzicht in strategieën om 
trombotische complicaties in patiënten met een leverziekte te voorkomen of te behandelen. 
Er is echter nog veel toekomstig onderzoek nodig om inzicht te krijgen in de beste preventie 
en behandeling van hemostatische veranderingen in patiënten met een leverziekte.
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Dankwoord
Het schrijven van een proefschrift doe je natuurlijk niet alleen. Ik weet dat dit een cliché is, 
maar ook voor mij is dit zeker waar! Daarom wil ik in dit laatste (en meest gelezen) deel 
van dit proefschrift mijn dank betuigen aan de steun, inzet en interesse van velen. Zonder 
jullie bijdrage was het zeker niet gelukt! Daarnaast kan promoveren niet zonder afwisseling, 
ontspanning en afleiding, daarom wil ik graag van de gelegenheid gebruik maken om ook 
mijn familie en vrienden te bedanken.
Prof. dr. J.A. Lisman, beste Ton, ik had mij geen betere eerste promotor kunnen wensen! 
Wat ben jij gedreven, een getalenteerd schrijver en een bron van motiverende ideeën. Als 
promotor ben jij iemand die altijd voor zijn promovendi klaar staat. Binnen no time reageer 
jij op e-mails en heb jij stukken nagekeken, dag of nacht, zelfs in je vakantie! Dit heeft geleid 
tot een snelle voortgang van mijn onderzoeken. Dat ik altijd bij je kon aankloppen, maakt 
enerzijds dat ik me zeer goed “begeleid” voelde, anderzijds dat ik juist zelfstandig durfde te 
werken. Daarnaast ben je ook wel eens in voor een feestje. Als promovendus ben ik erachter 
gekomen dat het thuisbrengen van je promotor en het eventueel schoonmaken van de auto 
nadien ook tot de taken van een promovendus kan behoren. Zonder gekheid, ik kan je niet 
genoeg bedanken voor al je hulp, zoals het verbeteren van een artikel, de aanwezigheid bij 
een presentatie of de vele aanbevelingsbrieven die je voor mij hebt geschreven!
Prof. dr. R.J. Porte, beste Robert, tijdens de JSM cursusweek op Schiermonnikoog 
inspireerde jij mij voor het onderzoek binnen jullie onderzoeksgroep. Aanvankelijk ben ik 
begonnen met een proefproject, maar al gauw stelde je voor om ook mijn wetenschappelijke 
stage binnen jullie onderzoeksgroep te voltooien als start voor een MD/PhD traject. Ik wil 
je graag bedanken voor de mogelijkheden die je mij hebt geboden en het vertrouwen dat 
je in mij had om het traject succesvol te kunnen doorlopen. Daarnaast heb ik veel van je 
geleerd rondom het initiëren van een onderzoek. Tot slot heb ik veel bewondering voor de 
manier waarop jij onderzoek weet te combineren met het werken als chirurg en hoofd van 
verscheidene afdelingen! 
Dear assessment committee: prof. dr. D. Valla, prof. dr. F.W.G. Leebeek, and prof. dr. K. 
Meijer, thanks for your critical reading and the assessment of my thesis. 
Graag bedank ik de Junior Scientific Masterclass voor de mogelijkheid om te kunnen 
promoveren tijdens mijn studie Geneeskunde in het kader van het MD/PhD-traject. Dr. Joke 
van der Mark-van der Wouden en Jans van Aalst-Ubels in het bijzonder bedankt dat ik 
altijd bij jullie terecht kon met vragen over het traject!
Onderzoekers en analisten van het Chirurgisch onderzoekslaboratorium Jelle Adelmeijer, 
Susanne Berghuis-Veldhuis, Prof. dr. Henri Leuvenink, Jacco Zwaagstra, Janneke 
Wiersema-Buist en Petra Ottens, ik heb jullie hulp, gezelligheid en ondersteuning altijd 
gewaardeerd. Jelle, een bijzonder dank voor jou, jij hebt mij bij alle studies ontzettend veel 
geholpen met alle laboratoriumanalyses. Zonder jou hulp had ik het nooit zo snel allemaal 
kunnen afronden! Daarnaast vond ik het altijd gezellig om even op het lab bij te praten over 
de laatste roddels of sporten zoals schaatsen. Jacco, bedankt voor het wegwijs maken in het 
lab, we hebben zo onze onenigheden betreffende het dragen van hakken op het lab gehad, 
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maar er was altijd een prettige werksfeer. Henri, ik herinner me nog dat je mijn mentor was in 
het tweede jaar van de studie, toen inspireerde je me al binnen het onderzoek.
Mede promovendi/studenten in het Chirurgisch onderzoekslaboratorium Dafna, Sarah, 
Laura, Alix, Anne, Yvonne, Rianne, Greg, Marc, Geert, Andrie, Pepijn, Sanna, Michael 
en Anne Marieke, bedankt voor de gezellige tijd op het lab en in het Triade gebouw. Dafna 
bedankt voor je wijze raad rondom het onderzoek en promoveren! Het was altijd erg gezellig 
samen op congressen, hopelijk kan ik voortaan de douche zonder je vinden…
In 2015 I was given the opportunity to spend a few months of my PhD time at the Virginia 
Commonwealth University (VCU) Medical Center in Richmond, Virginia, USA. I would like to 
thank especially my supervisor Dr. Arun J. Sanyal for his kind invitation and initiation of the 
collaboration between our research groups to study the hemostasis in patients with NAFLD. 
Thank you also for the invitation to write the review with you and Dr. M. Shadab Siddiqui. 
Also my special thanks to Sherry Hill Boyett, thank you for the help with the inclusion of 
patients, I could not have done it without you. You were so kind to show me around and 
I miss our working together and our small talks. Dr. M. Shadab Siddiqui, thank you for 
writing two papers together. Dr. R. Todd Stravitz thank you for showing me around in the 
clinic. I would like to thank Kalyani Daita with the help in finishing the inclusion of patients 
in the study. Furthermore, Julie Farnsworth thank you for your help with the flow cytometry 
analysis. Other colleagues and friends in Richmond, Sophie Cazanave, Amon Asgharpour, 
Robert Vincent, and Faridoddin Mirshahi – thank you for welcoming me so warmly into your 
research group. Although our time together was brief, I very much valued it and I wish you all 
the best.
Graag bedank ik alle co-auteurs die een bijdrage hebben geleverd aan dit proefschrift, 
waaronder Freeha Arshad, Edris Alkozai, Hans Blokzijl, Arie P. van den Berg, en Joost C. 
M. Meijers.
Wytse Kloosterman, ontzettend bedankt voor je artistieke hulp bij het ontwerpen van de kaft 
en voor de mooie vormgeving van mijn proefschrift. Ik wens je veel succes met alles en veel 
schaatsplezier!
Gerda Potze en Marleen Vonder, wat fantastisch dat jullie samen mijn paranimfen willen 
zijn! Lieve sis Gerda, bedankt voor je altijd luisterend oor. Ik ben ontzettend trots om jou als 
zus te mogen hebben! Marleen, bedankt voor je onvoorwaardelijke vriendschap en wijze 
raad rondom het promoveren. Op naar jouw promotie, heel veel succes!
Lieve vrienden bedankt voor de nodige ontspanning en afleiding tijdens mijn studententijd 
en het promoveren. Margrit, wij kennen elkaar al sinds onze geboorte, het is heel speciaal 
dat wij nog steeds zulke goede vriendinnen zijn! Monica en Kim we gaan snel weer samen 
stappen..! Lieve geneeskunde vriendinnetjes Kelly en Marieke, samen konden we ons druk 
maken om de volgende moeilijke toets of gewoon lekker thee drinken en kletsen.
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Zonder de J.F. van Gils Symposium Commissie waren mijn coschappen in Zwolle nooit zo 
leuk geweest. Annewiek, Caren, Laura, Tijn en Jorrit, samen hebben we heel wat gezellige 
avonden beleeft en een mooi symposium met spetterend afsluitend feest neergezet!
Dear family in the United States of America, during my stay in Richmond I really enjoyed 
spending time with you guys during the weekends. Special thanks to Ben, Patricia and 
Nikkie, I can’t tell you how much I appreciated your kindness in letting me stay at your home. 
Please remember that you are always welcome to stay at our place when your travels bring 
you to the Netherlands.
Lieve schoonzus Chantal wat fijn dat je de fotografie op mijn promotiefeest wil doen! Alvast 
bedankt daarvoor.
Lieve familie, ouders Geertje en Willem en broer Luuk, ik kan jullie niet genoeg bedanken 
voor alle onvoorwaardelijke steun in alles wat ik onderneem. Jullie staan altijd voor mij klaar.
Allerliefste Sebastian, bedankt voor al je liefde en dat je me altijd laat voelen dat je zo trots 
op me bent. Met jou samen wintersporten, reizen, hardlopen, koken of bakken, bank hangen 
of gewoon samen zijn maakt mij ontzettend gelukkig! Laten we dit nog lang samen doen.
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Curriculum Vitae
Nederlands
Wilma Potze werd geboren op 22 januari 1990 te Hardenberg. Zij volgde haar lagere school 
opleiding aan de Kardoen te Ommen en de middelbare schoolopleiding aan het Vechtdal 
College te Hardenberg, waar zij in 2008 haar VWO diploma behaalde. In datzelfde jaar begon 
zij aan de opleiding Farmacie aan de Rijksuniversiteit Groningen waar zij haar propedeuse 
cum laude heeft behaald. In 2009 begon Wilma aan haar opleiding Geneeskunde aan 
de Rijksuniversiteit Groningen. Tijdens haar opleiding werkte ze als student assistent op 
verscheidene afdelingen in het Universitair Medisch Centrum Groningen (UMCG), was ze 
actief binnen de studentenschaatsvereniging TJAS en deed ze vrijwilligerswerk bij het 
Rode Kruis in Groningen. Daarnaast volgde zij tijdens haar bachelor het Honours College 
programma waarmee zij in aanraking kwam met het doen van onderzoek. In het tweede jaar 
van haar opleiding deed zij een pilot project bij de afdeling Dermatologie in het UMCG. In 
het derde jaar van de opleiding geneeskunde begon Wilma met een pilot project bij de 
onderzoeksgroep van Prof. dr. Ton Lisman en Prof. dr. Robert J. Porte waar ze gefascineerd 
raakte van het onderzoek naar de hemostase in patiënten met een leverziekte. Na het behalen 
van haar bachelor diploma in 2012 (cum laude) begon zij met haar wetenschappelijke stage 
van de master geneeskunde. Daarna werd Wilma aangenomen voor het MD/PhD traject, 
waarbij de masteropleiding gecombineerd wordt met een promotieonderzoek. Na haar 
eerste jaar coschappen in het UMCG deed zij een fulltime jaar onderzoek, waarvan een deel 
in Richmond, Virginia werd uitgevoerd. Daarna volgde Wilma haar senior coschappen in Isala 
in Zwolle, waar ze ondertussen ook heeft mee geholpen aan de organisatie van het J.F. van 
Gils symposium in 2015. In datzelfde jaar won zij de GUF-100 award, een prijs toegekend 
aan de meest excellente student van elke faculteit aan de Rijksuniversiteit Groningen. Na 
haar senior coschappen deed Wilma haar semi-arts stage bij de interne geneeskunde en 
de spoedeisende hulp in het Wilhelmina ziekenhuis. In november 2016 behaalde zij haar 
master geneeskunde diploma. Een paar maanden later ronde zij haar promotieonderzoek 
vervroegd af, waarvan de resultaten in dit proefschrift zijn beschreven. Sinds januari 2017 is 
Wilma werkzaam als ANIOS op de interne geneeskunde in de Isala in Zwolle.
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English
Wilma Potze was born on the 22nd of January 1990 in Hardenberg, the Netherlands. She 
attended the ‘Kardoen’ primary school in Ommen and thereafter went to high school (‘Vechtdal 
College’) where she graduated in 2008. Before she enrolled in the study of Medicine at the 
University of Groningen in 2009, she studied one year of Pharmaceutics at the University of 
Groningen (first year diploma cum laude). During her medical studies, Wilma worked as an 
assistant at different departments at the University Medical Center Groningen, was a member 
of the Promotion and Competition Committee at the student speed skating association TJAS 
in Groningen, and worked as a volunteer at the Rode Kruis in Groningen. Furthermore, she 
successfully attended the Honours College program at the University of Groningen during 
her Bachelor of Medicine. As part of this program she performed a part-time research project 
at the Department of Dermatology. In the third year of medical school Wilma started a pilot 
project in the research group of Prof. dr. Ton Lisman and Prof. dr. Robert J. Porte, where she 
developed an enthusiasm for medical research on the hemostasis in liver diseases. After 
finishing her Bachelor of Medicine (cum laude), she continued with her research internship of 
the Master of Medicine, entitled: ‘Efficacy of anti-hemostatic drugs in patients with cirrhosis’. 
Based on this work, Wilma successfully applied for the MD/PhD program to combine her 
Master of Medicine with a PhD project. After a year of clinical rotations at the University 
Medical Center Groningen, she performed one year of fulltime research on hemostasis in 
(fatty) liver diseases, part of which was performed in Richmond, Virginia. During her second 
year of clinical rotations in Isala in Zwolle, Wilma organized the yearly J.F. van Gils symposium 
in 2015. Wilma graduated from medical school in November 2016. Officially she had one 
year of research of the MD/PhD program left, but she had enough publications to shorten the 
program and defend her PhD thesis in April 2017. Currently Wilma is working as a resident in 
Internal Medicine at the Isala in Zwolle.
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